<SEC-DOCUMENT>0001698530-19-000099.txt : 20190730
<SEC-HEADER>0001698530-19-000099.hdr.sgml : 20190730
<ACCEPTANCE-DATETIME>20190730161535
ACCESSION NUMBER:		0001698530-19-000099
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20190730
DATE AS OF CHANGE:		20190730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXICURE, INC.
		CENTRAL INDEX KEY:			0001698530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				815333008
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-230175
		FILM NUMBER:		19985665

	BUSINESS ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077
		BUSINESS PHONE:		847-673-1700

	MAIL ADDRESS:	
		STREET 1:		8045 LAMON AVE, SUITE 410
		CITY:			SKOKIE
		STATE:			IL
		ZIP:			60077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Max-1 Acquisition Corp
		DATE OF NAME CHANGE:	20170221
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>exicure424b5july2019.htm
<DESCRIPTION>424B5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb86a374739f54077afeacab4067a4ee0"></a></div><div style="line-height:120%;padding-bottom:0px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Filed Pursuant to Rule 424(b)(5)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registration No. 333-230175</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ee2724;font-weight:bold;">The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;">SUBJECT TO COMPLETION, DATED JULY 30, 2019 </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRELIMINARY PROSPECTUS SUPPLEMENT </font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(To Prospectus dated July 24, 2019) </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:18pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:16px;text-align:center;padding-left:96px;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Shares </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;"><img src="image96.jpg" alt="image96.jpg" style="height:61px;width:254px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are offering                shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">We are an &#8220;emerging growth company&#8221; under applicable Securities and Exchange Commission rules and are subject to reduced public company reporting requirements.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is quoted on the OTC Market Group&#8217;s OTCQB</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">Market quotation system under the ticker symbol &#8220;XCUR.&#8221;  On July 29, 2019, the last reported sale price of our common stock was $1.85 per share. In connection with this offering, our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;XCUR.&#8221;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading &#8220;Risk Factors&#8221; beginning on page </font><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s0de3f0d68d1642109563c706f1afeec7"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">S-7</font></a><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:78.57142857142857%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:76%;"></td><td style="width:2%;"></td><td style="width:7%;"></td><td style="width:2%;"></td><td style="width:3%;"></td><td style="width:7%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">PER</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SHARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">TOTAL</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public offering price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriting discounts and commissions(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds, before expenses, to us</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:24px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) We have agreed to reimburse the underwriters for certain expenses. We refer you to &#8220;Underwriting&#8221; beginning on page </font><a style="font-family:inherit;font-size:10pt;" href="#s3f7468131fd44e529cd4e71a9cb29f8c"><font style="font-family:inherit;font-size:10pt;">S-21</font></a><font style="font-family:inherit;font-size:10pt;">&#32;of this prospectus supplement for additional information regarding total underwriting compensation.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain of our existing stockholders, who are affiliated with certain of our directors, have indicated an interest in purchasing up to an aggregate of approximately $         million in shares of common stock in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of common stock in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, fewer or no shares of common stock in this offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase an additional shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $     , and the total proceeds to us, before expenses, will be $      . </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Delivery of the shares of common stock is expected to be made on or about           , 2019.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sole Book-Running Manager </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Guggenheim Securities </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">The date of this prospectus supplement is           , 2019. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s81d427491a0b4e31b012df8b8dfd99ef"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prospectus Supplement</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:92%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sdbf3a3a03c53444eaf21c12117950e5a"><font style="font-family:inherit;font-size:10pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sdbf3a3a03c53444eaf21c12117950e5a">S-ii</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s614b0af0920546c7aedefa494e64ff59"><font style="font-family:inherit;font-size:10pt;">PROSPECTUS SUPPLEMENT SUMMARY</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s614b0af0920546c7aedefa494e64ff59">S-1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sdb0d5914a63c43d2b90646964d9dbc12"><font style="font-family:inherit;font-size:10pt;">THE OFFERING</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sdb0d5914a63c43d2b90646964d9dbc12">S-6</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0de3f0d68d1642109563c706f1afeec7"><font style="font-family:inherit;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0de3f0d68d1642109563c706f1afeec7">S-7</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sc4095f7a0fb04618874d77e4f6b95c2a"><font style="font-family:inherit;font-size:10pt;">NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sc4095f7a0fb04618874d77e4f6b95c2a">S-10</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6d5dfe5bcf3840f6bd8e1a264bb00fa2"><font style="font-family:inherit;font-size:10pt;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6d5dfe5bcf3840f6bd8e1a264bb00fa2">S-12</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7dcd0dc2d6c34aac9ecd65fa17679e1a"><font style="font-family:inherit;font-size:10pt;">CAPITALIZATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7dcd0dc2d6c34aac9ecd65fa17679e1a">S-13</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21e859dac72a4c7884c7d129bc08b734"><font style="font-family:inherit;font-size:10pt;">DILUTION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s21e859dac72a4c7884c7d129bc08b734">S-15</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s136836b275e74deca2c3ae6ee02e371a"><font style="font-family:inherit;font-size:10pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s136836b275e74deca2c3ae6ee02e371a">S-17</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3f7468131fd44e529cd4e71a9cb29f8c"><font style="font-family:inherit;font-size:10pt;">UNDERWRITING</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3f7468131fd44e529cd4e71a9cb29f8c">S-21</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s646a769de5614dfc8e42e01a434529f6"><font style="font-family:inherit;font-size:10pt;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s646a769de5614dfc8e42e01a434529f6">S-26</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sfcf5b8dd4dd94ba98f9259f5d88e5bfd"><font style="font-family:inherit;font-size:10pt;">EXPERTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sfcf5b8dd4dd94ba98f9259f5d88e5bfd">S-26</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80fbb0e66354466fafb532484d402d23"><font style="font-family:inherit;font-size:10pt;">WHERE YOU CAN FIND MORE INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80fbb0e66354466fafb532484d402d23">S-26</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#saac52903fd7d427580da07d81af78779"><font style="font-family:inherit;font-size:10pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#saac52903fd7d427580da07d81af78779">S-27</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prospectus</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:92%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB47EA0831745F109CA35BF5AE13E50F"><font style="font-family:inherit;font-size:10pt;">ABOUT THIS PROSPECTUS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB47EA0831745F109CA35BF5AE13E50F">1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3ADC48A609650CA9B60D9ED405B39DF"><font style="font-family:inherit;font-size:10pt;">WHERE YOU CAN FIND MORE INFORMATION</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3ADC48A609650CA9B60D9ED405B39DF">1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s28EAC80121DF516CB2FF397855E2926E"><font style="font-family:inherit;font-size:10pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s28EAC80121DF516CB2FF397855E2926E">2</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s657DDCC6965854D8B39227E8891D3D47"><font style="font-family:inherit;font-size:10pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s657DDCC6965854D8B39227E8891D3D47">4</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF0CDF82958F5688859BF5383D78F29D"><font style="font-family:inherit;font-size:10pt;">ABOUT THE COMPANY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF0CDF82958F5688859BF5383D78F29D">6</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC2BC7DCAB55C5E7782901F2AE71DC1B9"><font style="font-family:inherit;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC2BC7DCAB55C5E7782901F2AE71DC1B9">10</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49FA59900F7A58ABA13E8D7E0354865C"><font style="font-family:inherit;font-size:10pt;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49FA59900F7A58ABA13E8D7E0354865C">11</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s820955F6EC6E5C07941B4FBF3118214E"><font style="font-family:inherit;font-size:10pt;">DIVIDEND POLICY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s820955F6EC6E5C07941B4FBF3118214E">12</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76B3E07129B85BD293A782F3FC42D6D8"><font style="font-family:inherit;font-size:10pt;">GENERAL DESCRIPTION OF SECURITIES WE MAY OFFER</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76B3E07129B85BD293A782F3FC42D6D8">13</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56418280EEB357A18C7731BA63FBBC80"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF CAPITAL STOCK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56418280EEB357A18C7731BA63FBBC80">14</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CE3FE94DABC504791FE039F62658173"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF DEBT SECURITIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CE3FE94DABC504791FE039F62658173">19</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE5C4C8641B3153CFA20ECC9D053E5E11"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF DEPOSITARY SHARES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE5C4C8641B3153CFA20ECC9D053E5E11">26</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC029E39C898D5A8D93511EA101977BE7"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF WARRANTS, OTHER RIGHTS AND UNITS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC029E39C898D5A8D93511EA101977BE7">27</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s48671C3AA9CE51BA96105E2B5C636502"><font style="font-family:inherit;font-size:10pt;">PLAN OF DISTRIBUTION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s48671C3AA9CE51BA96105E2B5C636502">29</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE6DBF9466A7531AA0036D49F4137DD2"><font style="font-family:inherit;font-size:10pt;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE6DBF9466A7531AA0036D49F4137DD2">32</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7E3A28EE30F577A834B442EEF79CF65"><font style="font-family:inherit;font-size:10pt;">EXPERTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7E3A28EE30F577A834B442EEF79CF65">33</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-i</font></div></div><hr style="page-break-after:always"><div><a name="sdbf3a3a03c53444eaf21c12117950e5a"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus supplement and the accompanying prospectus are part of a shelf registration statement on Form S-3 (File No. 333-230175), as amended, that we filed with the Securities and Exchange Commission, or SEC, on July 11, 2019 and was declared effective by the SEC on July 24, 2019, pursuant to which we may from time to time offer various securities in one or more offerings. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein or therein. The second part, the accompanying prospectus, including the documents incorporated by reference into the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference herein or therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference in the accompanying prospectus - the statement in the document having the later date modifies or supersedes the earlier statement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Neither we nor the underwriters have authorized anyone to provide information different from that contained in this prospectus supplement and the accompanying prospectus that we have authorized for use in this offering. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the underwriters take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither the delivery of this prospectus supplement and the accompanying prospectus, nor the sale of our common stock means that information contained in this prospectus supplement and the accompanying prospectus, is correct after their respective dates. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus supplement and the accompanying prospectus in making your investment decision. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">This prospectus supplement does not contain all of the information that is important to you. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus supplement. You should rely only on the information contained or incorporated by reference in this document. You should assume that the information in this prospectus supplement and the accompanying prospectus, as well as the information we have filed with the SEC and incorporated by reference in this document, is accurate only as of its date or the date which is specified in those documents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are offering to sell, and seeking offers to buy, and the underwriters are soliciting offers to buy, these securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus supplement and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference herein are the property of their respective owners.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless the context otherwise requires, in this prospectus supplement the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar names refer to Exicure, Inc. and its subsidiaries. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-ii</font></div></div><hr style="page-break-after:always"><div><a name="s614b0af0920546c7aedefa494e64ff59"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS SUPPLEMENT SUMMARY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of Exicure and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference in this prospectus supplement and the accompanying prospectus, including the information referred to under the heading &#8220;Risk Factors&#8221; in this prospectus supplement beginning on page S-7. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. We have advanced our SNA therapeutic candidates through three Phase 1 clinical trials. These candidates include AST-008 addressing immuno-oncology, and XCUR17 and AST-005 addressing psoriasis. We have also shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical development programs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Immuno-oncology </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-008&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors. We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that the administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in mouse models of colon cancer, breast cancer, lymphoma and melanoma. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008,&#160;applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, the administration of AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the U.S. Food and Drug Administration, or the FDA, opened the investigational new drug application, or IND, for AST-008 and informed us&#160;that our proposed Phase 1b/2 trial may proceed. During the first half of 2019, we opened five clinical trial sites and began recruiting and dosing patients in that trial. The Phase 1b/2 is an open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. We plan to recruit patients with advanced or metastatic Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma, and melanoma. The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab. Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1. As of July 28, 2019, we have dosed nine patients in the first three cohorts of the Phase 1b stage of the clinical trial.  We have observed no treatment related serious adverse events, or SAEs, nor have we observed any dose-limiting toxicity, or DLT, among the treated subjects. We are now proceeding to the fourth dosing cohort in the clinical trial.  We intend to disclose results from the Phase 1b stage of the clinical trial in late 2019 and initiate the Phase 2 stage of the trial in 2020.</font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-1</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inflammatory diseases </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">XCUR17 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the keratinocytes of the skin. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We filed a clinical trial authorization, or CTA, for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017, and we began dosing patients in April 2018. The Phase 1 clinical trial, which had final patient visits in the fourth quarter of 2018, was a randomized, double-blinded, placebo-controlled trial in 21 patients with mild to moderate chronic plaque psoriasis designed to assess the safety of XCUR17 formulated as a topical gel, and to evaluate early signs of efficacy. All patients received three strengths of XCUR17 gel, a vehicle gel, and a positive comparator (Daivonex&#174; cream), which were all applied on different areas of psoriatic skin within each individual patient. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the fourth quarter of 2018, we reported results from the Phase 1 trial of XCUR17. In the case of XCUR17, of the 21 treated patients, 11 treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, 17 of the 21 patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There were no adverse safety events related to treatment with XCUR17 observed. In addition to the safety, tolerability and clinical assessments, the trial measured psoriatic infiltrate thickness over the 26-day treatment period. No relevant changes in mean psoriatic infiltrate thickness were observed for the three XCUR17 gels or the active ingredient-free vehicle gel. At this time, assessments of IL-17RA mRNA levels from skin biopsies collected from the treated areas in patients have not yet been correlated with the clinical or infiltrate thickness assessments. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Dermelix License Agreement </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2019, we entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome, or NS, and, at Dermelix&#8217;s option, up to five additional rare skin indications. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dermelix will initially develop a targeted therapy for the treatment of NS. NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">SPINK5 </font><font style="font-family:inherit;font-size:10pt;color:#000000;">gene, which encodes the serine protease inhibitor LEKTI involved in skin barrier function. NS affects approximately one in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility. In partnership with Dermelix, we will seek to open an IND for a proposed SNA therapeutic for NS in 2020.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the terms of the Dermelix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early-stage development for each indication up to IND enabling toxicology studies. Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales </font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">milestones per indication in each of six indications. In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Other Inflammatory Diseases </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that one of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. As a consequence, we are also conducting early stage research activities in ophthalmology, pulmonology, and gastroenterology. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe promising therapeutic targets for SNAs include antibody targets with confirmed therapeutic benefit. We envision inhibiting these targets with local application of SNAs in a variety of therapeutic areas. We believe that this approach combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapy. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Genetic disorders </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are investigating the utility of our SNA technology for the treatment of neurological conditions and have ongoing research programs underway. In the fall of 2018, we completed a biodistribution study in rats comparing nusinersen</font><font style="font-family:Arial;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">to nusinersen in SNA format. Nusinersen, marketed by Biogen Inc., is a linear nucleic acid therapeutic approved by the FDA in late 2016 for the treatment of spinal muscular atrophy, or SMA. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On June 26, 2019, we announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system. In our study, 7mg of radio-labeled SNAs were injected intrathecally into cynomolgus monkeys. The biodistribution of the SNAs was followed for 14 days by PET/CT scans. SNAs were observed throughout the entire brain and were found both in the brain stem as well as inside the brain. High content of SNA was observed in all 46 regions of the brain examined. These key data indicate that the SNA platform may be well-suited for development of new therapeutics directed towards diseases of the central nervous system.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases. Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s ataxia, and Batten disease. We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">AST-005 </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting TNF for the treatment of mild to moderate psoriasis. AST-005 is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue Pharma L.P., referred to as the Purdue Collaboration. As part of our collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis. In April 2018, Purdue notified us that it had declined to exercise its option to develop AST-005 at that time, but that it also intended to retain rights relating to the TNF target, and Purdue reserved its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005. </font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2019, Purdue notified us that it will not be selecting any collaboration targets pursuant to the Purdue Collaboration. As a result, we will not receive any research, regulatory and commercial sales milestones contingent upon successful development of such collaboration targets. Purdue re-asserted its right to develop new anti-TNF therapeutic candidates. At this time, there are no active development activities underway for a new anti-TNF therapeutic candidate. As a consequence, we also believe that it is highly unlikely that we will receive any research, regulatory and commercial sales milestones for any anti-TNF therapeutic candidates. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Clinical Development Programs </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our clinical development programs include the development of one SNA therapeutic candidate to address unmet medical needs in the treatment of solid tumors and one SNA therapeutic candidate to address unmet medical needs in the treatment of mild to moderate psoriasis. We are also conducting early stage research activities in neurology, ophthalmology, respiratory and gastrointestinal applications. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The table below sets forth the stage of development of our SNA therapeutic candidates as of July 28, 2019: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;"><img src="pipeline072819.jpg" alt="pipeline072819.jpg" style="height:167px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">TLR9 = Toll-like Receptor 9; IL17RA = Interleukin 17 Receptor Alpha</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Board of Director Appointments</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On July&#160;21, 2019, our Board of Directors, or the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed each of Timothy P. Walbert and Jeffrey L. Cleland to the Board, effective immediately. Each of Mr. Walbert and Dr. Cleland will serve as a Class&#160;II director, to hold office until the date of the annual meeting of stockholders following the year ending December&#160;31, 2021 or until his earlier death, resignation or removal.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Immediately following completion of the offering, we expect to appoint an individual designated by Abingworth LLP, an expected investor in the offering, to serve as a member of the Board and a Class I Director, and we may appoint an additional director recommended by another expected investor in the offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Financial Update</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">While we have not finalized our full financial results for the fiscal quarter ended June 30, 2019, we expect to report that we had approximately $17.2 million of cash as of June 30, 2019. This amount is preliminary, has not been audited and is subject to change pending completion of our unaudited financial statements for the three and six months ended June&#160;30, 2019. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of June 30, 2019. We expect to complete our unaudited financial statements for the quarter ended June&#160;30, 2019 subsequent to the completion of this offering. It is possible that we or our independent registered public accounting firm may identify items that require us to make adjustments to the preliminary estimated cash balance set forth above and those changes could be material. </font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Accordingly, undue reliance should not be placed on this preliminary estimate. The preliminary estimate is not necessarily indicative of any future period and should be read together with the sections titled &#8220;Risk Factors&#8221; and &#8220;Note Regarding Forward-Looking Statements&#8221; in this prospectus supplement, and our financial statements, related notes and other financial information incorporated by reference herein.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Corporate Information </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We were originally incorporated in the State of Delaware on February 6, 2017 under the name &#8220;Max-1 Acquisition Corporation.&#8221; Prior to the Merger (as defined below), Max-1 was a &#8220;shell&#8221; company registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act, with no specific business plan or purpose until it began operating the business of Exicure Operating Company, or Exicure OpCo, through a transaction on September 26, 2017, or the Merger. Exicure OpCo was originally formed as a limited liability company under the name AuraSense Therapeutics, LLC in the State of Delaware in June 2011 and was a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. AuraSense Therapeutics, LLC was subsequently converted into AuraSense Therapeutics, Inc., a Delaware corporation, on July 9, 2015, and changed its name on the same date to Exicure, Inc. Immediately after giving effect to the Merger and the initial closing of the 2017 Private Placement, the business of Exicure OpCo became our business. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our corporate headquarters are located at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077, and our telephone number is (847) 673-1700. We maintain a website at www.exicuretx.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or our other filings with the SEC, and should not be relied upon. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-5</font></div></div><hr style="page-break-after:always"><div><a name="sdb0d5914a63c43d2b90646964d9dbc12"></a></div><div><br></div><div style="padding:48px 48px 48px 48px; border:0.5pt solid #000000;"><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">THE OFFERING</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:32%;"></td><td style="width:68%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock offered by us</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriters&#8217; option to purchase additional shares</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have granted the underwriters an option for a period of up to 30 days from the date of this prospectus supplement to purchase up to an additional          shares of our common stock at the public offering price less the underwriting discounts and commissions. </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock to be outstanding after this offering</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;shares (                shares assuming the underwriters exercise in full their option to purchase          additional shares). </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Use of proceeds</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to use the net proceeds from this offering (i) to advance AST-008 through a Phase 1b/2 clinical trial; (ii) to develop an SNA therapeutic candidate for a neurology condition and advance it into Phase 1 clinical trials; and (iii) for general corporate purposes. See &#8220;Use of Proceeds.&#8221;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk factors</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page S-7 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OTCQB </font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Market Symbol</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XCUR</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Anticipated Nasdaq Symbol</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with this offering, our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;XCUR.&#8221;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Outstanding Shares</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The number of shares of our common stock to be outstanding after this offering is based on 44,358,000 shares of our common stock outstanding as of March 31, 2019, and excludes: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,125,659 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2019 at a weighted-average exercise price of $2.26 per share; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,790 shares of our common stock issued upon stock option exercises subsequent to March 31, 2019 through July 29, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,750 shares of our common stock reserved under the Exicure, Inc. 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694,372 shares of our common stock reserved for issuance under the Exicure, Inc. 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">413,320 shares of our common stock issuable upon the exercise of outstanding warrants as of March 31, 2019, at a weighted average exercise price of $3.00 per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as otherwise indicated herein, all information in this prospectus supplement, including the number of shares that will be outstanding after this offering, does not assume or give effect to the exercise of the underwriters&#8217; option to purchase additional shares in this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain of our existing stockholders, who are affiliated with certain of our directors, have indicated an interest in purchasing up to an aggregate of approximately $         million in shares of common stock in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of common stock in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, fewer or no shares of common stock in this offering.</font></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-6</font></div></div><hr style="page-break-after:always"><div><a name="s0de3f0d68d1642109563c706f1afeec7"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Investing in our common stock involves a high degree of risk. Before investing in our common stock, you should carefully consider the risks described below, together with all of the other information contained in this prospectus supplement and the accompanying prospectus and incorporated by reference herein and therein, including from our Annual Report on Form 10-K for the year ended December 31, 2018, as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC. Some of these factors relate principally to our business and the industry in which we operate. Other factors relate principally to your investment in our securities. The risks and uncertainties described therein and below are not the only risks facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially and adversely affect our business and operations. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">If any of the matters included in the following risks were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially and adversely affected. In such case, you may lose all or part of your investment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to this Offering </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">You will experience immediate and substantial dilution in the net tangible book value per share of the common stock you purchase in this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The offering price per share of our common stock being offered is substantially higher than the net tangible book value per share of our outstanding common stock. As a result, investors purchasing shares of our common stock in this offering will incur immediate dilution of $     per share, after giving effect to the sale of an aggregate of             shares of our common stock at an offering price of $      per share, and after deducting underwriting fees and estimated offering expenses payable by us. As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. See &#8220;Dilution&#8221; on page S-15 of this prospectus supplement for a more detailed discussion of the dilution you will incur if you purchase shares of our common stock in this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, as of March 31, 2019, we had outstanding options to acquire 5,125,659 shares of our common stock and outstanding warrants to acquire 413,320 shares of our common stock. The issuance of shares of our common stock upon exercise of the stock options or warrants could result in dilution to the interests of other holders of our common stock and could adversely affect our stock price. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Substantial future sales or other issuances of our common stock could depress the market for our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Sales of a substantial number of shares of our common stock, or the perception by the market that those sales could occur, could cause the market price of our common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with this offering, we and our directors, executive officer, and certain of our significant stockholders have entered into lock-up agreements for a period of 90 days following this offering (which period may be extended under certain circumstances). We and our directors, executive officers, and certain of our significant stockholders may be released from such lock-up agreements prior to the expiration of the lock-up period at the sole discretion of Guggenheim Securities (See &#8220;Underwriting&#8221; beginning on page S-21 of this prospectus supplement). Upon expiration or earlier release of the lock-up, we and our directors, executive officers and certain of our significant stockholders may sell shares into the market, which could adversely affect the market price of shares of our common stock. </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Future issuances of our common stock or our other equity securities could further depress the market for our common stock. We expect to continue costs associated with our research and development programs, such as the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">therapeutic candidates, and general and administrative costs associated with our operations, and to satisfy our funding requirements, we may need to sell additional equity securities. The sale or the proposed sale of substantial amounts of our common stock or our other equity securities may adversely affect the market price of our common stock and our stock price may decline substantially. Our stockholders may experience substantial dilution and a reduction in the price that they are able to obtain upon sale of their shares. New equity securities issued may have greater rights, preferences or privileges than our existing common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have broad discretion in the use of the net proceeds of this offering and, despite our efforts, we may use the net proceeds in a manner that does not increase the value of your investment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our management will have broad discretion in the application of our existing cash and the net proceeds from this offering, including for any of the purposes described in the section titled "Use of Proceeds," and you will not have the opportunity as part of your investment decision to assess whether such proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our existing cash and the net proceeds from this offering in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may not be able to meet the continued listing requirements for the Nasdaq Capital Market or another nationally recognized stock exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading restrictions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is quoted on the OTC Market Group&#8217;s OTCQB </font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">Market quotation system under the ticker symbol &#8220;XCUR.&#8221; In connection with this offering, our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;XCUR.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Further, in order to remain listed on the Nasdaq Capital Market, we will be required to meet the continued listing requirements of the Nasdaq Capital Market or  any other U.S. or nationally recognized stock exchange to which we may apply and be approved for listing. We may be unable to satisfy these continued listing requirements, and there is no guarantee that our common stock will remain listed on the Nasdaq Capital Market or any other U.S. or nationally recognized stock exchange. If, after listing, our common stock is delisted from the Nasdaq Capital Market or any other U.S. or nationally recognized stock exchange, we could face significant material adverse consequences, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a limited availability of market quotations for our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduced liquidity with respect to the market for our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a determination that our common stock is a &#8220;penny stock,&#8221; which will require brokers trading in our common stock to adhere to different rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a limited amount of news and analyst coverage; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased ability to issue additional shares of our common stock or obtain additional financing in the future.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">An active trading market for our common stock may never develop following this offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Prior to this offering, trading in our common stock on the OTC Market Group&#8217;s OTCQB </font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">Market quotation system has been limited and sporadic. An active trading market for our common stock may never develop or be sustained, which may affect your ability to sell your common stock and could depress the market price of your </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">common stock. In connection with this offering, our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;XCUR.&#8221;  Listing on the Nasdaq Capital Market may not ensure that an actual market will develop for our common stock. As a result, no assurances can be given that you will be able to readily sell your common stock at a price equal to or above the price you paid.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We do not currently intend to pay dividends on our common stock, and any return to investors is expected to come, if at all, only from potential increases in the price of our common stock. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have never declared or paid cash dividends on our capital stock, and you should not rely on an investment in our common stock to provide dividend income. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, our term loan facility contains certain covenants that limit our ability to pay or make any dividend and the terms of any future debt agreements may further preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-9</font></div></div><hr style="page-break-after:always"><div><a name="sc4095f7a0fb04618874d77e4f6b95c2a"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus supplement, together with the accompanying prospectus includes and incorporates by reference &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this prospectus supplement and the accompanying prospectus. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing,&#8221; &#8220;goal,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and IND application, Investigational Medicinal Product Dossier, CTA, New Drug Application, or NDA, or other regulatory submissions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our or a current or future collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance of any approved therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commercialization of any approved therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to establish and maintain collaborations and retain commercial rights for our therapeutic candidates in the collaborations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates of our expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to our need for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain additional funds for our operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reliance on third parties to conduct our preclinical studies and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ability of our third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;our ability to attract and retain qualified key management and technical personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;our financial performance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our use of proceeds from this offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In Part II., Item 9A. Controls and Procedures of our Annual Report on Form 10-K for the year ended December 31, 2018, which is incorporated by reference in this prospectus supplement, the statements regarding our internal controls; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the impact of government regulation and developments relating to our competitors or our industry. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks and uncertainties outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus supplement and the accompanying prospectus, and in any other documents incorporated herein or therein (including in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and other filings we make with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any forward-looking statement in this prospectus supplement and the accompanying prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus supplement also contains estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-11</font></div></div><hr style="page-break-after:always"><div><a name="s6d5dfe5bcf3840f6bd8e1a264bb00fa2"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $    million, or approximately $     million if the underwriters exercise their option to purchase additional shares in full, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently intend to use the net proceeds from this offering to (i) to advance AST-008 through a Phase 1b/2 clinical trial; (ii) to develop an SNA therapeutic candidate for a neurology condition and advance it into Phase 1 clinical trials; and (iii) for general corporate purposes. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The amounts and timing of our use of the net proceeds from this offering will depend on a number of factors, such as the timing and progress of our commercialization efforts, research and development efforts, the timing and progress of any partnering efforts, technological advances and the competitive environment for our products. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from the sale of the shares of our common stock offered by us hereunder. Accordingly, our management will have broad discretion in the timing and application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-12</font></div></div><hr style="page-break-after:always"><div><a name="s7dcd0dc2d6c34aac9ecd65fa17679e1a"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAPITALIZATION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table sets forth our cash and our capitalization as of March&#160;31, 2019:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on an actual basis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">on an as adjusted basis to reflect the sale by us of&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock in this offering at the public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">You should read the data set forth in the table below in conjunction with our financial statements, including the related notes, and "Management's Discussion and Analysis of Financial Condition and Results of Operations" from&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">our Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2019, which is incorporated by reference into this prospec</font><font style="font-family:inherit;font-size:10pt;color:#000000;">tus supplement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of March 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjusted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(unaudited)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,196</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding, actual and as adjusted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.0001 par value; 200,000,000 shares authorized, 44,358,000 shares issued and outstanding, actual;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares issued and outstanding, as adjusted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,431</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total capitalization</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;The number of shares of our common stock to be outstanding after this offering is based on 44,358,000 shares of our common stock outstanding as of March 31, 2019, and excludes: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,125,659 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2019 at a weighted-average exercise price of $2.26 per share; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,790 shares of our common stock issued upon stock option exercises subsequent to March 31, 2019 through July 29, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,750 shares of our common stock reserved under the ESPP; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694,372 shares of our common stock reserved for issuance under the 2017 Plan; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">413,320 shares of our common stock issuable upon the exercise of outstanding warrants as of March 31, 2019, at a weighted average exercise price of $3.00 per share.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as otherwise indicated herein, all information in this prospectus supplement, including the number of shares that will be outstanding after this offering, does not assume or give effect to the exercise of the underwriters&#8217; option to purchase additional shares in this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-14</font></div></div><hr style="page-break-after:always"><div><a name="s21e859dac72a4c7884c7d129bc08b734"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DILUTION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Purchasers of our common stock in this offering will experience immediate dilution to the extent of the difference between the public offering price per share of our common stock, and the as adjusted net tangible book value per share of our common stock immediately after this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our net tangible book value as of March 31, 2019 was approximately $15.6 million, or $0.35 per share of our common stock. Net tangible book value per share of our common stock is determined by dividing total tangible assets less total liabilities, excluding items such as intangibles, by the aggregate number of shares of our common stock outstanding as of March 31, 2019. Dilution per share to new investors represents the difference between the amount per share paid by purchasers for our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately following the completion of this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">After giving effect to the sale of                 shares of our common stock in this offering at the public offering price of $     per share, and after deducting the underwriting discounts and commissions and the estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2019 would have been approximately $    , or approximately $     per share of our common stock. This represents an immediate increase in net tangible book value of $     per share of our common stock to our existing stockholders and an immediate dilution in net tangible book value of $     per share of our common stock to purchasers in this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table illustrates this calculation on a per share basis: </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Offering price per share in this offering</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net tangible book value per share as of March 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.35</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increase in net tangible book value per share attributable to purchasers in this offering</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As adjusted net tangible book value per share immediately after this offering</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilution per share to purchasers in this offering</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If the underwriters exercise their option in full to purchase additional shares of our common stock in this offering at the public offering price of $    per share, the as adjusted net tangible book value per share after the offering would be $    per share, the decrease in the net tangible book value per share to existing stockholders would be $    per share and the dilution to new investors purchasing securities in this offering would be $   per share. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The above table is based on 44,358,000 shares of our common stock outstanding as of March 31, 2019. Unless specifically stated otherwise, the information in this prospectus supplement is as of March 31, 2019 and excludes: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,125,659 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2019 at a weighted-average exercise price of $2.26 per share; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,790 shares of our common stock issued upon stock option exercises subsequent to March 31, 2019 through July 29, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">431,750 shares of our common stock reserved under the ESPP; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">694,372 shares of our common stock reserved for issuance under the 2017 Plan; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">413,320 shares of our common stock issuable upon the exercise of outstanding warrants as of March 31, 2019, at a weighted average exercise price of $3.00 per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as otherwise indicated herein, all information in this prospectus supplement, including the number of shares that will be outstanding after this offering, does not assume or give effect to the exercise of the underwriters&#8217; option to purchase additional shares in this offering. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To the extent that options or warrants are exercised, other equity awards vest, new equity awards are issued under the 2017 Plan or pursuant to inducement awards, or we issue additional shares of common stock in the future, there may be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-16</font></div></div><hr style="page-break-after:always"><div><a name="s136836b275e74deca2c3ae6ee02e371a"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following discussion is a summary of certain material U.S. federal income tax considerations for non-U.S. holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a non-U.S. holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a non-resident alien individual;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax purposes; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any such change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus. There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a non-U.S. holder holds shares of our common stock as a capital asset within the meaning of Section 1221 of the Code, generally property held for investment.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#8217;s individual circumstances nor does it address U.S. state, local or non-U.S. taxes, the alternative minimum tax, the rules regarding qualified small business stock within the meaning of Section 1202 of the Code, the Medicare tax on net investment income or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">insurance companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">tax-exempt or governmental organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">financial institutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">brokers or dealers in securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulated investment companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pension plans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;qualified foreign pension funds&#8221; as defined in Section 897(I)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">persons that have a functional currency other than the U.S. dollar;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">persons deemed to sell our common stock under the constructive sale provisions of the Code;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;"><font style="font-family:inherit;font-size:10pt;">or other integrated investment;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">certain U.S. expatriates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This discussion is for general information only and is not tax advice. Accordingly, all prospective non-U.S. holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and non-U.S. tax consequences of the ownership and disposition of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Distributions on Our Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">As described in the &#8220;Risk Factors&#8221; section above, we do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#8217;s investment, up to such holder&#8217;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#8220;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#8221; Any such distributions will also be subject to the discussions below under the sections titled &#8220;Backup Withholding and Information Reporting&#8221; and &#8220;FATCA.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to the discussion in the following two paragraphs in this section, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dividends that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is a corporation may also, under certain circumstances, be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">A non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) to the applicable withholding agent and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Gain on Sale or Other Taxable Disposition of Our Common Stock</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to the discussions below under &#8220;Backup Withholding and Information Reporting&#8221; and &#8220;FATCA,&#8221; a non-U.S. holder generally will not be subject to any U.S. federal income or withholding tax on any gain realized upon such holder&#8217;s sale or other taxable disposition of shares of our common stock unless:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the gain is effectively connected with the non-U.S. holder&#8217;s conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such non-U.S. holder in the United States, in which case the non-U.S. holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the non-U.S. holder is a foreign corporation, the branch profits tax </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:8px;"><font style="font-family:inherit;font-size:10pt;">described above in &#8220;Distributions on Our Common Stock&#8221; also may apply;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the non-U.S. holder is a nonresident alien individual who is present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder, if any (even though the individual is not considered a resident of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the non-U.S. holder&#8217;s holding period, if shorter) a U.S. real property holding corporation, unless our common stock is regularly traded on an established securities market and the non-U.S. holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Backup Withholding and Information Reporting</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. holders may have to comply with specific certification procedures to establish that the holder is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above in &#8220;Distributions on Our Common Stock,&#8221; generally will be exempt from U.S. backup withholding.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">FATCA</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i) if the foreign entity is a &#8220;foreign financial institution,&#8221; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii) if the foreign entity is not a &#8220;foreign financial institution,&#8221; such foreign entity identifies certain of its U.S. investors, if any, or (iii) the foreign entity is otherwise </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">exempt under FATCA. Such withholding may also apply to gross proceeds from the sale or other disposition of our common stock, although under recently proposed U.S. Treasury Regulations, no withholding would apply to such gross proceeds. The preamble to the proposed regulations specifies that taxpayers (including withholding agents) are permitted to rely on the proposed regulations pending finalization. Under certain circumstances, a non-U.S. holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">The preceding discussion of U.S. federal income tax considerations is for general information only.  It is not tax advice.  Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-20</font></div></div><hr style="page-break-after:always"><div><a name="s3f7468131fd44e529cd4e71a9cb29f8c"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNDERWRITING</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Guggenheim Securities, LLC is acting as representative of each of the underwriters named below. Subject to the terms and conditions set forth in the underwriting agreement between us and the underwriters, each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.2991452991453%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Underwriter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Guggenheim Securities, LLC</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the non-defaulting underwriters may be increased or the underwriting agreement may be terminated. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The underwriters are offering the shares subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain of our existing stockholders, who are affiliated with certain of our directors, have indicated an interest in purchasing up to an aggregate of approximately $          million in shares of common stock in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer or no shares of common stock in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, fewer or no shares of common stock in this offering.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Commissions and Discounts; Expenses </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The underwriters have advised us that they propose initially to offer the shares to the public at the public offering price set forth on the cover of this prospectus supplement and to dealers at that price less a concession not in excess of $      per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following table shows the public offering price, underwriting discounts and commissions and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common stock from us, as applicable.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:53%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Full Exercise</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public offering price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Underwriting discounts and commissions to be paid by us</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds, before expenses, to us</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $               , which includes certain expenses incurred by the underwriters in connection with this offering that will be reimbursed by us. We have agreed to reimburse the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">underwriters for certain expenses incurred by them in connection with this offering (including certain fees and expenses of counsel for the underwriters in an amount not to exceed $225,000, and fees and expenses related to filings with and review by FINRA). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Option to Purchase Additional Shares </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have granted the underwriters an option to purchase up to an additional                &#160;shares of common stock at the public offering price, less the underwriting discounts and commissions, within 30 days from the date of this prospectus supplement. If the underwriters exercise this option, each underwriter will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#8217;s initial amount reflected in the above table. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">No Sales of Similar Securities </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with this offering, we have agreed with the underwriters that, subject to certain customary exceptions, without the prior written consent of Guggenheim Securities, LLC on behalf of the underwriters, we will not, for a period ending 90 days after the date of this prospectus supplement, or the Lock-Up Period, (a)&#160;directly or indirectly, issue, offer, sell, agree to issue, offer or sell, solicit offers to purchase, grant any call option, warrant or other right to purchase, purchase any put option or other right to sell, pledge, borrow or otherwise dispose of any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, or make any public announcement of any of the foregoing, (b)&#160;establish or increase any &#8220;put equivalent position&#8221; or liquidate or decrease any &#8220;call equivalent position&#8221; (in each case within the meaning of Section&#160;16 of the Exchange Act and the rules and regulations thereunder) with respect to any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, or (c)&#160;otherwise enter into any swap, derivative or other transaction or arrangement that transfers to another, in whole or in part, any economic consequence of ownership of any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, whether or not such transaction is to be settled by delivery of any shares of our common stock, securities convertible into or exercisable or exchangeable for shares of our common stock, other securities, cash or other consideration. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with this offering, certain of our stockholders and our directors and executive officers have agreed with the underwriters that, subject to certain customary exceptions, without the prior written consent of Guggenheim Securities, LLC on behalf of the underwriters, we and they will not, for the Lock-Up Period, directly or indirectly, (a)&#160;offer, sell, agree to offer or sell, solicit offers to purchase, grant any call option or purchase any put option with respect to, pledge, borrow or otherwise dispose of, any shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock, or (b)&#160;establish or increase any &#8220;put equivalent position&#8221; or liquidate or decrease any &#8220;call equivalent position&#8221; with respect to any shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock (in each case within the meaning of Section&#160;16 of the Exchange Act, and the rules and regulations promulgated thereunder), or otherwise enter into any swap, derivative or other transaction or arrangement that transfers to another, in whole or in part, any economic consequence of ownership of shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock, whether or not such transaction is to be settled by delivery of shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock, other securities, cash or other consideration. Guggenheim Securities, LLC may, in its sole discretion, permit the transfer of these shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock during the Lock-Up Period in whole or in part and at any time, with or without notice. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Nasdaq Capital Market Listing </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with this offering, our common stock has been approved for listing on the Nasdaq Capital Market under the symbol &#8220;XCUR.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Price Stabilization and Short Positions </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our common stock. However, the representative may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering. &#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option described above. The underwriters may close out any covered short position by either exercising their option or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. &#8220;Naked&#8221; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the closing of the offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Similar to other purchase transactions, the underwriters&#8217; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on The Nasdaq Capital Market, in the over-the-counter market or otherwise. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Passive Market Making </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any underwriters who are qualified market makers on The Nasdaq Capital Market may engage in passive market making transactions in the securities on The Nasdaq Capital Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Electronic Distribution </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Other Relationships </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">customary fees, commissions and expenses. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Selling Restrictions </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Notice to Prospective Investors in the European Economic Area </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Member State, with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of shares may be made to the public in that Relevant Member State other than: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representative; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">C.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">provided that no such offer of shares shall require us or the representative to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#8220;qualified investor&#8221; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the representative has been obtained to each such proposed offer or resale. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We, the representative and each of our and the representative&#8217;s and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus supplement has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering contemplated in this prospectus supplement may only do so in circumstances in which no obligation arises for us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for us or the underwriters to publish a prospectus for such offer. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">For the purpose of the above provisions, the expression &#8220;an offer to the public&#8221; in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#8220;2010 PD Amending Directive&#8221; means Directive 2010/73/EU. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">MiFID II Product Governance </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any person offering, selling or recommending the shares, or a distributor, should take into consideration the manufacturers&#8217; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the shares (by either adopting or refining the manufacturers&#8217; target market assessment) and determining appropriate distribution channels. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Notice to Prospective Investors in the United Kingdom </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; (as defined in the Prospectus Directive)&#160;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Notice to Prospective Investors in Canada </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument&#160;45-106&#160;Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&#160;31-103&#160;Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Pursuant to section 3A.3 of National Instrument&#160;33-105</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#160;Underwriting Conflicts</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;(NI&#160;33-105),&#160;the underwriters are not required to comply with the disclosure requirements of NI&#160;33-105&#160;regarding underwriter conflicts of interest in connection with this offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-25</font></div></div><hr style="page-break-after:always"><div><a name="s646a769de5614dfc8e42e01a434529f6"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Redwood City, California. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo LLP, Boston, Massachusetts, is acting as counsel for the underwriters in connection with certain legal matters related to this offering.</font></div><div><a name="sfcf5b8dd4dd94ba98f9259f5d88e5bfd"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The consolidated financial statements of Exicure, Inc. as of December 31, 2018 and 2017, and for each of the years in the two-year period ended December 31, 2018, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. &#160;The audit report covering the December 31, 2018 consolidated financial statements refers to the adoption of Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 606,&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The audit report covering the December 31, 2018 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and will be required to raise additional capital or alternative means of financial support to fund operations, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</font></div><div><a name="s80fbb0e66354466fafb532484d402d23"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">http://www.sec.gov</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We make available free of charge on our website our annual, quarterly and current reports, including amendments to such reports, as soon as reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. Please note, however, that we have not incorporated any other information by reference from our website, other than the documents listed under the heading &#8220;Incorporation of Certain Information by Reference&#8221; on page S-27 of this prospectus supplement. In addition, you may request copies of these filings at no cost by writing or telephoning us at the following address or telephone number: </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8045 Lamon Avenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Suite 410</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Skokie, IL 60077</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(847) 673-1700</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-26</font></div></div><hr style="page-break-after:always"><div><a name="saac52903fd7d427580da07d81af78779"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">SEC rules permit us to incorporate information by reference in this prospectus and the applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and the applicable prospectus supplement, except for information superseded by information contained in this prospectus or the applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and the applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (Commission File No. 000-55764), other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 8, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our Quarterly Reports on Form 10-Q and Form 10-Q/A for the fiscal quarter ended March 31, 2019, filed with the SEC on May 8, 2019 and May 14, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our Definitive Proxy Statement on Schedule 14A (other than information furnished rather than filed), filed with the SEC on April&#160;30, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our Current Reports on Form&#160;8-K&#160;filed with the SEC on February 1, 2019, February 22, 2019, March 14, 2019, June 17, 2019, June 27, 2019 (other than information&#160;furnished&#160;rather than filed) and July 23, 2019; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the description of our common stock contained in our Form 10-12(g) filed with the SEC on March 21, 2017, and any amendment or report filed thereafter for the purpose of updating such information. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or the applicable prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To obtain copies of these filings, see &#8220;Where You Can Find More Information&#8221; on page S-26 of this prospectus supplement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">S-27</font></div></div><hr style="page-break-after:always"><div><a name="s56E34EA2540C54F286EF973B4F4D3139"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROSPECTUS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="image96.jpg" alt="image96.jpg" style="height:61px;width:254px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$125,000,000</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt Securities</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Depositary Shares </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Rights </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Units </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:23.717948717948715%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">From time to time, we may sell up to an aggregate total offering price of $125,000,000 of our shares of Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants, other Rights or Units, in each case in one or more issuances and at prices and on terms that we will determine at the time of the offering. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus describes the general manner in which any of these securities may be offered using this prospectus. We will specify in an accompanying prospectus supplement the terms of the securities offered and other details regarding the offering thereof. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is quoted on the OTC Market Group&#8217;s OTCQB</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Market quotation system under the ticker symbol &#8220;XCUR.&#8221; On July 10, 2019, the last reported sale price of our common stock was $2.65 per share.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The securities covered by this prospectus may be sold directly by us to investors, through agents designated by us from time to time or through underwriters or dealers at prices and on terms to be determined at the time of offering. We will include in an applicable prospectus supplement the names of any underwriters or agents and any applicable commissions or discounts. Additional information on the methods of sale appears under &#8220;Plan of Distribution&#8221; in this prospectus. We will also describe in an applicable prospectus supplement the way(s) in which we expect to use the net proceeds we receive from any sale. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:23.717948717948715%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">We are an &#8220;emerging growth company&#8221; as defined under the federal securities laws, and, as such, are eligible for reduced public company reporting requirements. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Investing in our common stock involves a high degree of risk. Before making an investment decision, please read &#8220;Risk Factors&#8221; on page </font><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC2BC7DCAB55C5E7782901F2AE71DC1B9"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10</font></a><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;of this prospectus, as well as &#8220;Special Note Regarding Forward-Looking Statements&#8221; on page </font><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s657DDCC6965854D8B39227E8891D3D47"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4</font></a><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;of this prospectus. You should read the entire prospectus carefully before you make your investment decision. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus or any accompanying prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">This prospectus may not be used to offer or sell any securities unless accompanied by a prospectus supplement.&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">The date of this prospectus is&#160;July 24, 2019.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s1521271BBC855BCAB264A071F35477F5"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:92%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB47EA0831745F109CA35BF5AE13E50F"><font style="font-family:inherit;font-size:10pt;">ABOUT THIS PROSPECTUS</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCB47EA0831745F109CA35BF5AE13E50F">1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3ADC48A609650CA9B60D9ED405B39DF"><font style="font-family:inherit;font-size:10pt;">WHERE YOU CAN FIND MORE INFORMATION</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF3ADC48A609650CA9B60D9ED405B39DF">1</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s28EAC80121DF516CB2FF397855E2926E"><font style="font-family:inherit;font-size:10pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s28EAC80121DF516CB2FF397855E2926E">2</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s657DDCC6965854D8B39227E8891D3D47"><font style="font-family:inherit;font-size:10pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s657DDCC6965854D8B39227E8891D3D47">4</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF0CDF82958F5688859BF5383D78F29D"><font style="font-family:inherit;font-size:10pt;">ABOUT THE COMPANY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBF0CDF82958F5688859BF5383D78F29D">6</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC2BC7DCAB55C5E7782901F2AE71DC1B9"><font style="font-family:inherit;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC2BC7DCAB55C5E7782901F2AE71DC1B9">10</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49FA59900F7A58ABA13E8D7E0354865C"><font style="font-family:inherit;font-size:10pt;">USE OF PROCEEDS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s49FA59900F7A58ABA13E8D7E0354865C">11</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s820955F6EC6E5C07941B4FBF3118214E"><font style="font-family:inherit;font-size:10pt;">DIVIDEND POLICY</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s820955F6EC6E5C07941B4FBF3118214E">12</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76B3E07129B85BD293A782F3FC42D6D8"><font style="font-family:inherit;font-size:10pt;">GENERAL DESCRIPTION OF SECURITIES WE MAY OFFER</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s76B3E07129B85BD293A782F3FC42D6D8">13</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56418280EEB357A18C7731BA63FBBC80"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF CAPITAL STOCK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s56418280EEB357A18C7731BA63FBBC80">14</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CE3FE94DABC504791FE039F62658173"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF DEBT SECURITIES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CE3FE94DABC504791FE039F62658173">19</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE5C4C8641B3153CFA20ECC9D053E5E11"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF DEPOSITARY SHARES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE5C4C8641B3153CFA20ECC9D053E5E11">26</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC029E39C898D5A8D93511EA101977BE7"><font style="font-family:inherit;font-size:10pt;">DESCRIPTION OF WARRANTS, OTHER RIGHTS AND UNITS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC029E39C898D5A8D93511EA101977BE7">27</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s48671C3AA9CE51BA96105E2B5C636502"><font style="font-family:inherit;font-size:10pt;">PLAN OF DISTRIBUTION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s48671C3AA9CE51BA96105E2B5C636502">29</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE6DBF9466A7531AA0036D49F4137DD2"><font style="font-family:inherit;font-size:10pt;">LEGAL MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE6DBF9466A7531AA0036D49F4137DD2">32</a></div></td></tr><tr><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7E3A28EE30F577A834B442EEF79CF65"><font style="font-family:inherit;font-size:10pt;">EXPERTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7E3A28EE30F577A834B442EEF79CF65">33</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">You should rely only on the information contained or incorporated by reference in this prospectus and in an applicable prospectus supplement to this prospectus. We have not authorized any other person to provide you with different or additional information. If anyone provides you with different, additional or inconsistent information, you should not rely on it. We do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making an offer to sell these securities or soliciting any offer to buy these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any applicable prospectus supplement or any free writing prospectus we authorize to be delivered to you is accurate only as of the date of that document or any other date set forth in that document. Additionally, any information we have incorporated by reference in this prospectus or in any applicable prospectus supplement is accurate only as of the date of the document incorporated by reference or other date set forth in that document, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any sale of securities. Our business, financial condition, results of operations, cash flow and prospects may have changed since that date. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">This prospectus, any applicable prospectus supplement and the information incorporated herein or therein by reference contains market data, industry statistics and other data that have been obtained or compiled from information made available by independent third parties. We have not independently verified the accuracy and completeness of such data. This prospectus, any applicable prospectus supplement and the information incorporated herein or therein by reference include trademarks, service marks and trade names owned by us or other companies. Solely for convenience, we may refer to our trademarks included or incorporated by reference in this prospectus, any applicable prospectus supplement or any free writing prospectus without the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;or </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;symbols, but any such references are not intended to indicate that we will not assert, to the fullest extent permitted under applicable law, our rights to our trademarks or other intellectual property. All trademarks, service marks and trade names included or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners. Use or display by us of other parties&#8217; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#160;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Except where the context otherwise requires, when used in this prospectus, the terms &#8220;Exicure,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Exicure, Inc., a Delaware corporation,</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">and, where appropriate, its subsidiaries.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ii</font></div></div><hr style="page-break-after:always"><div><a name="sCB47EA0831745F109CA35BF5AE13E50F"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THIS PROSPECTUS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus forms a part of a registration statement that we have filed with the U.S. Securities and Exchange Commission, or the SEC, using a shelf registration process. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">By using a shelf registration statement, we may, from time to time, offer and sell the securities described in this prospectus with an aggregate total offering price not exceeding $125,000,000 in one or more offerings. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus describes the general manner in which we may offer the securities described in this prospectus. Each time we sell securities pursuant to the registration statement we will provide a prospectus supplement that will contain specific information about the offering and the securities offered, and may also add, update or change information contained in this prospectus. If there is any inconsistency between information in this prospectus and any accompanying prospectus supplement, you should rely on the information in the most recent applicable prospectus supplement and documents incorporated by reference herein and therein. This prospectus may not be used to offer to sell, solicit an offer to buy or consummate a sale of our securities unless it is accompanied by a prospectus supplement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus, together with any accompanying prospectus supplement, contains important information you should know before investing in our securities, including important information about us and the securities being offered. You should carefully read both documents, as well as the additional information contained in the documents described under &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in both this prospectus and the applicable prospectus supplement, and in particular the annual quarterly and current reports and other documents we file with the SEC. Neither this prospectus nor any accompanying prospectus supplement is an offer to sell these securities or is soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </font></div><div><a name="sF3ADC48A609650CA9B60D9ED405B39DF"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933, as amended, or the Securities Act, with respect to the securities offered by this prospectus and the applicable prospectus supplement. This prospectus and the applicable prospectus supplement do not contain all of the information set forth in the registration statement and its exhibits and schedules in accordance with SEC rules and regulations. For further information with respect to us and the securities being offered by this prospectus and the applicable prospectus supplement, you should read the registration statement, including its exhibits and schedules. Statements contained in this prospectus and the applicable prospectus supplement, including documents that we have incorporated by reference, as to the contents of any contract or other document referred to are not necessarily complete, and, with respect to any contract or other document filed as an exhibit to the registration statement or any other such document, each such statement is qualified in all respects by reference to the corresponding exhibit. You should review the complete contract or other document to evaluate these statements. You may obtain copies of the registration statement and its exhibits through the SEC&#8217;s website or through us, at www.sec.gov or at our website www.exicuretx.com.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers, including us, that file electronically with the SEC. You may obtain documents that we file with the SEC through the SEC&#8217;s website or through us, at www.sec.gov or at our website </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:underline;">www.exicuretx.com</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our website and the information contained or connected to our website is not incorporated by reference in this prospectus or any prospectus supplement, and you should not consider it part of this prospectus or any prospectus supplement. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s28EAC80121DF516CB2FF397855E2926E"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">SEC rules permit us to incorporate information by reference in this prospectus and the applicable prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this prospectus and the applicable prospectus supplement, except for information superseded by information contained in this prospectus or the applicable prospectus supplement itself or in any subsequently filed incorporated document. This prospectus and the applicable prospectus supplement incorporate by reference the documents set forth below that we have previously filed with the SEC (Commission File No. 000-55764), other than information in such documents that is deemed to be furnished and not filed. These documents contain important information about us and our business and financial condition. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 8, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our Quarterly Reports on Form 10-Q and Form 10-Q/A for the quarterly period ended March 31, 2019, filed with the SEC on May 8, 2019 and May 14, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our Definitive Proxy Statement on Schedule 14A (other than information furnished rather than filed), filed with the SEC on April&#160;30, 2019; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our Current Reports on Form&#160;8-K&#160;filed with the SEC on February 1, 2019, February 22, 2019, March 14, 2019, June 17, 2019 and June 27, 2019 (</font><font style="font-family:inherit;font-size:10pt;color:#000000;">other than information&#160;furnished&#160;rather than filed)</font><font style="font-family:inherit;font-size:10pt;color:#000000;">; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the description of our common stock contained in our Form 10-12(g) filed with the SEC on March 21, 2017, and any amendment or report filed thereafter for the purpose of updating such information.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of the initial registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, and any previously filed documents. All documents that we file (but not those that we furnish) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after the date of this prospectus and prior to the termination of the offering of any of the securities covered under this prospectus shall be deemed to be incorporated by reference into this prospectus and will automatically update and supersede the information in this prospectus, the applicable prospectus supplement and any previously filed documents. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this prospectus or the applicable prospectus supplement shall be deemed to be modified or superseded for purposes of this prospectus and such applicable prospectus supplement to the extent that a statement contained in this prospectus or such applicable prospectus supplement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus and such applicable prospectus supplement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus or such applicable prospectus supplement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Documents incorporated by reference are available from us without charge, excluding all exhibits unless specifically incorporated by reference as an exhibit to this prospectus and the applicable prospectus supplement. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">Prospective investors may obtain documents incorporated by reference in this prospectus and the applicable prospectus supplement by requesting them in writing or by telephone from us at our executive offices at: </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exicure, Inc. </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8045 Lamon Avenue</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Suite 410</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Skokie, IL 60077 </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(847) 673-1700 </font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Attention: Investor Relations and Corporate Communications</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s657DDCC6965854D8B39227E8891D3D47"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus, together with any accompanying prospectus supplement, includes and incorporates by reference &#8220;forward-looking statements&#8221; within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this prospectus. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing,&#8221; &#8220;goal,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials and Investigational New Drug application, or IND, Investigational Medicinal Product Dossier, Clinical Trial Application, or CTA, New Drug Application, or NDA, or other regulatory submissions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our receipt and timing of any milestone payments or royalties under any current or future research collaboration and license agreements or arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to identify and develop therapeutic candidates for treatment of additional disease indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our or a current or future collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the rate and degree of market acceptance of any approved therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the commercialization of any approved therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to establish and maintain collaborations and retain commercial rights for our therapeutic candidates in the collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the implementation of our business model and strategic plans for our business, technologies and therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our estimates of our expenses, ongoing losses, future revenue and capital requirements, including our expectations relating to our need for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to obtain additional funds for our operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to obtain and maintain intellectual property protection for our technologies and therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our reliance on third parties to conduct our preclinical studies and clinical trials</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the ability of our third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our ability to attract and retain qualified key management and technical personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">our financial performance;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In Part II., Item 9A. Controls and Procedures of our Annual Report on Form 10-K for the year ended December 31, 2018, which is incorporated by reference in this prospectus, the statements regarding our internal controls; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the impact of government regulation and developments relating to our competitors or our industry.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. In evaluating such forward-looking statements, you should specifically consider various factors that may cause actual results to differ materially from current expectations, including the risks and uncertainties outlined under the heading &#8220;Risk Factors&#8221; contained in this prospectus and any related free writing prospectus, and in any other documents incorporated herein or therein (including in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and other filings we make with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act). </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any forward-looking statement in this prospectus reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. No forward-looking statement is a guarantee of future performance. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus, together with any accompanying prospectus supplement, also contains estimates, projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sBF0CDF82958F5688859BF5383D78F29D"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ABOUT THE COMPANY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">The following highlights information about us and our business contained elsewhere or incorporated by reference in this prospectus. It is not complete and does not contain all of the information that you should consider before investing in any of our securities. You should carefully read this prospectus together with the more detailed information incorporated by reference in this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA, technology. SNAs are nanoscale constructs consisting of densely packed synthetic nucleic acid sequences that are radially arranged in three dimensions. We believe the design of our SNAs gives rise to distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and enable therapeutic activity outside of the liver. We have advanced SNA therapeutic candidates through three Phase 1 clinical trials. These include AST-008 addressing immuno-oncology, and XCUR17 and AST-005 addressing psoriasis.  We have also shown in preclinical studies that SNAs may have therapeutic potential in neurology, ophthalmology, pulmonology, and gastroenterology.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical development programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Immuno-oncology</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-008&#160;is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications.&#160;TLR9 agonists bind to and activate TLR9 receptors.  We believe&#160;AST-008&#160;may be used for immuno-oncology applications as a monotherapy or in combination with checkpoint inhibitors. Checkpoint inhibitors are therapeutics that prevent tumors from evading destruction by the immune system. We have observed that administration of&#160;AST-008&#160;as a monotherapy can have anti-tumor activity in mouse models of colon cancer, breast cancer, lymphoma and melanoma. We have also observed that, in preclinical studies in a variety of tumor models,&#160;AST-008,&#160;applied in combination with certain checkpoint inhibitors, exhibited anti-tumor responses and survival rates that were greater than those demonstrated by checkpoint inhibitors alone. We have also demonstrated that&#160;AST-008&#160;was active when administered subcutaneously, intratumorally or intravenously, in both prevention and established mouse tumor models. The administration of&#160;AST-008&#160;also produced localized as well as abscopal anti-tumor activity in mouse cancer models. Additionally, administration of AST-008 in combination with certain checkpoint inhibitors conferred adaptive immunity in breast and colon cancer mouse models.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the&#160;Company&#160;that our proposed Phase1b/2 trial may proceed.  During the first half of 2019, we opened five clinical sites and began recruiting and dosing patients in that trial.  This is a Phase 1b/2, open-label, multi-center trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors.  We planned to recruit patients with advanced or metastatic: Merkel cell carcinoma, head and neck squamous cell carcinoma, cutaneous squamous cell carcinoma and melanoma.  The primary outcome measure is the safety and tolerability of&#160;AST-008&#160;alone and in combination with pembrolizumab.  Secondary outcomes include the recommended Phase 2 dose and disease assessment with RECIST 1.1.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inflammatory diseases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">XCUR17</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">XCUR17, is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha, or&#160;IL-17RA,&#160;a protein that is considered essential in the initiation and maintenance of psoriasis. Although the availability of inhibitors of TNF revolutionized the systemic treatment of severe psoriasis, studies of disease pathogenesis have shifted attention to the&#160;IL-17&#160;pathway, in which&#160;IL-17RA&#160;is a key driver of psoriasis. Our strategy is to reduce the levels of&#160;IL-17RA&#160;in the skin by topically applying XCUR17. In preclinical studies, XCUR17 inhibited&#160;IL-17RA&#160;in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">keratinocytes of the skin.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;We filed a CTA for a Phase 1 clinical trial of XCUR17 in patients with psoriasis in Germany in the third quarter of 2017 and we began dosing patients in April 2018. The Phase 1 clinical trial, which had final patient visits in the fourth quarter of 2018, was a randomized, double-blinded, placebo-controlled trial in twenty-one patients with mild to moderate chronic plaque psoriasis designed to assess the safety of XCUR17 formulated as a topical gel, and to evaluate early signs of efficacy. All patients received three strengths of XCUR17 gel, a vehicle gel, and a positive comparator (Daivonex&#174; cream), which were all applied on different areas of psoriatic skin within each individual patient.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17.  In the case of XCUR17, of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">There were no adverse safety events related to treatment with XCUR17 observed. In addition to the safety, tolerability and clinical assessments, the trial measured psoriatic infiltrate thickness over the 26-day treatment period. No relevant changes in mean psoriatic infiltrate thickness were observed for the three XCUR17 gels or the active ingredient-free vehicle gel. At this time, assessments of IL-17RA mRNA levels from skin biopsies collected from the treated areas in patients have not yet been correlated with the clinical or infiltrate thickness assessments.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dermelix License Agreement</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On February 17, 2019 we entered into a License and Development Agreement, or the Dermelix License Agreement, with DERMELIX, LLC, d/b/a Dermelix Biotherapeutics. Under the terms of agreement, Dermelix</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">licensed worldwide rights to research, develop, and commercialize Exicure&#8217;s technology for the treatment of Netherton Syndrome and, at Dermelix&#8217;s option, up to five additional rare skin indications.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Dermelix will initially develop a targeted therapy for the treatment of Netherton Syndrome (NS). NS is a rare and severe autosomal recessive disorder caused by loss-of-function mutations in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">SPINK5 </font><font style="font-family:inherit;font-size:10pt;color:#000000;">gene, which encodes the serine protease inhibitor LEKT1 involved in skin barrier function. NS affects approximately 1 in 200,000 children born each year, and is characterized by severely inflamed, red, scaled, itchy skin, and patients are at increased risk of mortality in the first year of life due to recurrent infections and dehydration as a result of the impaired skin barrier. Currently, there are no approved treatments for NS patients and off-label use of standard of care treatments are of limited utility.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under the terms of the Dermelix License Agreement, Exicure received an upfront payment of $1 million at closing of the transaction and will receive an additional $1 million upon the exercise of each of the five options granted to Dermelix. Exicure will be responsible for conducting the early stage development for each indication up to IND enabling toxicology studies.  Dermelix will undertake subsequent development, commercial activities and financial responsibility. For each of NS as well as any additional licensed product for which Dermelix exercises one of its options, Exicure is eligible to receive potential payments totaling up to $13.5 million upon achievement of certain development and regulatory milestones and up to $152.5&#160;million upon achievement of certain sales milestones per indication in each of six indications.  In addition, Exicure will receive low double-digit royalties on annual net sales for SNA therapeutics developed. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Other Inflammatory Diseases</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe that one of the key strengths of our proprietary SNAs is that they have the potential to enter a number of different cells and organs. As a consequence, we are also conducting early stage research activities in  ophthalmology, pulmonology, and gastroenterology.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We believe promising therapeutic targets for SNAs include antibody targets with confirmed therapeutic benefit. We envision inhibiting these targets with local application of SNAs in a variety of therapeutic areas. We believe that this approach combines the benefits of specifically inhibiting validated targets without the potential safety issues associated with systemic therapy.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Genetic disorders  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are investigating the utility of our SNA technology for the treatment of neurological conditions and have ongoing research programs underway.  In the fall of 2018, we completed a biodistribution study in rats comparing nusinersen to nusinersen in SNA format. Nusinersen, marketed by Biogen Inc., is a linear nucleic acid therapeutic approved by the FDA in late 2016 for the treatment of spinal muscular atrophy, or SMA. We found that more nusinersen in SNA format was retained in the rats&#8217; brain and spinal cord compared to nusinersen retained in the rats&#8217; brain and spinal cord at 24, 72 and 168 hours.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are now formulating our strategy for developing a pipeline of SNA therapeutics targeting neurological diseases.  Preclinical research is underway in a number of indications including, spinal muscular atrophy, Huntington&#8217;s disease, spinocerebellar ataxia type 3 (SCA3), SCA2, SCA1, Friedreich&#8217;s ataxia, and Batten disease.  We believe this preclinical research may lead to a therapeutic candidate for one of the above neurological indications.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">AST-005</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">AST-005 is&#160;an SNA targeting TNF for the treatment of mild to moderate psoriasis. AST-005 is intended to be administered locally in a gel to psoriatic lesions. In a completed Phase 1 clinical trial,&#160;AST-005,&#160;when topically administered to the skin of patients with mild to moderate psoriasis, resulted in no drug associated adverse events, and demonstrated a reduction of TNF mRNA. The TNF mRNA reduction elicited by the highest strength of&#160;AST-005&#160;gel was statistically significant when compared to the effects of the vehicle.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">On December&#160;2, 2016, we entered into a research collaboration, option and license agreement with Purdue Pharma L.P., referred to as the Purdue Collaboration. As part of our collaboration with Purdue, a Phase 1b clinical trial was conducted in Germany to evaluate the effect of AST-005 gel in patients with chronic plaque psoriasis. The trial demonstrated that AST-005 is safe and tolerable in patients at higher doses than were previously studied, however, the study did not result in a statistically significant decrease in echo lucent band thickness, one of the key indicators of efficacy in patients with psoriasis. In April 2018, Purdue notified the Company it had declined to exercise its option to develop AST-005 at that time, but that it also intended to retain rights relating to the TNF target, and Purdue reserved its right to continue joint development, with Exicure, of new anti-TNF drug candidates and to retain its exclusivity and other rights to AST-005.  </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In April 2019, Purdue notified us that it will not be selecting any collaboration targets pursuant to the Purdue Collaboration. As a result, we will not receive any research, regulatory and commercial sales milestones contingent upon successful development of such collaboration targets. Purdue re-asserted its right to develop new anti-TNF therapeutic candidates. At this time, there are no active development activities underway for a new anti-TNF therapeutic candidate. As a consequence, we also believe that it is highly unlikely that we will receive any research, regulatory and commercial sales milestones for any anti-TNF therapeutic candidates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We intend to build a leading nucleic acid therapeutics company based on our proprietary SNA technology. The key elements of our strategy are: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Advance AST-008 through clinical development for immuno-oncology applications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Continue research and development in neurological applications </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Advance SNA platform in dermatological indications. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Use our proprietary SNA technology to develop additional therapeutic candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Enter into additional partnerships to accelerate development and commercialization of our SNA therapeutic candidates; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Build, enhance and protect our proprietary SNA intellectual property.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Clinical Development Programs</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our clinical development programs include the development of one SNA therapeutic candidate to address unmet medical needs in the treatment of solid tumors and one SNA therapeutic candidate to address unmet medical needs in the treatment of mild to moderate psoriasis. We are also conducting early stage research activities in neurology, ophthalmology, respiratory and gastrointestinal applications. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The table below sets forth the stage of development of our SNA therapeutic candidates as of July 10, 2019:</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><img src="a201907developmentpipeline.jpg" alt="a201907developmentpipeline.jpg" style="height:167px;width:624px;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">TLR9 = Toll-like Receptor 9; IL17RA = Interleukin 17 Receptor Alpha</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Our Corporate Information </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We were originally incorporated in the State of Delaware on February 6, 2017 under the name &#8220;Max-1 Acquisition Corporation.&#8221; Prior to the Merger (as defined below), Max-1 was a &#8220;shell&#8221; company registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act, with no specific business plan or purpose until it began operating the business of Exicure Operating Company (Exicure OpCo) through a transaction on September 26, 2017, or the Merger. Exicure OpCo was originally formed as a limited liability company under the name AuraSense Therapeutics, LLC in the State of Delaware in June 2011 and was a clinical-stage biotechnology company developing gene regulatory and immuno-oncology therapeutics based on its proprietary SNA technology. AuraSense Therapeutics, LLC was subsequently converted into AuraSense Therapeutics, Inc., a Delaware corporation, on July 9, 2015, and changed its name on the same date to Exicure, Inc. Immediately after giving effect to the Merger and the initial closing of the 2017 Private Placement, the business of Exicure OpCo became our business.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our corporate headquarters are located at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077, and our telephone number is (847) 673-1700. We maintain a website at www.exicuretx.com, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC will be available free of charge through the website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or our other filings with the SEC, and should not be relied upon.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><a name="sC2BC7DCAB55C5E7782901F2AE71DC1B9"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">An investment in our securities is speculative in nature and involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the discussion of the material risks of investing in our securities contained in our filings with the SEC, as well as in the applicable prospectus supplement, in evaluating us and our business and prospects before you decide to purchase any of our securities. You should also be aware that this document and other public statements we make may contain statements that do not relate strictly to historical fact, any of which may be forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and should take into account the considerations relating to such statements discussed under &#8220;Risk Factors&#8221; or any similar heading in the applicable prospectus supplement and in our filings we make with the SEC including (i)&#160;our Annual Report on Form&#160;10-K&#160;for the fiscal year ended December&#160;31, 2018, which is on file with the SEC and is incorporated herein by reference and (ii)&#160;other documents we file with the SEC that are deemed incorporated by reference into this prospectus. Any of the risks and uncertainties set forth therein could materially and adversely affect our business, results of operations, cash flow and financial condition, which in turn could materially and adversely affect the trading price or value of our securities. As a result, you could lose all or part of your investment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><a name="s49FA59900F7A58ABA13E8D7E0354865C"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless otherwise described in the applicable prospectus supplement, we intend to use the net proceeds from the sale of any securities described in this prospectus for preclinical studies and clinical trials, with the remainder of any net proceeds from sales of securities being used for continued technology platform development, working capital and general corporate purposes.  We may set forth additional information concerning our expected use of net proceeds from sales of securities in the applicable prospectus supplement relating to the specific offering. Pending use of net proceeds as described above, we may invest net proceeds in interest-bearing, investment-grade securities. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><a name="s820955F6EC6E5C07941B4FBF3118214E"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIVIDEND POLICY</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently intend to retain future earnings, if any, for use in the operation of our business and to fund future growth. We have never declared or paid cash dividends on our common stock and we do not intend to pay any cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors in light of conditions then-existing, including factors such as our results of operations, financial condition and requirements, business conditions and covenants under any applicable contractual arrangements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s76B3E07129B85BD293A782F3FC42D6D8"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GENERAL DESCRIPTION OF SECURITIES WE MAY OFFER</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may offer shares of common or preferred stock, various series of senior or subordinated debt securities, depositary shares, warrants, other rights to purchase securities or units consisting of combinations of the foregoing, in each case from time to time under this prospectus, together with the applicable prospectus supplement, at prices and on terms to be determined by market conditions at the time of offering. This prospectus provides you with a general description of the securities we may offer. At the time we offer a particular type or series of securities, we will provide an applicable prospectus supplement describing the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">designation or classification; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">aggregate principal amount or aggregate offering price; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">voting or other rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">rates and times of payment of interest, dividends or other payments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">liquidation preference;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">original issue discount; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">maturity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">ranking; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">restrictive covenants; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">redemption, conversion, exercise, exchange, settlement or sinking fund terms, including prices or rates, and any provisions for changes to or adjustments in such prices or rates and in the securities or other property receivable upon conversion, exercise, exchange or settlement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any securities exchange or market listing arrangements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">important U.S. federal income tax considerations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">This prospectus may not be used to offer or sell securities unless accompanied by an applicable prospectus supplement. The applicable prospectus supplement may add, update or change information contained in this prospectus or in documents incorporated by reference in this prospectus. You should read the prospectus supplement related to any securities being offered. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may sell the securities directly to or through underwriters, dealers or agents. We and our underwriters, dealers or agents reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement (i) the names of the underwriters or agents and applicable fees, discounts and commissions to be paid to them; (ii) details regarding over-allotment options, if any; and (iii) net proceeds to us. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following descriptions are not complete and may not contain all the information you should consider before investing in any securities we may offer hereunder; they are summarized from, and qualified by reference to, our amended and restated certificate of incorporation, bylaws and the other documents referred to in the descriptions, all of which are or will be publicly filed with the SEC, as applicable. See &#8220;Where You Can Find More Information.&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><a name="s56418280EEB357A18C7731BA63FBBC80"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following summary description sets forth some of the general terms and provisions of our capital stock. Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should refer to the applicable provisions of the General Corporation Law of the State of Delaware, or the DGCL, and our certificate of incorporation and bylaws as in effect at the time of any offering. Copies of our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated Bylaws are included as exhibits to the registration statement of which this prospectus forms a part. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have authorized capital stock consisting of 200,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of July 10, 2019, we had 44,369,790 shares of common stock issued and outstanding, and no shares of preferred stock issued and outstanding. Unless stated otherwise, the following discussion summarizes the terms and provisions of our amended and restated certificate of incorporation and our amended and restated bylaws, each of which has been publicly filed with the SEC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The holders of shares of our common stock are entitled to one vote per share on all matters to be voted upon by our stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of our common stock are entitled to receive ratably any dividends that may be declared from time to time by our board of directors out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, the holders of shares of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. Our common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. The outstanding shares of our common stock are fully paid and non-assessable, and any shares of our common stock to be issued upon an offering pursuant to this prospectus will be fully paid and nonassessable upon issuance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We have never paid cash dividends on our common stock. Moreover, we do not anticipate paying periodic cash dividends on our common stock for the foreseeable future. Any future determination about the payment of dividends will be made at the discretion of our board of directors and will depend upon our earnings, if any, capital requirements, operating and financial conditions and on such other factors as our board of directors deems relevant.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">The following description of our preferred stock and the description of the terms of any particular series of our preferred stock that we choose to issue hereunder are not complete. These descriptions are qualified in their entirety by reference to our amended and restated certificate of incorporation and the certificate of designation, if and when adopted by our board of directors, relating to that series. The rights, preferences, privileges and restrictions of the preferred stock of each series will be fixed by the certificate of designation relating to that series.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We currently have no shares of preferred stock outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the holders of our common stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our board of directors may specify the following characteristics of any preferred stock:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the maximum number of shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the designation of the shares;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the annual dividend rate, if any, whether the dividend rate is fixed or variable, the date or dates on which dividends will accrue, the dividend payment dates, and whether dividends will be cumulative;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the price and the terms and conditions for redemption, if any, including redemption at our option or at the option of the holders, including the time period for redemption, and any accumulated dividends or premiums;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any sinking fund or similar provision, and, if so, the terms and provisions relating to the purpose and operation of the fund;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms and conditions, if any, for conversion or exchange of shares of any other class or classes of our capital stock or any series of any other class or classes, or of any other series of the same class, or any other securities or assets, including the price or the rate of conversion or exchange and the method, if any, of adjustment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the voting rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or restrictions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Any preferred stock to be issued upon an offering pursuant to this prospectus will be fully paid and nonassessable upon issuance.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Outstanding Warrants</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;As of July 10, 2019, we had outstanding warrants as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">32 warrants that entitle holders to purchase an aggregate of 413,320 shares of common stock, with a term of three years and an exercise price of $3.00 per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Options.</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;As of July 10, 2019, we had outstanding options to purchase common stock as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">5,078,873 reserved for issuance upon exercise of outstanding stock options granted under Company incentive plans and 729,368 available for future issuance pursuant to our existing stock incentive plan.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Other Convertible Securities</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;As of July 10, 2019, other than the securities described above, we do not have any outstanding convertible securities.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Anti-Takeover Effects of Provisions of Our Charter Documents </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately&#160;one-third&#160;of the board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of our outstanding voting stock from obtaining control of our board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation provides that directors may be removed only for cause by the affirmative vote of the holders of at least 66 and 2/3% of the voting power of all of our outstanding stock.&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation provides that certain amendments of our certificate of incorporation and amendments by our stockholders of our amended and restated bylaws require the approval of at least 66 and 2/3% of the voting power of all of our outstanding stock. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could delay changes in management.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation also provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. However, this exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, this provision applies to Securities Act claims and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such provision, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. This exclusive-forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. At an annual meeting, stockholders may only consider proposals specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors. Additionally, at an annual meeting, stockholders may only consider nominations brought before the meeting by or at the direction of our board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder at the time of giving notice and at the time of the meeting, who is entitled to vote at the meeting and who has complied with the notice requirements of our amended and restated bylaws in all respects. The amended and restated bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of our stockholders. However, our amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated bylaws provide that a special meeting of our stockholders may be called only by our Secretary and at the direction of our board of directors by resolution adopted by a majority of our board of directors. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of our board of directors by calling a special meeting of stockholders prior to such time as a majority of our board of directors, the chairperson of our board of directors, the president or the chief executive officer believed the matter should be considered or until the next annual meeting</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">&#160;provided</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace our board of directors also could be delayed until the next annual meeting.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our amended and restated certificate of incorporation and amended and restated bylaws do not allow our stockholders to act by written consent without a meeting. Without the availability of stockholder action by written consent, a holder controlling a majority of our capital stock would not be able to amend our amended and restated bylaws or remove directors without holding a stockholders&#8217; meeting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Anti-Takeover Effects of Delaware Law</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We are subject to the provisions of Section&#160;203 of the DGCL, or Section&#160;203. Under Section&#160;203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">prior to this time, our board of directors approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">at or subsequent to such time, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 and 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Under Section 203, a &#8220;business combination&#8221; includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder, subject to limited exceptions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In general, Section&#160;203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in management. It is possible that these provisions may make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Following such time, if any, as our capital stock is listed on a national securities exchange or is held of record by more than 2,000 stockholders, we will be subject to the provisions of Section 203 of the DGCL, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Stock Exchange Listing </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Our common stock is currently quoted on OTC Market Group&#8217;s OTCQB</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Market quotation system under the ticker symbol &#8220;XCUR.&#8221;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Transfer Agent and Registrar </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><a name="s2CE3FE94DABC504791FE039F62658173"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF DEBT SECURITIES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material features, terms and provisions of any debt securities that we may offer under this prospectus. This summary does not purport to be exhaustive and may not contain all of the information that is important to you. Therefore, you should read the applicable prospectus supplement relating to the debt securities and any other offering materials that we may provide. We may issue debt securities from time to time, in one or more series, as senior, subordinated or junior subordinated, convertible or non-convertible and secured or unsecured debt. Any senior debt securities will rank equally with any unsubordinated debt. Subordinated debt securities will rank equally with any other subordinated debt of the same ranking we may issue. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities at predetermined conversion rates, and conversion may be mandatory or at the holder&#8217;s option. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Debt securities will be issued under one or more indentures, which are instruments between us and a national banking association or other eligible party acting as trustee on behalf of holders of debt securities. Following is a summary of certain general features of debt securities we may offer; we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement, which may differ in certain respects from the terms we describe below. You should read the applicable prospectus supplement, any free writing prospectus we may authorize and the indentures, supplemental indentures and forms of debt securities relating to any series of debt securities we may offer. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">General</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Except as we may otherwise provide in the applicable prospectus supplement, the relevant indenture will provide that debt securities may be issued from time to time in one or more series. The indenture will not limit the amount of debt securities that may be issued thereunder, and will provide that the specific terms of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing resolution, an officers&#8217; certificate or a supplemental indenture, if any, relating to such series. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will describe in each applicable prospectus supplement the following terms relating to any series of debt securities, including, to the extent applicable: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the title or designation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the debt securities will be secured or unsecured, and the terms of any security;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the debt securities will be subject to subordination, and any terms thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any limit upon the aggregate principal amount;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the interest rate, which may be fixed or variable, or the method for determining the rate, the date interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining them;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the manner in which the amounts of payment of principal of, premium (if any) or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock exchange index or financial index;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the currency of denomination;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if payments of principal of, premium (if any) or interest will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the place or places where the principal of, premium (if any) and interest will be payable, where debt </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:16px;padding-top:0px;text-align:left;"><font style="font-family:inherit;font-size:10pt;color:#000000;">securities of any series may be presented for registration of transfer, exchange or conversion, and where notices and demands to or upon the Company in respect of the debt securities may be made;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the form of consideration in which principal of, premium (if any) or interest will be paid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms and conditions upon which we may redeem the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund, amortization or analogous provisions or at the option of a holder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the dates on which and the price or prices at which we will repurchase the debt securities at the option of holders and other detailed terms and provisions of these obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the portion of principal amount payable upon declaration of acceleration of the maturity date, if other than the principal amount;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the debt securities are to be issued at any original issuance discount and the amount of discount with which the debt securities may be issued;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the debt securities will be issued in certificated or global form and, in such case, the depositary and the terms and conditions, if any, upon which interests in such global security or securities may be exchanged in whole or in part for the individual securities represented thereby; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">provisions, if any, for defeasance in whole or in part and any addition or change to provisions related to satisfaction and discharge; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the form of the debt securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms and conditions upon which convertible debt securities will be convertible or exchangeable into our securities or property or those of another person, if at all, and any additions or changes, if any, to permit or facilitate the same; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any provisions granting special rights to holders upon the occurrence of specified events; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any restriction or condition on transferability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any addition or change in the provisions related to compensation and reimbursement of the trustee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any addition to or change in the events of default described in this prospectus or in the indenture and any change in the acceleration provisions so described;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the debt securities will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether we will be restricted from incurring any additional indebtedness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any addition to or change in the covenants described in this prospectus or in the indenture, including terms of any restrictive covenants; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any other terms which may modify or delete any provision of the indenture. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the U.S. federal income tax considerations and other special considerations applicable to any debt securities in the applicable prospectus supplement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Conversion or Exchange Rights</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. We will set forth in the applicable prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable for our common stock or other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or other securities that the holders of debt securities receive would be subject to adjustment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Consolidation, Merger or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Except as we may otherwise provide in the applicable prospectus supplement, the indenture will provide that we may not merge or consolidate with or into another entity, or sell other than for cash or lease all or substantially all our assets to another entity, or purchase all or substantially all the assets of another entity unless we are the surviving entity or, if we are not the surviving entity, the successor, transferee or lessee entity expressly assumes all of our obligations under the indenture or the debt securities, as appropriate. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders additional protection in the event we experience a change of control or in the event of a highly-leveraged transaction (whether or not such transaction results in a change of control), which could adversely affect them. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Events of Default Under the Indenture</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in the applicable prospectus supplement, the following will be events of default under the indenture with respect to any series of debt securities that we may issue: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if we fail to pay interest when due and our failure continues for 90 days and the time for payment has not been extended or deferred; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if we fail to pay the principal, or premium, if any, when due whether by maturity or called for redemption; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if we fail to pay a sinking fund installment, if any, when due and our failure continues for 30 days; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if we fail to observe or perform any other covenant relating to the debt securities, other than a covenant specifically relating to and for the benefit of holders of another series of debt securities, and our failure continues for 90 days after we receive written notice from the trustee or holders of not less than a majority in aggregate principal amount of the outstanding series; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">if specified events of bankruptcy, insolvency or reorganization occur as to the Company. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">No event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) will necessarily constitute an event of default with respect to any other series. The occurrence of an event of default may constitute an event of default under any credit or similar agreements we may have in existence from time to time. In addition, the occurrence of certain events of default or an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in the applicable prospectus supplement, if an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than a majority in principal amount of the outstanding series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities are discount securities, that portion of the principal amount as may be specified in the terms of such securities) of and premium and accrued and unpaid interest, if any, on all such debt securities. Before a judgment or decree for </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">payment of the money due has been obtained with respect to any series, the holders of a majority in principal amount of that series (or, at a meeting of holders at which a quorum is present, the holders of a majority in principal amount represented at such meeting) may rescind and annul the acceleration if all events of default, other than the non-payment of accelerated principal, premium, if any, and interest, if any, have been cured or waived as provided in the applicable indenture (including payments or deposits in respect of principal, premium or interest that had become due other than as a result of such acceleration) and the Company has deposited with the trustee or paying agent a sum sufficient to pay all amounts owed to the trustee under the indenture, all arrears of interest, if any, and the principal and premium, if any, on the debt securities that have become due other than by such acceleration. We refer you to the applicable prospectus supplement relating to any discount securities for the particular provisions relating to acceleration of a portion of the principal amount thereof upon the occurrence of an event of default. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to the terms of the indenture, and except as we may otherwise provide in a prospectus supplement, if an event of default under the indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to that series, provided that, subject to the terms of the indenture, the trustee need not take any action that it believes, upon the advice of counsel, might involve it in personal liability or might be unduly prejudicial to holders not involved in the proceeding. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in the applicable prospectus supplement, a holder of the debt securities of any series will only have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies if: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the holder previously has given written notice to the trustee of a continuing event of default with respect to that series; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the holders of at least a majority in aggregate principal amount outstanding of that series have made written request, and such holders have offered reasonable indemnity to the trustee to institute the proceeding as trustee; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount outstanding of that series (or at a meeting of holders at which a quorum is present, the holders of a majority in principal amount of such series represented at such meeting) other conflicting directions within 60 days after the notice, request and offer. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in the applicable prospectus supplement, these limitations will not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, them. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will periodically file statements with the applicable trustee regarding our compliance with specified covenants in the applicable indenture. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Modification of Indenture; Waiver</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Except as we may otherwise provide in the applicable prospectus supplement, we and the trustee may, without the consent of any holders of any series, execute a supplemental indenture to change the indenture with respect to specific matters, including, among other things: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to surrender any right or power conferred upon us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to provide, change or eliminate any restrictions on payment of principal of or premium, if any; provided that any such action shall not adversely affect the interests of the holders of debt securities of any series in any material respect; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to change or eliminate any of the provisions of the indenture; provided that any such change or elimination shall become effective only when there is no outstanding debt security created prior to the execution of such supplemental indenture that is entitled to the benefit of such provision and as to which such supplemental indenture would apply; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to evidence any successor entity to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to evidence and provide for the acceptance of appointment by a successor trustee with respect to one or more series of debt securities and to add or change provisions of the indenture to facilitate the administration thereof by more than one trustee; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to cure any ambiguity, mistake, manifest error, omission, defect or inconsistency in the indenture or to conform the text of any provision in the indenture or in any supplemental indenture to any description thereof in the applicable section of a prospectus, prospectus supplement or other offering document that was intended to be a verbatim recitation of a provision of the indenture or of any supplemental indenture; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to add to or change or eliminate any provision of the indenture as shall be necessary or desirable in accordance with any amendments to the U.S. Trust Indenture Act of 1939; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to make any change in any series of debt securities that does not adversely affect in any material respect the interests of the holders thereof; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">to supplement any of the provisions of the indenture to such extent as shall be necessary to permit or facilitate the defeasance and discharge of any series of debt securities; provided that any such action shall not adversely affect the interests of holders of any debt securities. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In addition, and except as we may otherwise provide in the applicable prospectus supplement, under the indenture the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount outstanding (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount represented at such meeting) that is affected. We and the trustee may, however, make the following changes only with the consent of each holder of any outstanding debt securities affected: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">extending the fixed maturity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or any premium payable upon redemption;</font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reducing the principal amount of discount securities payable upon acceleration of maturity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">making the principal of or premium or interest payable in currency other than that stated; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">impairing the right to institute suit for the enforcement of any payment on or after the fixed maturity date; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">materially adversely affecting the economic terms of any right to convert or exchange; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment or waiver; or modifying, without the written consent of the trustee, the rights, duties or immunities of the trustee. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except for certain specified provisions, and except as we may otherwise provide in the applicable prospectus supplement, the holders of at least a majority in principal amount of any series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount represented at such meeting) may, on behalf of the holders of all debt securities of that series, waive our compliance with provisions of the indenture. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The holders of a majority in principal amount of the outstanding debt securities of any series may, on behalf of all such holders, waive any past default under the indenture with respect to that series and its consequences, other than a default in the payment of the principal of, premium or any interest; provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Discharge</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Except as we may otherwise provide in the applicable prospectus supplement, the indenture will provide that we can elect to be discharged from our obligations with respect to one or more series of debt securities. In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, the premium, if any, and interest on, the debt securities of the affected series on the dates payments are due. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Form, Exchange and Transfer</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in the applicable prospectus supplement, we will issue debt securities only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. Except as we may otherwise provide in the applicable prospectus supplement, the indenture will provide that we may issue debt securities in temporary or permanent global form and as book-entry securities that will be deposited with a depositary named by us and identified in a prospectus supplement with respect to that series. </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities or the indenture, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Except as we may otherwise provide in a prospectus supplement, if we elect to redeem the debt securities of any series, we will not be required to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Information Concerning the Trustee</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The trustee, other than during the occurrence and continuance of an event of default under the indenture, will undertake to perform only those duties as are specifically set forth in the indenture. Upon an event of default, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee will be under no obligation to exercise any of the powers given it by the indenture at the request of any holder unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Payment and Paying Agents</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of interest on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Unless we otherwise indicate in the applicable prospectus supplement, we will pay principal of and any </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">premium and interest at the office of the trustee or, at the option of the Company, by check payable to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the trustee our sole paying agent for payments. We will name in the applicable prospectus supplement any other paying agents that we initially designate. We will maintain a paying agent in each place of payment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">All money we pay to a paying agent or the trustee for the payment of principal or any premium or interest which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Governing Law</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The indenture and the debt securities will be governed and construed in accordance with the laws of the State of New York. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">No Personal Liability of Directors, Officers, Employees and Stockholders</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. No incorporator, stockholder, employee, agent, officer, director or subsidiary of ours will have any liability for any obligations of ours or, due to the creation of any indebtedness under the debt securities, the indentures or supplemental indentures. The indenture will provide that all such liability is expressly waived and released as a condition of, and as consideration for, the execution of such indentures and the issuance of the debt securities. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="sE5C4C8641B3153CFA20ECC9D053E5E11"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF DEPOSITARY SHARES</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may offer depositary shares representing fractional interests in shares of our preferred stock of any series. In connection with the issuance of any depositary shares, we will enter into a deposit agreement with a depositary. Depositary shares may be evidenced by depositary receipts issued pursuant to the related deposit agreement. Additional information regarding any depositary shares we may offer, the series of preferred stock represented by those depositary shares and the related deposit agreement will be set forth in the applicable prospectus supplement.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="sC029E39C898D5A8D93511EA101977BE7"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF WARRANTS, OTHER RIGHTS AND UNITS </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may from time to time issue warrants or other rights, or Rights, in one or more series, for the purchase of shares of our common stock or preferred stock. We may issue Rights independently or together with such securities, and such Rights may be attached to or separate from them. Rights will be evidenced by a Rights certificate issued under one or more Rights agreements between us and a Rights agent which will act solely as our agent in connection with the Rights and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of Rights. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may issue securities in units, or Units, each consisting of two or more types of securities. For example, we might issue Units consisting of a combination of shares of our common stock and warrants to purchase shares of our common stock. If we issue Units, the applicable prospectus supplement will contain information with regard to each of the securities that is a component of the Units. In addition, the applicable prospectus supplement will describe the terms of any Units we issue. The forms of any certificates and agreements relating to such Units will be filed as exhibits to the registration statement of which this prospectus forms a part by amendment thereof or as exhibits to a Current Report on Form 8-K incorporated herein by reference. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The applicable prospectus supplement and such forms may add, update or change the terms and conditions of the Rights or Units described in this prospectus. You should read the prospectus supplements, Rights agreements and Rights certificates that contain the terms of the Rights in their entirety. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The particular terms of each issue of Rights or Units will be described in the applicable prospectus supplement, including, to the extent applicable: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the title of the Rights or Units; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any initial offering price; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the title, aggregate principal amount or number and terms of the securities purchasable upon exercise of the Rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the principal amount or number of securities purchasable upon exercise of each Right and the price at which that principal amount or number may be purchased upon exercise of each Right; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the currency or currency units in which any offering price and any exercise price are payable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the title and terms of any related securities with which the Rights are issued and the number of the Rights issued with each security; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any date on and after which the Rights or Units and the related securities will be separately transferable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any minimum or maximum number of Rights that may be exercised at any one time; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the date on which the right to exercise the Rights will commence and the date on which the right will expire; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">a discussion of U.S. federal income tax, accounting or other considerations applicable to the Rights or Units; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">whether the Rights represented by the Rights certificates, if applicable, will be issued in registered or bearer form and, if registered, where they may be transferred and registered; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any anti-dilution provisions of the Rights or Units; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any redemption or call provisions applicable to the Rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any provisions for changes to or adjustments in the exercise price of any Rights; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any additional terms of the Rights or Units, including terms, procedures and limitations relating to exchange and exercise of the Rights or Units. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Rights certificates will be exchangeable for new Rights certificates of different denominations and, if in registered form, may be presented for registration of transfer, and Rights may be exercised, at the corporate trust office of the Rights agent or any other office indicated in the applicable prospectus supplement. Before the exercise of Rights, holders of Rights will not be entitled to payments of any dividends, principal, premium or interest on securities purchasable upon exercise of the Rights, to vote, consent or receive any notice as a holder of and in respect of any such securities or to enforce any covenants in any indenture, or to exercise any other rights whatsoever as a holder of securities purchasable upon exercise of the Rights. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s48671C3AA9CE51BA96105E2B5C636502"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PLAN OF DISTRIBUTION</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may sell the offered securities in and outside the United States (1) through underwriters or dealers, (2) directly to one or more purchasers, including to a limited number of institutional purchasers, to a single purchaser or to our affiliates and stockholders, (3) through one or more brokers or dealers; (4) through agents or (5) through a combination of any of these methods. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may also sell directly to investors through subscription rights distributed to our stockholders on a pro rata basis. In connection with any distribution of subscription rights to stockholders, if all of the underlying securities are not subscribed for, we may sell the unsubscribed shares of our common stock directly to third parties or may engage the services of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If underwriters or dealers are used in the sale, the securities will be acquired by the underwriters or dealers for their own account and may be resold from time to time in one or more transactions, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">in one or more transactions at a fixed price or prices, which may be changed from time to time; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">in &#8220;at-the-market offerings,&#8221; within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">through a market maker or into an existing trading market on an exchange or otherwise; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">at prices related to those prevailing market prices; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">at negotiated prices. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The applicable prospectus supplement will set forth the following information to the extent applicable: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the terms of the offering; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased by each of them; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the name or names of any managing underwriter or underwriters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the purchase price of the securities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any options under which underwriters may purchase additional securities from us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">the net proceeds from the sale of the securities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any delayed delivery arrangements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any underwriting discounts, commissions and other items constituting underwriters&#8217; compensation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any initial public offering price; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any discounts or concessions allowed or reallowed or paid to dealers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any commissions paid to agents; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">any securities exchanges or markets on which the securities may be listed.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Sale through Underwriters or Dealers </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If any securities are offered through underwriters, the underwriters will acquire the securities for their own account and may resell them from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Underwriters may offer and sell securities to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters. Unless otherwise provided in the applicable prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all of the offered securities if they purchase any of them. In connection with the sale of securities, underwriters may be deemed to have received compensation from us in the form of underwriting discounts or commissions and dealers may receive compensation from the underwriters in the form of discounts or concessions. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">In order to facilitate the offering of securities, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. Specifically, the underwriters may overallot in connection with the offering, creating a short position in the securities for their account. In addition, to cover overallotments or to stabilize the price of the shares, the underwriters may bid for, and purchase, shares in the open market. Finally, an underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed shares in transactions to cover syndicate short positions, in stabilization transactions, or otherwise. Any of these activities may stabilize or maintain the market price of the offered securities above independent market levels. The underwriters are not required to engage in these activities, and may discontinue any of these activities at any time. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Some or all of the securities that we offer through this prospectus may be new issues of securities with no established trading market. Any underwriters to whom we sell securities for public offering and sale may make a market in those securities, but they will not be obligated to do so and they may discontinue any market making at any time without notice. Accordingly, we cannot assure you of the liquidity of, or continued trading markets for, any securities offered pursuant to this prospectus. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If any securities are offered through dealers, we will sell the securities to them as principals. They may then resell those securities to the public at varying prices determined by the dealers at the time of resale. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Direct Sales and Sales through Agents </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may sell the securities directly to purchasers. If the securities are sold directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities, we will describe the terms of any such sales in the applicable prospectus supplement. We may also sell the securities through agents designated from time to time. Sales may be made by means of ordinary brokers&#8217; transactions on the OTCQB</font><font style="font-family:inherit;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;color:#000000;">&#32;Market at market prices, in block transactions and such other transactions as agreed by us and any agent. In the applicable prospectus supplement, we will name any agent involved in the offer or sale of the offered securities, and we will describe any commissions payable to the agent. Unless otherwise provided in the applicable prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">At-the-Market Offerings </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">To the extent that we make sales through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to the terms of a sales agency financing agreement or other at-the-market offering arrangement between us, on one hand, and the underwriters or agents, on the other. If we engage in at-the-market sales pursuant to any such agreement, we will issue and sell our securities through one or more underwriters or agents, which may act on an agency basis or a principal basis. During the term of any such agreement, we may sell securities on a daily basis in exchange transactions or otherwise as we agree with the underwriters or agents. Any such agreement will provide that any securities sold will be sold at prices related to the then prevailing market prices for our securities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Therefore, exact figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time. Pursuant to the terms of the agreement, we may agree to sell, and the relevant underwriters or agents may agree to solicit offers to purchase blocks of our common stock or other securities. The terms of any such agreement will be set forth in more detail in the applicable prospectus supplement. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Remarketing Arrangements </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Offered securities may also be offered and sold, if we so indicate in the applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as our agents. Any remarketing firm will be identified and the terms of its agreements, if any, with us and its compensation will be described in the applicable prospectus supplement. Remarketing firms may be deemed to be underwriters of the offered securities under the Securities Act. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Delayed Delivery Contracts </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">If we so indicate in the applicable prospectus supplement, we may authorize agents, underwriters or dealers to solicit offers by certain institutions to purchase securities from us pursuant to contracts providing for payment and delivery on a specified future date. The applicable prospectus supplement will describe the conditions to those contracts and the commission payable for solicitation of those contracts. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">General Information </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">We may have agreements with the agents, dealers, underwriters and remarketing firms to indemnify them against certain civil liabilities, including liabilities under the Securities Act, or to contribute with respect to payments that the agents, dealers or underwriters may be required to make. Agents, dealers, underwriters and remarketing firms may be customers of, engage in transactions with or perform services for us in the ordinary course of their businesses. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Each underwriter, dealer and agent participating in the distribution of any of the securities that are issuable in bearer form will agree that it will not offer, sell or deliver, directly or indirectly, securities in bearer form in the United States or to United States persons, other than qualifying financial institutions, during the restricted period, as defined in United States Treasury Regulations Section 1.163-5(c)(2)(i)(D)(7).&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><a name="sAE6DBF9466A7531AA0036D49F4137DD2"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL MATTERS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Redwood City, California. Any underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement</font><font style="font-family:Arial;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="sB7E3A28EE30F577A834B442EEF79CF65"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXPERTS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">The consolidated financial statements of Exicure, Inc. as of December 31, 2018 and 2017, and for each of the years in the two-year period ended December 31, 2018, have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. &#160;The audit report covering the December 31, 2018 consolidated financial statements refers to the adoption of Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 606,&#160;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;color:#000000;">. The audit report covering the December 31, 2018 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and will be required to raise additional capital or alternative means of financial support to fund operations, which raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s13F1D259088551F88038E8F0A050545D"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Shares</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="image96.jpg" alt="image96.jpg" style="height:61px;width:254px;"></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Exicure, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Common Stock</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:23.717948717948715%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PROSPECTUS SUPPLEMENT</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:23.717948717948715%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sole Book-Running Manager </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">Guggenheim Securities </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;, 2019</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.15384615384616%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a201907developmentpipeline.jpg
<TEXT>
begin 644 a201907developmentpipeline.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" *Y"B,# 1$  A$! Q$!_\0
M'0 !  ,! 0 # 0            8'" 4$ @,) ?_$ !0! 0
M      #_V@ , P$  A #$    <L'U@
M
M
M          ';/ 3@Z0                                 !99#CB@
M                          LLAQQ0
M  7*4T
M         5N3D@I8IU@                                 "VR"$?
M                          !;9!"/@
M   OLH0
M          J@GY7A8IU@                                 "VR"$?
M                           !;9!"/@
M    OLH0
M           J@GY7A8IU@                                 "VR"$?
M                            !;9!"/@
M     OLH0                                        _IZ#S
M                J@GY7A8IU@                                 "
MVR"$?  /0>H 'C/8<\^(               !T#QGU@    ML@A'P
M                      7V4(            3TU(#SE;&=#Z@      :3(
MR4D             ?:7J4<>8 GII@]YRC,1$B]2CCS
M %4$_*\+%.L                                  6V00CX !<1?1ZSX
M'G,TFIC%AQ@              6$24I@VB9E(0    "VR"$?
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M5Q&BTR'D>+E*Q-/'T&<">%='/+;.F5<1H  %MD$(^
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M5!>1C4UB4B5H;G,>FD#Z3-YK(S"6R=DA1:QC@^L  ML@A'P
M                 7V4(            6"::,2 T&=\XI."NRU"ASL$L.6?
M2?<3@KLM0H<L,BY]A*C+Q9AH$R\:Y,.DI->F4#4)B0TN<8HPW"8]-A%-G0)L
M97-B&&2URVC,1M0P\>0 _I*RQ2UR.F<3:AAX^PMDFY9IBTV@8](T;C,A&N"M
M#QEO&&CX            J@GY7A8IU@
M   "VR"$?   -0D9*$/0;D,8'?-+&8#6Q6!W3X%,%_&-#TEU$S)P9R)F>@SF
M:!.F=4ZY&2QS+AH I$K4W,8O+R/$9^-K&833)G(KL_I_   6V00CX
M                       +[*$            +!--&)3I&L2ISHDL,_D_*
MX/(;(/H,FEL$L,_D_*X+Z(N>4LXR47$6R9N-?&+"3FH#+1IPQ4:5.$4@;C,;
M&Q3+P.@0XV"88+8+=,PFU3#YXP#895!29=!<!DXVJ8?-#G\*+-G&*#9!FHC)
MLDQZ:M*((Z2<IT^(           *H)^5X6*=8    '].B #Z0? \P
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MA+V(&2DRB6$:%,VEW&=3[S29[BGBAP  6V00CX
M        +[*$               !\CHG-/X  #Y'1.:?P  Z)XCZR6&MC$)Z
M3Q     ]A\3R@  'H/F>0 'V'3.:?4#T'S/(>\\9\ :$(D1LUJ8K.6>D^P\0
M            *H)^5X6*=8     %D&C#%8--G'.:<$JP]A;Y_2HSSENG+/.1
MDM(^LJ<^DL<\))BH3EDM++(J5B2P[I6Q89SR<%[&9CG'H( 3XGA$RL0
M6V00CX             -"'VF=@             6V00CX
M               +[*$                         !W"]3-P
M         !81<9]Q5Y4@              *H)^5X6*=8     %D&C#%8--DH
M*:-$&1"^#QG.)09C-LE8E3EJ$6)<? I UZ4N=XZ9F8V(4*6X4J= L,RN:9(T
M?67D9K)>=,JDT^40749R(      6V00CX             +$/F5P
M     "VR"$?                              !?90@
M                                                !5!/RO"Q3K
M    L@T88K!ILC11)L\S>:E(.>8L<Q8;5,6G%+'+3)8<(H(UP8<).;",SFC2
MNB4$3(<6(96-,D:( :D,3%^G3..20S&?T_@     +;((1\
M              %MD$(^                              #1!'0
M                ?T^P^H                    'S/Z?6
M      93)<5X6*=8     %D&C#%8--D6*--G&<#2!09%R:E9&V3$9])M\R(6
M$3@H,U^8Y).:+,QFG#'9/SADK+8,D&M"O2OS5!B8OHZ9$BW#(Q?9 2O
M"VR"$?    /D2$\)R@      ?8>TYYT3GGQ />>4^H      D1'SX@  %MD$
M(^     >\[A%    "7$9.Z<LYP    /Z?P[)]AP@          :1.\
M               #TG>(P                    #I'L."
M     86)$5X6*=8     $_+Z,C T01LILUH4$=$T(?,I(JTU^8]/&:C)(1<]
M)01KD@Y*C/)5YHXL(YYF(^LU8>,XA "K37I#B&'1*,--$Y(J9?.6     6V0
M0CX   )&:G/4= IPS\      3,U08K-PF,3B@&QB@"N  #0A3Y&P #YFQ#'
M   +;((1\     L@T68L    -R&12]"JBM@   #M&EC)Y=9T2@P
M 7V4(                     "0E[&:                     6(3$HH
M                 J@GY7A8IU@               "6&MC#H
M     +;((1\   &JCA&<R5F@#+YURTCZRISSEEG()B5,<(EY9)R2^3$Y<A4A
M_2X#F%VF?R(%LGVE7'N-;%'%#EDDP*X(:2TN\S&   "VR"$?     +(-%F+"
M^2,EA%<E8$G+J(N7X9$)Z0@C!=I("LRM2QRSSQ%)%OETF>#D'K*N)Z6L<PI(
M\)?Y#BPBIR!      OLH0                     $A+V,T
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M]C-                     +$)B44                  503\KPL4ZP
M                               !;9!"/@   VZ9K*V/Z24C)8Y:9+#A
M&?#8AA<M@MLHDTL8J)P:C,5FY3%IKDS:5\;+,]G@+<)4>DQP;F,@EQD_(>3P
MH0L,HLBH   +;((1\     L@T68L-KF83B&SC#AN,QL1PW.9"-'%.%P%5%/@
M_I>A."0%?%4&I#$Q?ITR&ELF2"3FQ#$)M\Q<2 TP8L     !?90@  !H@D9X
MRAR,    '>+7(F?TK4 &DS-@  !WBURB@  2$O8S0
M "Q"8E%                  %4$_*\+%.L             >H^9X@
M             6V00CX   -,G1,VEDF@3&QM R(6$3@SZ;!,,%L%NF=#79C$
ML@OPQ6;E,6FHRJBJ39QF8T<9U/07F8Y-RF2"R"8F92VRLS5)CP^(   +;((1
M\     L@T68L-KF7CC&SS"YLXHXC1K QZ:.*<+ /M*)-,%$&HC$YHPYY5!JL
MQN7,=,J@U(9.+$+6,A&XS%A(C3!BP     %]E"   &O#,A8A*2"'4*_)V>\I
M<ZQ;Q$R,%[E+'].L>L[)21=91Q;1(2G#M%GD-(T7N9>  !(2]C-
M            +$)B44                  503\KPL4ZP            !K
M@D)BP^D                   ML@A'P   =$T>6"<HSZ5L:C)(1<])G@U08
MU+-+2,P&A2U"!DB,C&R3(Y)S2IQ3Z2BBRRQ"'DC,@FJB6&/#3IWR*%"%[&7@
M   "VR"$?     )L709A-1%#',--F42=E_D5/>9\+K*U(P:+.\5@4B:5) 0T
M\A2)J0C)$#W%)ESEL',,]D>-5&8#M%Y&80     7V4(   :\/ =PH0MHKT\!
M9A&3QE@E#DX*^+P(&?TG96Q9A2QH\SB7*5 ?8>H^9H$RJ7N9>  !(2]C-
M                  +$)B44                  503\KPL4ZP
M    )2:X.84$5<3L]I+2F2=$P*X(:=@MD^TJXC0            +;((1\
M                         %MD$(^
M "^RA   #7AFDCQ]1J@ST38LTA!'"]#*A.#D%UD#/Z3LH@N K4T49_+!*/)&
M7F5(7T99+W,O   D)>QF@                    %B$Q**
M     *H)^5X6*=8            &A#HD?)V9/-$%G%3D/+_*0+Y,D%P'\/82
MXR,            "VR"$?                            !;9!"/@
M                          OLH0   T:4*<P%_%-GC-&'H*'.V7,1\I4M
M@B)_26E2EDD'+H,W&CSJ%%EE'O/>4,6H4,  "0E[&:    #TDL/X<(Y!+B(@
M       E9%     6(3$HH   F)]AS2.$D.*>4      'J)410\P  !5!/RO"
MQ3K            'W&U"!'-+@,;ERGH,WFBR?D/)X4(1PMPE1Z3'
M     +;((1\                            %MD$(^
M               "^RA                      2$O8S0    2@U.5D6@9
M(-7F.CXGP/M/F><'K/(#YGR/J +=-!&(     6(3$HH   VN5.6&466D441H
M^D_IZCR ])])\#^GWGG -;D()B9.   *H)^5X6*=8            M T,5*"
MQRO3[SXF>2]B8F92VRLS7)G4]!>9CD            %MD$(^       #[CV
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M?"I@       "["($"        +;((1\
M %]E"                      D)>QF@    E!J@K(B95!LXQB;&,H%T$L*
M_.H6*5N<(M,X!PRB #91C4    %B$Q**   -KE6')*:-+E&ENE:DO) =8J<O
MDB!3AIDJ\EAE4$@-/F;2)   %4$_*\+%.L
M        6V00CX        -!G6,S'WEN'7((0 M4\9WRI"X#FGD(<<4MTZ!4
MY[36)6IGD\X       +;((1\                              %]E"
M                    D)>QF@    E!H4RD ;*,:FQ2D2QCZR*$@(27L9K+
MS(804K\ V48U    !8A,2B@  #:IBH U 427 0TNXJ@G17)Z"SB@C0Q4)Z"D
MS^FPCC$+*)   *H)^5X6*=8                                  ML@
MA'P        :#.L9F+/+-(.:%,0FN#S%3DY/<0$OPR\3\DI""UC,1JTKLSD>
M<       %MD$(^                              "^RA "\R<'E*6(.
M    :)* /*         "1'J(F"0E[&:    #U$A(H 3,AA,2)$^.$?$\!-"*
M'"):=$@9\0"9D,    !8A,2B@  ":D* )0<([!S"1GD/214GARR(';)80,\A
M]A-P?40D   J@GY7A8IU@                                 "VR"$?
M        !H,ZQF8[I=))R?F*35I2)51M(S>5Z;(,^F@#GG#+1,:&J3/A7(
M     !;9!"/@                              OLH0 T^4Z<LU,8S+?/
M>4T6R4T6B0DM,\Y3AKHR>34GI5QYR9DD*C.P2([Q$R4%(D\)R5"=0DQ)2G31
M9SS-()"7L9H                    !8A,2B@                 "J"?E
M>%BG6                                  +;((1\        &@SK&9C
M31RBDS:9B@U<4.5H:Y( 5::Z,QEUE>E6EG%,FPR@BM3^        ML@A'P
M                            7V4( :?*7(0;-*++*(R>,F91IHXJ<DI]
MQ "Z3-QI$SD:9*)+4*;+J(,>HZIPB4%8E\%%%LE<DG."?>=4X)20)"7L9H
M                  !8A,2B@                 "J"?E>%BG6
M                          +;((1\        %YG3,\EK%^D1.V9G-!E*
ME?$T-%G%)89S.<:3/2544(:0+-,=''       !;9!"/@
M              OLH0 T^4N<0UF46660@CAYS0)5A]IW3@$%-!&?2[S+!L4H
M\FY1)J$KDX1)B'D](J764H=(\9_#DDL/B1DJP$A+V,T
M    L0F)10                 !5!/RO"Q3K
M           %MD$(^              :#/X00TP9'(P           "VR"$?
M                              !?90@!>Y.CRE*$1-&'H*'(N:B,YGS-
M"G\,]%Z&?"\R7%8G.+M.<4V=(Y)W2-DM(26<20JT^H_AX"0'*+D,J D)>QF@
M                    %B$Q**                  *H)^5X6*=8
M                            ML@A'P             "0%QGM( 5<
M         6V00CX                              +[*$
M+,)>4(         2$O8S0                    "Q"8E%
M     %4$_*\+%.L                                  6V00CX
M                       +;((1\                              %
M]E"                      D)>QF@                    %B$Q**
M               *H)^5X6*=8                                  M
ML@A'P                            6V00CX
M         +[*$                     !(2]C-
M +$)B44                  503\KDE9[P
M        "=D8.6                            "=D8.6
M                  "SRL                      =4LTIT
M          $L.^5H                  08F1#C:A.P
M                 "DBQR3                             I(L<DP
M                            ,V&DP
M                                   #"9V""GZ %C@
M                    &?"U27                             SX6J2
MX                              &3C6(
M                                      !^<9V"O#] "QP
M                        #/A:I+@                            9
M\+5)<                              #)QK$
M                                           _.,[!7A^@!8X
M                            !GPM4EP  !](/N
M      ,^%JDN                              !DXUB
M                                                  ?G&=@KP_0
ML<'A/*     = ] !D$M$NT                        SX6J2X PP=(VJ4
MB9=/K-''&*'..3TWD#*I31?9=YAH^PW<90(46>:M               !GPM4
MEP                              ,A'U@
M                              %Q%O@       'YQG8*\/T +'!F,IP'
MR/B>H\IZCRGR/B#3Q<(!CPM,HP^XZYP"U":E%D<)^5^:_,RFQC*)I<R.?>?T
MV@9/*X+Q-#             &?"U27 CQA,YQ^@QF,X!>1T2T"G2D#:(!^:I^
MCQ^=1I$\AQR=F>S1I0ANH               &?"U27
M             Q^1,
M           O@O0        _.,[!7A^@!8X,Q%.@M,JPLT^!X""%GE8G\-.E
MQ &/"TS'I^D!^<Y^@YALT60,E)PCUG:,WGZ%&%#9A^?A^E!^<)M\R@;Q/SB-
MC%/FAB:@           SX6J2X&7R%'-+2-#&>"E25&UBG2D#:)E<ZIF(_3 _
M- T8=8XYVRH":D6-N@               SX6J2X
M         &/R)@
M       %\%Z        'YQG8*\/T +'!F(JDL@]1%#OG3(,?PF)YBO#1I<0!
MCPM,R6?HR?GB;],)FC"*'=/ ?$Z1G@V68E-YF!S])#\XS<YB,V@8?-WD)+*.
M\           #/A:I+C^'YQ%['U%)%A$^)69A/T-*=*0-HE0GL,=&M3,!H\J
M,Y9HLQB;D,1GZ.@               SX6J2X
M      &/R)@
M    %\%Z        'YQG8*\/T +'!F(IT^1/CZ3Y$A*B)J?>04^)ITN( IXE
M)4IHTSP7\426,<D]YYS^'J.2542@O$H,TD9Q-%%0%4%[%B             &
M?"U27'%*1-$ S@6Z4.>(T&30AQ!RZ0"OBAS01,S-)Z32!5I2I>)9@
M        ,^%JDN!#RA#O&AS[@"-G/(T6R"OR4'8*)(H#NFA        "/D>*
M[+-(L7"         8_(F
M              7P7H        ?G&=@KP_0 L<&8BMCWGT%L&A3XF7BI"5GB
M/H-#%Q                           SX6J2X
M       &?"U27 QB;$*T/ 6N586&1 CI)"QRJ2MB\"9'B*H.(7@<$EI$CHG"
M.>=4\18)$2*%JD;(R3@K0GQ4Q?96!T2*%K'4        !C\B8
M                                          !?!>@       !^<9V"
MO#] "QP9B*D+:.67^3,%2F9"T054:7+B                          !G
MPM4EP                            ,^%JDN!0Q4Y-31ADLT"9P+_ #B%
M9$A+ * -3DR!5)PB\S(AKLR(601$CQ8)5IJ,SF7254<,LL@A<A!SUE^D!/X1
M<M ZX        ,?D3
M           +X+T        /SC.P5X?H 6.#,17I/CC$B-*'UF4RM2UCSD,-
M EQ                           SX6J2X
M    &?"U27 J$MXKPI \)L R^3(%9'U&P"@"S29 JDX1>9D0UV9"+*)65V6Z
M4.3D]1<ACT^XUX1 SL>0TT<4G8*<+K         ,?D3
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MM   /@>4]H .>>X^0           ,?D3
M                          +X+T        /SC.P5X?H 6.#,13YT2?%:
M%@$G(60@L\KH\AIPN( BYE4Z1J\S2?0<TUZ444J7V3\RJ=(U>8J-4$1*)+F+
MV,EGH/82HGAXS@%U@          &?"U27 RJ:E/M,;&R08U-E SZ3LL<RJ6T
M5.:H,>FP@4:1(E9;AFX]!<! 2,ENG&(:<4U04B=4@!."KR3%Y%$FDP
M#/A:I+@                              8_(F
M                                   7P7H        ?G&=@KP_0 L<&
M8BG3Y'>(^3LC1VR'$@(^#3I<0!A\OTA1S2ES;QBXV(8D/T(*;*7+](4<T@9I
M4QB?H,8++Z( ::,4FK2FSG&C2R0          #/A:I+@9!-? QL;)!C4V4#/
MI6!PRR#4)BLLDJ W<"H3^&?R>F@"O2,G#-3&-R5EUE3EIF>S["=DS(:3TGQD
M$U\       9\+5)<                              #'Y$P
M                                            "^"]        #\XS
ML%>'Z %C@SF5(     :0+7 ,.F@B$G,*6/T!,/&K3$A^A!GDKLT$0DYA C2A
MC$_0LP07\54:,,D'Z%'YYGW'Z%            SX6J2X&037P,;&R08U-E S
MZ3LFYBDV\5@3\R\:Y/B8B-1F9R;EZ%?$>.*:E,;$L- %-ECF?B[#Y&<"X2>$
M_,@FO@      #/A:I+@                              8_(F
M                                               7P7H        ?
MG&=@KP_0 L<        $4,K'2-8F934!G,O@J,I0OXGIE8Z1K$H NDK8HHN<
MNXRD=,J _0DQV2 U(           #/A:I+@93-3'W% E_ R.?:=4LTDI+"K3
M[B"G +W)<#,1[3ZR^#/)'RWS@$=+8.26@0$EA5QTR DM)Z5&7H44:3
M ,^%JDN                              !DPT:
M                                    =,Z8       !^<9V"O#] "QP
M                  1XPT=4N E!EPW42(           &?"U27 BA!BY
M       5D4T>(U.=@      H$NTZ(      !GPM4EP
M            ,G&L0
M                   #\XSL%>'Z %C@
M     &?"U27                             SX6J2X
M                &3C6(
M                       !^<9V"O#] "QP
M         #/A:I+@                            9\+5)<
M                    #)QK$
M                            _.,[!7!?)(@
M            " $I.L                            " $I.L
M                      "JBU0
M                             #.QVB+GZ %C@
M              &?"U27                             SX6J2X
M                         &3C6(
M                                !^<9V"O#] "QP
M                  #/A:I+@                            9\+5)<
M                             #)QK$
M                                     _.,[!7A^@!8X
M                      !GPM4EP                            ,^%
MJDN                              !DXUB
M                                         ?G&=@KP_0 L<&:RF
M#T$M(4#3A;X                          ,^%JDN/@85-7E1'K+?,8G,+
MU+J,P&TC-9(RKRMS^EK&LB%&13=YADC)\C?)T0              #/A:I+@
M                             9!.8
M                 :C)<                  ?G&=@KP_0 L<&8BG0  =,
MTJ9Q.*#3I<0                          ,^%JDN!5QCL^D_0TQ*:'+9,
MSEQF13>YE$E)4)I,L _-$_1PQH1 _1P^)5!31KX               &?"U27
M                               Q^1,
M                   UP30                  _.,[!7A^@!8X,Q%.@ '
MWFN2BRLP#3I<0                          ,^%JDN!YC\VR[38!^=1NT
ME ((9#-[F425%0$2(6;$+_/H/SK/T<!@4W$=@               &?"U27
M                             Q^1,
M                 UP30                  _.,[!7A^@!8X,Q%.@ %]E
MC&/S^ &G2X@#F'@/2=D          'E/,=,           &?"U27 RB<0JHW
M 9N)L6Z8M-TF C?AD(O8HDTF540PVP><_.L_1PCIBXWF
M9\+5)<#BGG/>=,    ',.F   <PZ8!SB/%?D]/B3<              &/R)@
M                                           &N":
M     'YQG8*\/T +'!F(IT 'WFXBARC@ :=+B ,B%8GL.^;>       .,93-
MB@ IDJ@UZ           #/A:I+CGF2#7!7I79H$RJ1LT>6F9V*>)F:O,\EN$
MM,AFGSNF4S6)#2M2_                #/A:I+@8<+1(^2HT0    4V7(
M 4V7( 426D= HT]Q?               ,?D3
M                    -<$T                  /SC.P5X?H 6.#,13H
M)N;(,>D" !ITN( R(6$7R?G4;=,G'D--%#D:+F*8/J)*10TX5^5R>DMHRF;K
M,XD=+/+&*H+H,I'W&RRHREC^%WE8FQS#IO$      SX6J2X
M               &?"U27 QL;)(\9>)&?PD9[R"'.-,F.2]2'DJ(N1 UB9@/
MK-/% '7.:>@ZI>YG8T 4B:               !C\B8
M                         !K@F@                 !^<9V"O#] "QP
M9B)86(?T_A4YH4SD7"#RE6$G+B ,B%A%\GY^EV&?2RSAGF-7'A,[%\E)EME?
MEJE4% GZ"F-S5QEXW2?G$:C*\(4:S(45N4Z?H<9'+D,K&A"/FJ0     #/A:
MI+@                            9\+5)<#"Q-3V&BC.YRR^S/IL$H4Z)
M!349D0O4JLJ VD90)N:0,IDN(67<<8EQ79.2)EZ@              Q^1,
M                                          UP30
M    _.,[!7A^@!8X,Q'>/*=DY9X#29DLFI_#[3Q$F+B ,B'.)J9^-N&.#1Q]
MYGLV"1XS^7D4V6F5Z4D;%,2GZ%F%C9QBLU:91-7E6GT';(L644P6H4*:Q(>9
M6/T/)<      9\+5)<#XD&)V   <X^\B1-P0T[I#2QP 00F94@.D20K4_I-2
MP05N30ZA B>@         SX6J2X&-C9(!G@NLR4=,U 9J+K*L--F1#BFQC$Y
MJHCQQC[BM2=%UF.3:QQCO@C1)0              8_(F
M                            :X)H                  ?G&=@KP_0
ML<&8B[B7'//<4>?P[A; !61RBX@"N2#'I+=.R500HO8KHLD\1#R5D:.^<8\I
M#CK%O%"EJG.*P+G/D1XGI11TB["BSAE9&ACU&23]!       9\+5)<"B"RB2
M$.)<?P\9SR2&.S5Y&B?@SB6D9Q-E ^DRB>(UV5J0TB1+3J$[,Q&JB2F)BQ32
MI0A:9*         #/A:I+@5H66 0(JLN<ZQ1)/BP"(DZ*Y/65>3@L$IX\9?)
M7YV2FRUR=                 &/R)@
M              &N":                  'YQG8*\/T +'!F(NXEX!_#EG
M5 !61RBX@                4\4$2(U$8W-,%E       SX6J2X&1C7)E(L
M@ILM8KL^DNLS0:F*D-/ SB6D9Q-E ^DYQELUV#'!KXH8BI*BI#9!7QQBHS91
MQS/!J          SX6J2X                              &/R)@
M                                       &N":
M 'YQG8*\/T +'!F(])V0   "+E@EQ                           SX6J
M2X&0#7YFD^HKHNTE1XCPE5&G#/QX#O']+2,XFR@ 9$-=D1*3--&?3K'A.(:5
M,:G>((:.+9,@&OP        #/A:I+@
M8_(F                                            :X)H
M          ?G&=@KP_0 L<&8R3$D    (,2DN(
M    &?"U27 R,:W,/%^&>2^B5GA/"4R7\5::>!G$M(R*7:=$O@&1#79GXGQ8
M9GTG98YD NXI,UZ>$QV:X,\FH         #/A:I+@
M           9!.*                                            :
MI)>                  ?G&=@KP_0 L<'Q/B     ?,_H
M            ,^%JDN!0Q9AT#Q'2/4?:?$_AY3ZS[CJ YIZR/GP/M)*#D'7.
M8>X^TYY]YZ3S'(/>=$'#*>+4)2         9\+5)<
M           #)QK$
M                   _.,[!7A^@!8X
M    !GPM4EP/B00GH               ! "?@         SX6J2X
M                      &3C6(
M                             !^<9V"NS9Y.P
M              "E"Q23                             I0L4DP
M                         ,W&D0
M                                #"YV"O3XG]
M                /X?T                             _A_0
M                       #^']
M                              /B=L_3@
M
M
M
M
M
M
M
M                                              ' .^<4[1P#O@\!
M\#I       ' .^#@'?  !_#^'#.\     <\^1ZSAG?  !SCYGN   ..=(^X
M  XYTC[@#X'S.>?(]P!P#O@X .^#@'?/@?,    ' /:1LFQP#O@X)Z#K'#/2
M>0_AWP< [X/@?,      '+/4>H   'P/F
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M-5$5)(?>#G'&.V>,[9P#V'3.&5 6(2 ^!V3BGW'C/N/Z9]--D3)4?,
M
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MAZBZ3(YH0XY6II,SP2,G9 34
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M ,N'T&JC*9JP&6RXB/%?G7+N*W*_+<. 14C!)"TBI"UBJ2NS811I7Y9AYC2
M
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MZ4B?PT.5,2XK$X!IDS,6@10[)?
M                                                  ..5H7& 427
MD?8                               #.IHH                 $..,
M64 4*7T
M
M
M
M                                #__$ #D0  $# P,# @0& @$#!0$!
M  4 ! 8" P<!%187-380$A0T0% 1$R P-V Q,S(A(B4C)"9&<)" _]H " $!
M  $% KG^S_\ R&W_ -+S32EV.8V+K+;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K
M;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K
M;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K
M;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K
M;6JVUJMM:K;6JVUJMM:J!1T:1+&Q#*P8VUJMM:K;6JVUJMM:K;6JVUJMM:K;
M6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;
M6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;
M6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJH%'1I$L;$,K!C;6
MJVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6
MJVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6
MJVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6JVUJMM:K;6
MJVUJMM:K;6JVUJMM:K;6JVUJHW&!3J([:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK
M5;:U6VM5MK5;:U6VM5MK5;:U6VM5MK5;:U3ZC2V[$MK5P>]^=%=O_HN->]2#
MOOWK&O>I!WW[]$_!_P"_D?G@W;7OSHKM_P#1<:]ZD'??O6->]2#OOWZ)^#_W
M\C\\&[:]^=%=O_HN->]2#OOWK&O>I!WW[]$_!_ZE\->_#[81^>#=M>_.BNW_
M -%QKWJ0=]_39;W7&NVNUMKM;:[6VNU<LUVJ]M=JJG6FK[#H.=5:7+=5JO\
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MG+!P\$?%N-=;4$*7FAA@X&OK6F@*.:ZZU:_L8U[U(.^_MX_\C-=G0KM<T\F
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M?U-'44FE\P_F+:EU'/JL:]ZD'??O6->]2#OOWZ)^#_KCDM%, A.]0X)>D1E
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M%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P<
MN#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%
MP< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< LLQT8' 1
MB'!'4;X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!
MP"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X.
M 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P
M"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"X. 7!P"FH1@QR'P< N#@%P<
MN#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%
MP< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N
M#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P
M< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#
M@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P<
M N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@
M%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P< N#@%P<
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M);<-8V"%66)S3I@6S-=KL24;B(/2+S'<JL7P\6BKL>SQN\!S3*M/PMU3WPZ
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M.N)\+9DZ;5JBQ:3T<U)6F[:TSLIRULO+%N/"K-ED.:#;?I=!#;[O+9:O0;&
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M+F7R.W;IM4?T#+ 9\6=_9);'K<G!P%^[< _5Z-OS*=?_ ,%/_\0 %!$!
M                X/_:  @! P$!/P%?<?_$ !01 0
M .#_V@ ( 0(! 3\!7W'_Q !;$  ! @,"!@T'" @$!0(& @,! @, !!$2,043
M(361DQ B,S1!46%Q<W2QLM$4,G*!DJ'!(S! 0E!2@Z,&%2!@8K/"X21#4_!C
M<(*$HM+Q)41DE,/B5'60%H#_V@ ( 0$ !C\"5S__ /(B8> N"SVPTI325*(O
MC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&
MB-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$
M:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P
M1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W
M!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HA
MYN9DFGD!DJ 4.&HB>;;ED(0AY:4I N%8W!&B-P1HC<$:(W!&B-P1HC<$:(W!
M&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<
M$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-
MP1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(
MW!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B'FYF2:>0&2H!0X:B)
MYMN60A"'EI2D"X5C<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W
M!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC
M<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B
M-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:
M(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B,(S#L@RX^C&V5E.4
M40(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-
MP1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(
MW!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1H
MC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&
MB-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$
M:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P
M1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W
M!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC
M<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B-P1HC<$:(W!&B
M-P1HC<$:(W!&B'4I% %70TI2 3E[8?Z17;#/-^XTQU<]Y,81ZPOO?;<QU<]Y
M,81ZPOO?;^%?QOY8_P"0#_I&&?7VP_TBNV&>;]QICJY[R8PCUA?>^VYCJY[R
M8PCUA?>^W\*_C?RQ_P @'_2,,^OMA_I%=L,\W[C3'5SWDQA'K"^]]MS'5SWD
MQA'K"^]]OX5_&_EC]TZXI=/1^S7_ $C#/K[8?Z17;#/-^XTQU<]Y,81ZPOO?
MM'%-K<I]Q-8WJ]JS&]7M68WJ]JS&]7M68L+0I"_NJ%#&]7M68((H1>#]A B6
M>(/"$&"E:2A0X%"GS<QU<]Y,81ZPOO?;^%?QOY8^E2P4 H47D/HF-Q;]D1N+
M?LB*.2C"Q_$V(4Y@\>3OC_+^HKPA3;B2A:30I/!\^HK;2HXY64CD$8/L(2BH
M7YH]'Z8EM M+4: <9A+N$U5/^@@]IAT#( H_L*+A*)5KSU"\\@@)EI=#7*!E
MTQ9#B"KBM04S,NA9/UZ44/7 17&2[F5M?PA+:!:6HT XS"7<)JJ?]!![3#H&
M0!1^R'_2,,^OMA_I%=L,\W[C3'5SWDQA'K"^]^U.XQQ+=4#SC3AC?+/MB+3:
MTK3QI-8&,<0W6ZT:1OEGVQ"U(4%I^3RI-> ;$_TZ^\?IZG5.XJ60JRJGG&)%
MN5:#>W557UE9.$[$EMAN*.'DB=IQI[H^;F.KGO)C"/6%][[?PK^-_+'TJ6YE
M]TQ,]&KLC?#OMF MJ;<-/J+5:2?5#4TD62K(I/$89GD"@>VB_2'^_=L6V&K+
M7^JX:)C(_+$\53X0$S3);K<J])]<-L(I;<59%HT%8\QK60I"A1230C8"L6V*
MBM"N')9VSC&S15DUBVPU9:_U7#1,9'Y8GBJ?" F:9+=;E7I/KV%=,KL$8.YG
M/Z=BDJPIREZKDCUQ53\LD\53X07"T'VQ>IDU]U^PW+M4QCAH*PZ^XANPVDK5
M1? (QC+8;9_U730&+3:V'C]U*B#[X4T\A3;B;TJ$-RS%"ZNZIIP5AR8=2WBV
MQ4T7 =0VEEDW./&E8*VRS,4^JA67WQY,VRM3]:8NF6+2W9=H_=*B?A%J8;!:
MNQK9JG82TRVIUQ5R4B+3BV&/X5*J?=!6E*)D#_1.71!!%". PU+M;HXJRFL.
M.K0W8;25';\$6F&J-?ZKAHF*I>EW#]T*/A!9F6E-.#@,,3C(266GQ:JK+DH=
MB9FG$MXI-5FB^#]AHIO4M15SUB7#96F3(-NS<5<NPMC"4U9+9^34NI)'%&+8
MF0Z^A84D!)]?!#$XR$EEI\6JJRY*'8F9IQ+>*359HO@B@RF M2$2P/\ K*H=
M$9)B6)YU>$6IEGY/_41E3L)98;4ZXJY*1%IQQAD_=4HD^Z,8\V'&?]5HU AM
MY"&[#B0H;?@,.R[M,8V;*J0$(25K.0)%Y@*7BI;D<5E]T%3>)F.1M67WPIMQ
M!;6G(4J%"/I3_I&&?7VP_P!(KMAGF_<:8ZN>\F,(]87WOF$](J,'\Z_AL-^D
M-B?<11F7\H<^57P[8W<<9,(;?E:R=L 3"06U>:ZCS3L6)9NH'G+5D2F/E9_;
M<2&O[P5RSJ9L#ZM+*H*5 I4,A!CR9#@;59*JJA4QCT/4(2$(2:FII 5,S89<
M/U$HM4]\)96\AZTFT"G)DY82\XI,HTK*+>51]49P->B_O!7+/(FZ?5I95!!%
M"+P8=<;?0UBU6=L(E&$*$T[,6K*6QQ4\8!F9U+:_NMHM>^"[+."<2+TA-%Z-
MB@RF Y,N)DTGZI%I6B/D\(;;^)K^\ 3*-H?-=1E2=AF:3--H2Z*V2#'DRW$N
MFR%53 ''&_&O9,?J^V+>/Q%O@K:I6'67'4NE;ENJ1R1+H;=2UBR3MA'DRW X
MJR%53#3PFV@'$!=+)X8>E%K#BFZ;8<U82TT@N.*R!*;S 5-3*);^!(MF/D\(
M;;B4U_> )E&T5YKB,J3^W,=7/>3&$>L+[WV_A7\;^6/I4MS+[IB:Z)79LSK?
M EP*TC^T%7W'4J^'QBCHK+LBVYR\0A3[NT9;% E(T 11R1*6?O!RJNR+*@'I
M9Y-1XP]+$[9I61788EYGZRD[;TN&%N)%&Y@8P<_#_OEB7;(JV@XQ?,(?F5^:
MTFUSPMR9VS2?E7?XCQ0I]W:,MB@2D: (HY(E+/W@Y579%E0#TL\FH\8?E5Y2
MVJ@/&."%=,KL$8.YG/Z8;EKF_.<4.!,!" EB7:3Z@(*699Q]L?7K9K&-EE')
MD4A5Z8_64LBR":/)%WI1(=)#C3@M-K24J')'DC#'E"V]J0DV4IY(4A*2Q,)%
M2VHUR<AA<RA/^)EQ:!XT\(B2_P"KNF%-.I"VU7I/#"F966\H0@T*RNR#S0W-
M- I"LA2> Q,82<;"7%T2HI&V6> 0VP[*8E#BK*5A=:<^2'&'4VFW!9(AUHWH
M44PA:D_XMX6EJXOX8,LTSY2\GS]M0)A36+,O,)%;!-:CDC]9LILN)-'J<(XX
MP?TR86TL50M)21R1Y'*2V.Q6U-#92GDARC99>;\YLFOKCRFGRDNH4/(32G9
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MZOS8VV$-MR-?W@NLJ$XV+[ HK1L.MMNI:+:;55"%S2YEMQ*2!92#L&9;F$-
M+***$,8QY+N.K2R+J4\8DL+XY&+JKY.F7A3#S0-"M!36%32YEMQ((%E(A]3;
MR&L40-L..$/N/H="EV*)')_;8#N27ES<MSAYA&7")KT/]X4ZRI,XVF^P**T?
M.S'5SWDQA'K"^]]-G>D'9$ITOP^FS'5SWDQA'K"^]]OX5_&_EC[5EIET$MMK
MJ;-\.)#<S522/,'C]D%E:,?*DUL5RIYHJIUQGD6V?A%1,J<Y$MJ^,+EI-LL,
M+R*6KSE#BY/I[_I&&?7VP_TBNV&>;YUOHU1/= ON[)Z97PCRE:,8X380GC,
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M/^:A&3)2)N71A"5*RFJ1CDWC+$ATD.*%Z4DP$NJ;:?\ K,N_#CBKC[++8_B
MCR65J)1)J5'_ ##X149#"&<(+Q$P,F,/FK\(#BQ*S-+E*LJC;S""1<TT:J@S
M#FU2,B&_NB&II(M 9%)XQ 6Q,H/\!-%#U09AY4LV[QI MGXQ-+?>9E&TJ :0
MZX$DCCB0\GF&G[-NN*6%4\V)>: KBEA5.. MB9;57@KE'JB99Q[6.-DI1:%3
MMA$]Y1,M,6BFF-6$UOAA$O-,OJ#X-EMP*-QAM]E5AULU282F8<3*3/"E9HD\
MQ@.8QH_Q5$*H\F9>X&FC72>"'9E\U6LZ.3YR8ZN>\F,(]87WOF0PUM4C*MPW
M)$!,NT+?"ZKSE>N+#TXPTO[JG #%I"T/-JX4FH,.3L@WBW$;9;*;E#D^>D?2
M/88FNB5V0WZ0CSAIB?Z=?>/[&#^A3#OH)[/VD/X05CUWAE/FCGXXGD(2$)#I
M 2+A^T$C*3D$+I_\M+T'.!D^9F.KGO)C"/6%][YQOHU1/= ON_--^B(G^E,2
M;3LZPVXD&J5. $93#;DN\AY&) M(-1>?FF)2WB\8:6J5I$UB&[3N)55Y>51R
M;$Z)F8:8M%-,8JE;X81+S33ZP\"0VL'@/T?"OXW\L?9N#^G1VPWTZ>Q7V6QZ
M*^R,&_B?T_8S_I&&?7VP_P!(KMAGF^PI#I(>] _8<QU<]Y,81ZPOO?,M.4^5
MF/E%'DX/=#<E++Q;KHM+6+PG80L*/DZC1U' 1! ?,P>)I-?[0\MA)0RI9*$G
M@$%,LC:I\YQ61*8^5PAEXD-?WCY&?"E<2VZ?&,3--V%<!X%<T,2R5!)=4$U/
M!#SQFVB&T%=+)X(2\HB585<I8RGF$?)X0JO^)K)VQB9E%*^:H>:KFV+3(#;
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M:VC3FAT2ZRN4M[0TRV?7"&Z.RR$"R$J1=HA2V7_)VJ[5M*1D$/>5;9QI0&,
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MDCXQ+]8'=5$R>'$?$1/6;Z ?^0V,'V;\<!L(I=;^.Q/G_CK[T27_ %]PQ/\
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MI,/KLMH<M*5?!8E9G&NVP;-A0[1$RN;=Q25-T!LD\/)$LN4=QJ4(H39(X>6
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MI-% C*(<F&9\/T1;2D-4M>_83-JFO)PHD)3B[51QWPY)2ZS-*2O%@I32T>:
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M!_0I[(5M3MT)L\L4.0_09CJY[R8PCUA?>^W\*_C?RQ^Q^*J)[G3W1L8.K_\
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M/+&/FG,4UBRFM"<OJB3$F_CL656MJ12[CAX3-0P\!50%;)'_ +P5NS##BK-
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MO##<Y*M8]2DXF89/#RPIMU%A8X(HS-.)3Q6LD6IAYU:#QDTV+:DU;:VQA\S
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M7&!^J-=T?;\CU0=J_P![L(_A_P!7T+"_6%0SZ^V'^D5VQ@KHSWCLR_5AWE;
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MUA4,^OMA_I%=L8*Z,]X_N-*=;'<7&!^J-=T?;<IUL=Q<8'ZHUW1]OX!_[?\
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M ) 87ZPJ&?7VP_TBNV,%=&>\?W&E.MCN+C _5&NZ/MN4ZV.XN,#]4:[H^W\
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MRTP'"6DM(VP%<FVXXPKEK_ASEB2]%SN'8P-S/?T1.=;/<3'_ &Z/C&#.9?\
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MIZD@]L-SS&&%SLG:LJ"B2 >5)K$I/I38QR*E/$;C[XPHU-3LQ,M(;)2AUPJ
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MU^]D'QV,),L;1M#U4A/U:Y8;>7Y[F)6?7&$^B3VQ-(5YK*&T)YK-KXF,%I:
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MNDV9FEQ<14CUQC)3!TNRX+EA&V'KA+\Q(RS[Z?-<=:2I0]<8J:EVIEJM;#R
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M!.B'7'IAN7VI"%.+"<M(PCY;/($R], _+N[=>3EOV)B5P@_Y-*+LVW;813;
MC*>6):6D7O*)1L&P[;"JY3PB%OMSC#C+?GN)=!2GG,!EC"<HZZ;D)>%3S;'Z
M3$F@!>RGI8Q*<*R9<NLXY.QA&=DIXOSS]O',XY*K%55.091EC /,SWU1B'\)
MRC3PR%"W@".> M"@M"LH4DU!B0PA-3Q9PBS8Q3&.2+5%$C:G*<L3#+,X&9M1
M1\FARBRFN7)?2,%RR)IE<PEC*T'!:'J@NS#S;#0O6ZJR(#4OA.5==-R$NBIV
M%R_E+/E"!536,%H#F@LRN$):8>'U&W03 5.3;,J#=C5A-8LR<_+S*_NMN G1
MLIE)4GRV?.*19O">$^^GKB5D4><A-7%?>7PF)^8PIC1(2OF,94Y*[4>ZIAQN
M4E1)3-/DW4*-_+$W(S"RX9)2;"E7V37)ZJ1@[])I49"KR>;2/KC_ -NP0V\T
MJVVXD+2H<(.Q@GTW.Q,85P"^?^*WRT\00?5L.RK1JS@N6MN<YI7M0(E_3<[T
M38P3/&=#A3C*O)<LTK3S8FN8_P H;&(_6LGC;K..3$AZ*>X=@NONH8:%ZW%6
M1&'IB>GT"WD0X^Z,HMFE*Q4&HXXQ3N%9-#@O27DY(2XRXEUM5RT&H.RZEN:9
M6IG= EP$HY^*,0WA246Z30)#PRQC9J8:EFOONK"1"O(IUB:*;PTX"1L6)R?E
MY9?W7' #H@KDYIF:2+RTL*IL 3L\Q+*-R77 "84]*S#<RUCT;=I04(P1U9'9
M ,Y-L2H-V-<":P?(IUB:I>&G 2-A<SY?+>3HR*=#J;(]<%R3FFII O+2PJD6
M)O"$M+K^XMT Z(/D<ZQ-$7AIP$B'7'IAN7VI"%.+"<M(PCY;/($R], _+N[=
M>3EOBIR",4<+2=NZF/3 4DA23E!'_*G &!_\M125#TUT^&PQ,S$LV\\Q7%J6
M*V8_1WG'?&Q/2I%<<RI'NB<E%&OD[U4\@4/$'8PGS(_F)B4]-SO&,-X-$PN7
MDW)AUR9Q=ZDI<.328F%232Y>::;*TKQA5:('#6'67EE?DKMA!/W:5IV[#3$J
MLM3,XHIMIO2D7TTB&U8495.3KB;3E7%)"3Q"D-+P.VX_@9^F.2I8HD<-]]+X
M8_1>4>+,L*8XCA-+1KS#@XXQ/DSA<IN^.5;Y^+W0O]&YAXO2+Q^1)X#2J2.>
M[GC 3K9HX@N*2>6J("\*XV=PBZ+3KQ=(HH\7]XG_ -%69YUK!ZW3CRF\H3XY
M(FYB2:<8F99HNV\856J936L-8Y16IAQ3(4>(91VQAB1#RV)0ONKF2@WH#EVF
MD+1(LJE)L)VCN,4JIY:Q,X.G%%<Q)$ *5?8XO52/TDYWOYT8-1).8J:<8;;;
M6. J6L?&,6\AZ8F"-M,%TA5>.ET84P#C2Y+ *I7C!%%:(E)#!B/\&M7^)<"P
M.;ANX8#;DHI]=,KJW5 G0:0C!LF^I<F_M2DG@*:T/,89PDTV4S<R]1U=HY=K
MQ>J,?),EIR893C"5DUR<L87])K^J'<%8]3."I(FT$?PY"><F"TTPY+/4R/I=
M437F)I$[^C.$',89>UB5'@I>!R<,8-1).8J:<8;;;6. J6L?&,6\AZ8F"-M,
M%TA5>.ET84P#C2Y+ *I7C!%%:-B0PHUD<E7;)4.(W'2/?'ZXR6/)?**?]-:1
M@F<F-SPE;3:^]4E/> A,HD_*3CH13^$93\-,&2I133;5OTL8DJ]]8P?)SB,9
M+K!)2%$7.&,,RLXP7&9<G%@+(IMB(P$EO)8#H3_X1C,+XW"&$'=LZXIU0HKD
MI\81@R7=6J2F<EE1O!3DKS'8?F7-S9;4XKF K$YAG#3BW)="["&4JH..SR "
MD";_ $?9<EY]E0*6VW#M])R&'3A-K$S]&PZFH.7&#+DX[X8PAA=;LRUE1+R]
MLA*4@^-8P=A3 RER]5TL6JV5#X'+#^%;-;+06E)X5'S1I,+P[AY;DXJ86<6W
M:(! R5R=D?KO 2G)%^4(4I"5DY*WBL'#RDC'):RHX,96SVPYAS#JW)Q4PLV$
M%9%:9*FG9R1*81_19MQJ:0Y0LI<]^V_WEC!BYAO$OJF$%QNM;*L6JHC!6!\#
MCRC##\LTG:9<55 ]\&;FSY3A9W*MTY;%> >,8"6UD<27"FG'5$!6%FE3^$'=
ML\ZMQ7G&^E#[XEY1IY:\$S]-JLW5--(/NB1_1W!ZRVY.4QA!I6IH$\U]82U,
M,+FWZ;9Y3BDY>0 PQ)H?6[@>=(R+X 32O..R)3K8[BX<_P#ZK_\ %!=PDZXO
M!THLMLRR56057J/O$-84P3C)53;H"D6R>8@WUB2?PDWC58C'Y%%.WLWY(F)N
M<9+C\N^G%J"R*<.QA#G;_F)C!OH+[ZHF)69?<1@N7(=<:;-+:SD'88F)[!S:
MY9Z6%LBV5!8X;XDW9A1<>3:;*S>:')[HPS("87+RJGWE3!;O4@.7::1,&2:7
M+S3;94AS&%5H@<-8=8>65^2NV$$_=ID';'Z2<[W\Z,',RBBB:<9;2VH&E"5J
MC$OM.3$P1MIDN$*KQ@70_P#HV\\79)[*T3P&EH'UW<\8 YF?YBH<PL6SY<@H
M:#EH^;7B]<2&%VVBB<<8V[A6:<N2)N9G7G$8*E3M&4FF0^:/=E,+3@]I4E-@
M;1>,4H$\M8FL&3RBN9DKE+\XIXCS1/8.EWBQY64M.+'W,6DJ]PAJ?EEOK=;2
M4@.J!%3PW<\82?\ TC?M3=KY.7<<L WY/5DR0S,?H\GR*<0L&F--*<=3<8EQ
M.%)FPV Z47%7#L2$HK*W)V<G,G&;*Y9A=O";Z:-H'U!]XPMV938FIPA:D&]*
M1YH.DZ8PFBF5#>-'_3E^$2P4:JEU*9T91[B-C!/IN=B8P!A]&1IQ*4/4Y!0_
M^)]T/33A^1:;+BCR 5C]*,.S ^7GUY#R6Q7WGW0QZ;G;&%_2:_JB:YC_ "A&
M#_T<D5V%S=,:0;ZFB1S7P&767'GZ99G&$*KS71(R$P\I_$*LMN*X46#9V%R<
MXC&2ZZ$I"B+HPS*SC!<9ER<6 LBFV(C!WZ,X-46U3(2%D&\$V4IKVPEJ887-
MOTVSRG%)R\@!AB30^MW \Z1D7P FE><=FSAK!OE"V)-<PZ[,XN]24N')I,3$
MY(-+8F)8!5<856Q7+6L(PCAY]V<:9_P\NQ;(%!PFD8(G<%*6RVZJN+*JTH14
M<Q!A;S!I-/*Q+1^Z3PZ!#6$<-!R=FIH8VRIP@)!NNRDQ+X<P$ZMAL+L.-%50
M/%//!PZT!53 4A)X%G)33"L-X<+DZ[-*)0A2R,E:5-($W@Q;C<B\L(>EBHD
M_5,2L^1:+,FFRD\*KA[X7AW#RW)Q4PLXMNT0"!DKD[(_7> E.2+\H0I2$K)R
M5O%8EYX@!Q:"' /O#(8?E9E]QO!LL<:I#=ZEG(.PQA)K]&TN.STV113BTA2!
MR')RZ8;=PTPJ9P@YMG ITT1R;4Q@[".!G%RJRL_)VZV2.$<,#RUHN)0C'H 4
M115GDB8FYQDN/R[Z<6H+(IPQ*_HK)O%EDTQY'#DM9>0)C$F6<4NF[EU5OGXO
M=#WZ,/OE^2<RL%7U32T--W/_ ,J<!J7YJL33VR-G]'><=\;!4;AEC#*_JDM
M?^>QA/F1_,3$IZ;G>,?I)SO?S8FNB5V1A'IQW=C CY%6P5@_^,)4DVDJ%01$
MM*3C^*?F-S2$%5<M.")M+V0NVK%>5%1L8*;:RK:Q5NG)579& .=SM1L87YG/
MZ8PQU-[N&'>M+[J8_29L^>I;A'J=_OL8?FV]P-W_ %+)'9'Z2<[W\Z, <S/\
MQ6QA/F7V")3 F!Z)G9FE7:75- !%<*?I-,N5\YMLJ(TD_",'R$HM;B&RFJG#
M4U**Q@[ISW8ENA3V1A?TFOZHP_+.Y'C;OY',NQ.NLY4-V[5.1%D^^, <S/\
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MP!*-97\F0?Q+ '9&"'GLC:\50GG*>W8P%*-Y7^(?Q* '88E.MCN+AS_^J_\
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M .!7_\0 +A !  $"! 4$ 04! 0$!     1$ (3%!4?%A<8'1\!"1H<&Q(#!
M4&#A<("0_]H " $!  $_(?D/_D3\S\T(T!AU5>K@1C?_  P
M                                            FE?'"'/RU9:5 !P?
MW8                                               !-*^.$.?EJR
MTJ #@_OP                                                   U
M[TN41U_\
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ML!^RA\,!+Q^*+]*\KH]/$ZU@4-RS5<CBUJMMC]V#\TJG%$;TA\^A8&#^5 G
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M >6J=4HE.J_0!<R8=)H>1GZ HM7:V"/L7K%-PB4 .D4B6?% R \<7K10DO0
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M3R4EC)Q@6RCC!Z%N:5 8+D./(XU$0"!JXW!RO0!_%]+R>%P@86XM85'K$?\
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MP+PJVBWM1=_,S*$+-3=]/VB!K%N8Q2T_8(&L6YC%+3]"U Z5TUOSYFKGHZ)
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M J2-'<(4'G"=:(5M:XZ9LIMAG1UN.2E)! K>)$<.$#0CQ&-R#D6FA#BD$5N
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M22222                                    0
M           0                              "
M                                              ""222222222222
M22222222222222222222222 22222222222222222222222222222 222222
M2222222222222222222222222"2222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222220"22222222222222222222222222220"22222222222222222222222
M222222202222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222 22222222222
M222222222222222222 2222222222222222222222222222222"222222222
M2222222222222222222222222222222"2222222222222222222222222222
M2222222222222222222222222222220"2222022222222222222222222222
M0"22222222222222222222222222222202222222222222  222222222222
M2222222222 "2"2  2222222222222222222222222222222222222222222
M2222222222222 222 0"2222222222222220"022222 2222222222222222
M222222222222222"222222222222"  00""2"" 2 00   0"00 "20200"2"
M0220 0"2222222222222222222222222222222222222222222222220"222
M"00"2   2 0" 020"  20 2220"222222222222222222222222222222022
M2222222222020"02 0""   0" "02"  ""2""22 00222 02222222222222
M22222222222222222222222222222222222222 22202""02 002002 02 2
M"" 22"22 2222222222222222222222222222222"222222222222"2200""
M2"   0 0 00020 2  0202"""000"  "2222222222222222222222222222
M222222222222222222220"222"02""""""2"2 "  00 0 ""220"22222222
M22222222222222222222220222222222222000""00202 "0    20220"22
M2"2"0"02220 """222222222222222222222 "2222222222222222"22222
M222 22202"0"0 022022 """2 0 0 "22 22222222222222222222222222
M22222"222222222222"2 "220022 22  222"20 222"22" 0000"2"22222
M2222222222222222 ""0222222222222222 0"22222220"222 0"20 "202
M2 00  22 0"2"220"2222222222222222222222222222220222222222222
M2222"222022222 "22222"2220222 2"222"022222222222222222222222
M"20"00" 2222""220"0 0 222222 22222222222222222222222222222 2
M222222222222222222222222222222"22222222222222222222222222"22
M222222222222222222"222222222222222222222220220 ""0020 "0022"
M"200 222220"22222222222222"22222222222220"222222222222222222
M222222222222022222222222222222222222222222222222222222222222
M2222222222222222222222222"2"0 """2"  20"0222222222222 222222
M22222222222222222222222 2222222222222222222222222222222"2222
M22222222222222222222222222222222222222202222222222222222222"
M222222202020"000"00"20" 22200"222220"22220"2222220 222222222
M2 2220"22222 22220222222222222222222202222222222222222222222
M"222222222222222222222"22222222222222222202222222222"22" 0 0
M"22 "22""2" "22222 222202"222222  "22222222"2222 22222222222
M "22220"022222222222"222222222222222222222222222222222222222
M22220"2222222222222222222222222222222222220"2222222222222222
M0"2222 02202"2 " 220 ""0 022220"2222220"" 0" 22 0 "2  222222
M22022222222222222222222222222222222222222222222 222222222222
M2222222222222222222222222"22222222222222222 2222222"20 22022
M02"00"2222222 222222220 "02  "02 22"020222222"22222222222222
M222222222222222222222222222220"22222222222222222222222222222
M22222222222222222222222220"2222"2202 "20"2"200"22"022220"222
M2222 200"0220 22222"2"2222202222""22220 22"22202222222222222
M222222222222 22222222222222222222222222222222222222222222222
M22222222 22222 2 22200 222"2 22 "02222 2222222220202""2"0 22
M" 0 222222"222 0 ""00"0 "2 20"2222222222222222222222220"2222
M222222222222222222222222222222"22222222222222222220"22200" "
M 202"2"  2 2020 22220"2222220 20020" """ 22""222222202220 2
M20   ""002" 2222222222222222222222222 2222222222222222222222
M222222222220"20  "  2222222222222 22222222222222222222222222
M222 2222222222222222222222222222222"222"222"00  "20200"22222
M22222222222222222220"222222222222222222222222222222222202 "2
M02"2222222222220"22222222222222222222222222220"2222222222222
M222222222222222220222022 020 2""" 02 2222222220""22222220222
M22 2220"2"2222222"2222222222222222220"20202" 2222222222222 2
M2222222222222222222222222222 2222222222222222222222222222222
M"2222222222222222222222222220 2 0"22222"22220"2220 222200220
M"2222222222222222220"""0 20"2222222222220"222222202222222222
M22222222220"222222222222222222222222222222022222222222222222
M2222222222200" 222" 0 22222 2220"" 220"""0222222222222222222
M2"22 22"0"2222222222222 22222222 ""222222220"22222222 222222
M2222222222222222222222222"22222222222222222222222222220022 "
M  "2222220"2222002""2 "2022222222222222222222222222222222222
M222220"222222222" 220 """ 2"22222220"22222222222222222222222
M222222202222222222222222222222222222"2200"0" 2222222 2222222
M 0 2 2002222222222222222222222222222222222222222 22222222202
M""002202""22222222 2222222222222222222222222222222"220222222
M"2222222222222222222022 """"2"22220"222220"2 00"22"222222222
M2222222222222222222222222222220"222222222" """222 " 22222222
M0"222222222222222222222222222222022" 0 0 020000 " 0 "2222222
M22222222222222222 222222222222222222222222222222222222222222
M2222222222222 222222222020000 20"0"22222222 2222222222222222
M222222222222222"200"2 2"""  2 "02000222222222222222222222220
M"2222222222222222222222222222222222222222222222222222220"222
M222222""  "2""0"2222222220"222222222222222222222222222222022
M2202" 00 2  "0 0 2"22222222222222222222222 22222222222222222
M22222222222222222222222222222222222222 222222222222222022222
M22222222 2222222222222222222222222222222"22 ""02" " 0""02220
M2222222222222222222222220"2222222222222222222222222222222222
M222222222222222222220"222222222222220"2222222222220"22222222
M222222222222222222222202222222222202222222222222222222222222
M2222222 2222222222222222222222222222222222222222222222222222
M222 22222222222222222222222222222 22222222222222222222222222
M22222"22222222222222222222222222222222222222222220"222222222
M2222222222222222222222222222222222222222222220"2222222222222
M2222222222222220"2222222222222222222222222222220222222222222
M22222222222222222222222222222222 222222222222222222220
M                            "                             "
M                              0                     "
M               0                  2 222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222022222222222222222222222222222222222222222222222
M222222222222222202"22222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222222222"
M022222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222202"2222222222222222
M22222222222222222222222"222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222"020     "20222222222222222222222222
M222"0 2 "0  0 "222222222222222222222222222222222222222222222
M222                                                      "22
M22222202"022""2022"  2" 0 "0"2222222222222222""""0"2"0"00222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222222222222"02"00 2""2
M0""000"00   0"2222222222222022 2 0 00 0"22222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222202"0 0""" 22"20  "222"02"2222
M222222222020"20"22 0"022222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222"02"0 " 2"2 0" 22 02002222222222222222222"2"20
M2 "22222222222222222222 22 2220 222222222"022222222222222222
M2222222222222222222222222222222222222222222222222222222202"0
M2"222 222222222222222222222222222222222222222222222222222222
M2222202   000 "20 2 0"0  22222222222222222222222222222222222
M222222222222222222222222222222222222222"02"""0  "22222222222
M222222222222222222222222222222222222222222222222  2 20"0222
M0  20   2222222222222222222222222222222222222222222222222222
M22222222222222222222202"00"020022222222222222222222222222222
M22222222222222222222222222222220"0""02"000"""22002"222222222
M222222222222222222222222222222222222222222222222222222222222
M2222"02 0""2 "2222222222222222222222222222222222222222222222
M22222222222222" 000"02 20 0"20 "0222222222222222222222222222
M222222222222222222222222222222222222222222222202"0222 "02222
M22222 22222222222222222220""22"0 "2222222022 22222222222"2"2
M2"2202222022 22222222222222222222222222222222222222222222222
M22222222222222222222222222222"02  "0  "22020222"20"20 222222
M22222220""22 0222 22222020""22222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222202"0220220220020 2"02" 2 "222222222222220220"0022
M"2 002222"22222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222"02"22
M222"200 2 """0 0"0 222222222222222"22 2202 ""2" 220022222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222202"222222220  0 2  2"2 "
M"22222222222222222 0"0 22"2"00 """ 2222222222222222222222222
M222222222222222
M          222222222"022222222222222222222 "222222222222220"2
M2222222222"2222220222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M202"22222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222"022222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222200"2222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222"222222222222222222222222222222222222222222222222222222
M222222222002222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222202"222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222"0222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222202"2   "0 2222222222222222222222222222200"22
M20""00022222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222222222"
M02222022"2222222222222222222222222222000 0"2 002""2222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222202"2220"20222222222
M222222222222222222220" 0 0 0222"2222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222"02222""2"22222222222220222222222222
M220  0  2  22"2222222222222222222022222222222"02222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222202"222 22022 "2222222"22 222222222222202000202 002"222
M2222222222222220 222222222222"222222222222222222222222222222
M2222222222222222222222222222222222222222222222222"02220022"2
M222000  "0 0 "0002 2222222222222222222222222222222222222200"
M 2  00"22220"22222222222222222222222222222222222222222222222
M222222222222222222222222222222202"20"20 0222"2 22002 2"02 2"
M2"222222222222222222222222222222222222220"0 202"0 220""22222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222"020"00 0"22"22 220"0 20"" "2"222222222"222""2
M2202202"02222222222222022222220020""2"2222222222222222222222
M2222222222222222222222222222222222222222222222222222222202"2
M 0022 22 "22"2 """" " "0 02222222222"00 22"200 2"0  0"222222
M22222"2   22 ""20"222222222222222222222222222222222222222222
M222222222222222222222222222222222222222"02020020"22222222222
M222222" "2222222222 0"""022 200022 0222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222202"20     22222222222222222222222222222
M"2"0 0""2220"  2"""22222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222"020     "222222222222222222222222222202 2 2"00022 0""""
M2222222222222222222222222222222222222222220
M                            22222222222222222202"02222202222
M2222222222222222222222222"" 2"2200"002"022""2222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222"022222222222222222222222222222
M2222222022222222222222222"2222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222000                                  "
M                  "                               0
M                                                      "2
M
M
M                                     "2222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222220202"22222222
M22220 222220"2222"222 2220"22 2222222222200 200 22222222220"
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222200"00" 2222 0022222"022"02""2"0
M" 0"2 " 2"02""0"2"" 2222"202"0"020 "00" 0  00" "222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222" 0" 02 " 2"202" "002"2 "" " 02 " 0" 2""02 00"2"
M00 20"22220  022202"2 0"0 22"""22222222222222222222222222222
M22222222222222222222222222222222222222222222222222222202"00
M00""0222""" " 2"" "  0220""0 22020220 """2"2 "" 002"2"0""20"
M202 0"0"2220022222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222 00"  222 "22"0020 0 02
M  "2" 0"0 0 2""0 ""  002"2 ""2200"2 20002222 "20"0"220""2222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222"2"22222222222222222222222222222222"2222
M22222222222222"2"2222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222223_Q  4$0$
M          #@_]H " $# 0$_$%]Q_\0 %!$!                    X/_:
M  @! @$!/Q!?<?_$ "X0 0$  @$"!0(%!0$! 0    $1 "$Q05$087'P\8&1
M($"AP=$P4&!PL8#AD/_:  @! 0 !/Q#W;N_^1/>>; =&9P  8LJ#;51O_!@
M                                                       !!0$<
M# [P/JY$-4,Q [ !_>P
M      ""@(X&!W@?5R(:H9B!V #^_@
M                    !S+C-N&Z1*>;_H
M
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MT\*>7([YAP!M70;<!P5I3LOLBQZY DAXE!\; K+<0%5N 4)IB:R+9(<>8]<
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M8@.2;01XII1X>!&RPD7U,*V&AK/S2NVA++Q],,3'O,9QN5R.1;1EYCX%0<!
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MA806HN'T5X  ]*U5_++ML\#;!1%'5<=1[ IIA&AW5AH] =L8G46#S5'UP*X
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M'JI:K^=7;0RKO!>U]UMPQK&6S5>A&6C>*6$J=78%1FJ@7-[%9#0X7:OGGO\
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M*?$USPV^=Q2(!W2N&'<5)JTM[<@"7DA$'!H,)C["04^NDM_+\NNV\&"$D Y
M^6=7(L2H *H50\..L-RQ1#$=C,XNACJND&PV'&=+7&5>%8%@+V/#QA:0>XN#
MAL$)@;:L 5"#9+EAN5)_9$KZ4[.#^<(A[@%'("/48X2J.B5H%ZPQZ9R?V8/#
M 'U#.7?FZ@VUH.EYSB\L::4'#63> O$W%\BZJ'F()$,+$0>8A(H^IY8P.RS]
M$5_3*.K%::1]%.TFX6(RGWH !YB#A@!N@QLXR\Z9P+SA][-/T05+YPROPAE
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M,8X2GW?&DSMD^T+]L%25MY8'W?JR7*/H"!*1UWGAA,.% *B&P;=W&/?*U0"
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MHCUJ82WFE-4/)->>1\66]+H4.#D^H$VDJ')$U($3>YE=T4 X1HL(:J ;\5X
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MDFCL;%L4-*!>+&3#YJP=M*?KEAP.)/* LU1!*4V5J[UF&J:^]K@T4*W3*T=
MFA>%>PAHEZ10?5^N$-%5)J"H,HD01$P!A''%VGE5AY-ZWN U.4XUTX9.O^+&
MS5)CV+O_ ([#0U+MOL/=XV=!-3X!=[!4//WP9+OKH104NW)MX#CP8P%7T"JO
M_?!-<!/KG[KVQWR/^7@,J?7483ZGT!CK,BDMD=T5.(>%0Y:"[/0 4+!MQ:0]
MY2V\X&>[]N#R"7Y1^J/K@^VP;( P"![KN8-]H 9ZCJ%Y&&;X(E/( _?!.T2
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M^G<)8J";YH'F9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\
M_C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\
M9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/
M@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\
M_C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\
M9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/
M@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\ _C/@'\9\
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M-4:OND1K0U8ZHUW<ZJG3[\)\@Z.882B'16JJHQTNE%)I0HCI'"JOTQ=R0/1
M[L.G1^2TJ>1@9M11!L8 0#L8%[X,,B*!X" (: 8;\M$\USP7R^_)I(Z6BB4=
M!2HFT ']D?3E0F$RFR@!2L%"U!:Z6N\HP>F^K"JA['7_ (M'@%J7"!&TH1$_
M 5N^NI(X3;AXR$D$E>@\W1.F,>ITNKH3@[+U\1W41).Y7Z).O.6O('DKR:66
M'IX,OL:(?<)KSN>-Z\*9(2@['I.*?D@KK[PB$>C9=+>F4^82"JF+:0@.AETF
M;\,QLNAB":#FK[A(,IYKG#2R(!L=?1!5T?Z"S??^WY+[/W_CAH1D)$ 5=THM
M6NF$K6=$&S5B CO3ERFA..6]4!QM23=.1.O,?7 IC(! P3LM,)EV8A<-4.PA
M?5\&'M$]&^B^[+YG$+Z-1:.C>&,%%4'@7:\G_.#[Z<^G+JVC @T0>4CT-F&L
M\4PZ  8(;7I%$* 0FD$F68@VH@ D*-S[,WO5)/04Y70&UT5RZ+A?U:4>F&$X
M45M@<9C K->-+!D8)HU2+>1-^EP'*W32H: !5<2+-^!V 'SEYY3>S6JR"3<
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M&NL1#;@G'R, @K=\3*V6W2Z.4@$3@S6]0FK0. ;1AUQI,:Z;"$HZ6"D$*L"
MZ +EJENV],?CIML&#=70&\$:\D/8@AXZ!43A,4X;--*=1$3UPCBL=*,*4=!O
M*$*922-9L!8JF#T0T6ZFG=Y?]8V_ T"@W-*BE18 756E:I:*&APWIHUC5[;+
MT/4=.<X"!BI7J$7F,M?@FSC.@1ZG_KY].F^_]OR7V?O_ *$-",A:*(G9&F'G
M%$0BE4"\3E\'RL!I7.X>EP(UB\]1N^A=44]'-(> ;)T2*MEE\%#=A%-& J;'
MA^,^[-M7ID=WT08/)H@U@*:L.HO0+#-1H@ (,Y*"LA@<!:73\J<X%=\_6\3N
MJZ.8H: 'H!HR"1U9*S0*D:,;CZ!],;ZY>"2B0@;I)3>V*):H4R,$]&$8D3+E
MWZQ<30@%!>+CLVU>F1W?1!@\FB#6 IJPZB] L,U&B  @SDH*R&!P%I=/RIS@
M5W\&"&$;@TWZYT@H."-.B">BW*'T=(Y'$;U:5VJY-(DI%T582K84KO&'FI0$
M:X+9V9@P-"%>C3M+A";!#WT26',@4 .Q'PHZM(<;"U=O67+522VML'==Y#-9
M.&T/^*CR1S;[I)( #HFOF_SCZ<SBB&_[:"/0_I$C81K7$8JI:RBZWK@IT;S>
MZ%.).A8R[1\"8BQJ0O*C;XZBTLH\D4PMQ3:4AD2M(CSJBX#^NUN(!1W"LYY9
M'<33K\:1V T* O@R/R)T2Y78 "<)U(-25["G]&"#8A$&D)M%\V&I73 M'>?\
ML1VAR5/<E(^>>O(%S"J*G"OT,\F-@+8M?A.<S%[.O,1U:""".D>N!+U^ Z;0
MPAH\OP<O5+0+J=U;?2'3&IW?0B/95]&*K.A;H ^@!X4&56G.4AQ+05Y"R*RM
ML/+:^IQ-#70(BK0EZKSO\!3P[?IJ'Z;?H?Z^?3IOO_;\E]G[_P 4-",# &24
M)+&!^O\ 4@P8,&#!@P8,&"Z%V)=(#*CZ?@U(#S:X.X7E@'TJK%@TRT-4/2S<
M(^4(G4YRH0M&OJ#0Z?EIO"KMGZWXI@&AZ"<2V'"B2K5>\-JW.;&(/AHL70HG
MH*KH+D$ >F01]%(=C-2 \VN#N%Y8!]*JQ8-,M#5#TLW"/E")U.<J$+1KZ@T.
MGY:;PJ[>#&B/8=LCBA6 L9>[2^K&:#-();49'48G68@+*6'P%C(EK0=8NC"N
MC()R4GLG*T'9(KM&-:':%1Q@QRQ+>2P'0JAX42D[!0D0ZB*8C @5S /K,^O'
MR)#=*G0AYR, @ (!P?G'TY-C,-/XP#T?TR1L)>(=HM)U'H& V()LP6]>;,Z9
MY3B[$H^ZUIKA$"(^>-'&MJ#90T$;Q[8:(T>7"0!56:Q#S"(MO<*IZ7V\"5 9
M JPNLK3W5W)@DNCHV*<>V6*H.M'?/!*HB XAJVQ-(DP@!\72IV*%XH==SQ\T
MCP]$7GD4:1PR<'!77:G9P>6=<4#)\C;M)$'J[G,\K% KHPL:G*1 TEN!U\_B
M<O%\U (WL(,BH8=.D[XA9W<1Y3;?5PH!<P.. "V!P^ RP<.XJJ!"G<!\$T"W
M8.]O/]3_ %\^G3??^WY+[/W_ ):&A&VO3@BP0)LTH0<FA"]^M>?*I^F S'CR
M.0&GFG 4>6DY%5VBJ2JJJKBC=Z3Z%#1X6,<^E4H1093L8$OR@J4-1FVNV.@I
M<+302,4/D9T0V60+2J. .2"J%V"<+YP<X;41\]"="T@-(!PVO3@BP0)LTH0<
MFA"]^M>?*I^F S'CR.0&GFG 4>6DY%5VBJ2JJJKAP*_)L2!I/T828-?UJV#?
M4>F&-@6Q1#A  TLVG>-QUEPSO$9$#0<#X*0'* MT@!)2?ACP)&'3IUPO0S#J
M8U[A4#?)D^@1,\) 764*I4@9 G=[]EX#C!KH0\YL^P[9K/":.INXHDZE^=?3
MNS9X+JW363MFBS^**$]D1^O@H55P.(R$4-'1R^!DR$D'4-)013KX4D?FH!^/
M%* V*&+*9-F(E= 0(.^!6[S?1UN(.1N^%>;300&A@!$@]'%@GK'J+KHBNK08
M0OF#TT<V=D=D<'K('@O4="" *6CD.31*@&.@ @Z'=5?!D7@WJM,GB4()%Q<5
M8$CH(4TAVX=F(>I6*&/4PV!" +;R0;:A V .R!),;=4[11!XZ7D!EL7F,25O
MK! .QB-P03U%WW6(" \/42VG81-ILI#W=Z R2BDX/.&1$'H1V78"[5 KH8#V
M4A2Y8[VSISBJF<5%D@M*4&=#$?)6SD*MA$"#O@1W^)?BM ]0^6'W_:)TB"AI
M;^^'XLI//+$6!041P[.S0NM7U\X.<2+B&QHH*%.EC@06TC]I;4*;-BR*V=0
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M]V#H-H.N7_X1&&A%#:3>+^5 V,4GZ7#8]*(7%>O:#T@P 1T%5W@!Z)QC#A@
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MB*$E&$OB'-OBX,=IB&I"$+M@8F4XZ[0AJ75([+HA>ZN.UL(54(6S>)A;HUH
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MX6&M3'10OH_T;#X6Z0JDWEHD3PZ/I2OD"7[(F$T3T;I89-57S\'_ *SU^J9
M)U67C2>DM6=Y'S,KIM$M.65<*BLYP>5A *5-!:M]L(A2X6S00%0%Z&#(_0D
MNT&K2\<X5KDV;H5U!4BZX0,@W0Z@-1:M=L(19Q)*'#3JI.F=*ZY> O(-Y<;P
M90N.6^&+LMX.,%N5'F@,!H=1#0#"(U\J4!+C07>FL<[8#@]'05+*LF2UP;1<
M0!8 JZ#6+: J(>%.P$O/&6, @T#1D1;=MP.7(>#0J$=- T3"NUE1[*"^>:]
M(,X=YE8(*P*X,CS9@""O/_&,O""R"7#7JN,]:#=Z)IZ/D@XQRR\M1$8@6-'D
MV(WTL8!,8 @'0#&"W7\/A4X!H+.:[%,;AA=6-*0Q'--); "'8;FI7;FHA#U"
MWDFG9,-+H4\UY*KP'=*EZVU5BW1$0>1_)GT[GNHPZ"FZ7[KJ,&5@#K5O4M[
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MMJ+!F6G.3)H%0LLAT7&5I&3@\VG7T(#N_A:AFF _7/BSM"#I4* I;DLR5XT
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MF^HY*4_R %%+KKPX<\^I.CE 'FN?2!6V%JO1<$ C1V)A\XK/:*BZP=79RVS
M)\^OM9YB!WU*0>CX=K&#F J:(-=>!R]8)E>* J$4'>,MB(%RD \UPX59UM F
MKHCS-*8-D%!+=CTDG <XI7:);'1EB0)-8B=MZ"@B<F"3805<4T><F+?VG3U+
MI?+Q!)3S.8*OD;QL;#I><L:/.3P<<F0W;D97D;SSPA%\4#S3PKG3>^^2?H'(
M*)';W4#9R'@<U+Z1,/T#DX/AMXK@>H>)Y6C8N6X2^5NDN*4F,HA!+$)7#N8
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M&4B/25=R:Q FD1J"+D1]>10?2>6--^1;H(:D!H3G\&G=S6/IBJ@#N])T%X/
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HG>[M_90%&&H)?75EO6WD""D:U:1;$:G 7QB1=?8:,(52KGU__!7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image96.jpg
<TEXT>
begin 644 image96.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" .<#OD# 1$  A$! Q$!_\0
M'0 !  (" P$!              <(!08! P0""?_$ !H! 0 # 0$!
M       #! 4! @;_V@ , P$  A #$    ;4@
M                                                        &IR^
M(&NUXTLQ83WS(^>R)7DG&G/(M>4
M
M
M
M                      07=KUHT:W6X  )NISV=S;78Z
M
M
M
M                                       !#EN"JFG4X   !.]*Q9C.
MM
M
M
M                                                      #'^N44
MVJ&+]>0   /IV[6/>W.'V
M
M
M
M             !#5N"JNG4     G6E8LUG6@
M
M
M
M                            *O:52$;D     &\PR76Q[P
M
M
M
M                                          %4].I#EN     #;HO=
MX<:^
M
M
M                                                        !76_
M6KU?K     2A6FM_E7
M
M
M
M           -'FCI1L40    +19MN;:<X
M
M
M
M                          I_K4HPL1    ;'X]WDQ;WHYT
M
M
M
M                                           8CUYI?L4M7D\   9'
MG;DY%W=89
M
M
M
M   !B_7FLFE6B&U#\N "0X);19MK:HO8
M
M
M
M                           & ]^8ULQ83WYR7GLAUY=OB]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             #5Y/'>[EO'?7SH
M
M
M                                                   '1WF,]<\O
M>='7UQWN^[RR/GU]@
M                 JWI5(4N0<F?\>I @EERI+*-:;Z
M                /'WF']^<1[YX.\Z.NCO/OCO=]_GN6\]S<?KW<Z
M
M      //WF&]\\O>>OSW-^.]KH                    '3WF+]<\O>='7U
MQWN^WRR7GU]@                           &/]<T&>/2)H].E\:S+YUV
M3QC^\X  !].YCSW8H_6T1>]RA][Q#)O,/OT<Z
M                                  -9D\48VJ/RX -RBDM5F6MSAD
M                           '!J4OC19X]&FCU*7SJ\OC#^O/     ,KY
M];1'ZW&'WO,,F_02;5%[
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MB.U#%MF'19_'6X        /0[O\ 7DE*M++56;.>/0
M  ZW(GM109=@T">+@           '8[)E:2<J=B3*TO(            !\E.
MM:E&]B(   "18);CY%W[                *H:E2'[4    &XQ276Q[OHYT
M            5OT*T 7JP  S7GU>3%OY'ST
M#3Y?$'7:\1VHL;Z\@            9GSZEVI-,E2;=89              !5
M+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M        _/G=SO-W@  &R1^[UXM\   0S;@K9HUL3Z\@     #V<[>S$OY?S
MZ            ^"*[4,%W8(]GB^0           ?;LDUY)QI6)0K2_0
M            !\$.VX*\WZ^MR>              !MT7NQ%"S+%6;D
M      &$]^:0[-'$^O(   %BZ%FPE"R               (<MP53TZ@   'J
MYV[&/>VV+V            !$MJ&I6I3   L-0LV)H60
M       (\GBKSH5XZGBX               !(,$L]T9Y1K3?0
M !5+3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5
M<          _/G=SO-W@  &R1^[UXM\  8WURJNG4BRS"       +*9]J>Z-
M@           ?)$-N&O%^MJ\G@              ;5'[L-0LR[4F^@
M          :#/'6+2JZ7+&                -ZADLYFVMYAD
M  $7V8J@ZM+@   ':[<S(N[]!(              -:D\4DV:/@[P   "T&;;
MF^G.             -'FCI3LT0.0<@V#QZO9AZ
M  &ES1UKT*T<6(@                 -OB]V2S[4G5I0           !5+3
MJ0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M      _/G=SO-W@  &R1^[UXM\ #59?%/]6GK4G@       ;G%)=C&N]CH
M        &C31UBTJNC31@               #=89+.9UK?H)
M   /-WE<="M!-V#Y<                 'V[.U*>QN?9]/.@
M5ET:L%7:X   &P^/=W<:]D?/0            !U.4PV*6B31@   2I6FMWE7
M              -?D\T5W,\#D'/1SDO%AZ&RQ>P
M!C?7*WZ%6%;D/PX                   ))KRV=S;6TQ^P          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\ :3-'3O6IXKUY       'V[=/'N[S#(
M        .CO*[7Z\"7J_6X                 /HG&E8LCGV?7SH
M      UJ3Q4G5J:7+&                   -OB]VVR[FU1>P
M!Y^\I7L4M,EC    EJK-;7+N             "N6A6K[>K    9WQZN[C7LK
MY]              8?WYHCOYP.<@Y ZMGCW91J3@
M 1C9BJWI5,%[\@                    >KG;'9]F=:5CZ          !5+
M3J0[;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M       _/G=SO-W@  &R1^[UXM\#2YHZ;:U/&^O(       $YTK%G,ZT
M      ->]^:E:M/1IHP                  !M4?NVV5<V^+V
M  (]GCJ+JT\9Z\@                   #W<[;#+N2C6E           &J2
M^*3[%'Q]X   !:/-MS93G            $>3Q4VUZ?PX   /MVXN3<D>O*
M            ,3[\T2^@S>0''7(.2R^5<FFA9                     ZW
M*W:-:!KM?@                      $I5IK9Y=OU<Z         !5+3J0[
M;@   'Z$86CW\Z                   -$FCI7L40  !*=::WF5<
M   _/G=SO-W@  &R1^[UXM\:W)XI;L4L-Z\@       9SQZO)C7_ '^>@
M      :'/'4/5IXCUY                    'KYVUF9;EBK,
M (IM0U.U*GG<      'T[M4?K?()-QA][''ZS_CU[O/?7SH\O>8KUS7Y/.K2
M^-+F\:!/'AO7D      #L=LYFVIOIS@          "%;D%6M*H   !Z^=NOC
MWMMB]@          #&>N4BV:& ]^0   )_HV+(9]H              #7Y/%
M(/H<T<N <CKDL?DW)MS[0                    Q?KE1]6G'D\0
MR/.[Q!)N47O:8O>P1^LSX]9#G?1Q]'0>/US%^N8+WYUR3SJ,OC2YH]3E\_+@
M       WZ&2WV3=R?GH         JEIU(=MP   #]",+1[^=
M       &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #9(_=Z\6_P"#
MUREFO1U*7P   !DN>I(K2;M#)G?'1K<GF/YXX]L1]#EMLNY+-68
M",+,52=2GY>\      ')M,?O>X)-SA][''ZS_CU[_/?7SO)Y>\Q/KF D\ZO)
MXTN;QH$\>$]^0      /IVRV=9G>E8          $36H:G:E3J<     ')(,
M$LNU)I5K2YOQZ      X-/E\17:AA^W#JLG@     #DLIGVIZHV
M  !4O4IQ):A    W"+W=;'O>GG0          *DZE.)K4(   &\0R71Q[O<Z
M              !J,\=,M_,'/0'+@Y+%Y-V;<ZV                   !K
M_OS3S7I:G)X      &UQ^Y<J32A6EW6&3[       ,5Z\QS8CBRU%%EF'P]X
M      -WADN3D7??SH        %4M.I#MN    ?H1A:/?SH
M      T2:.E>Q1   $IUIK>95P         #\^=W.\W>   ;)'[O5BWZD:M.
M*+,(   VB/W8.A8ERK-Z.=  &,]>8WL1RW5F          BZS%4C5I]#@
M  Y-]@DEZK-*U6;.^/0      U&7Q%=J&'[4.I2^      .2Q="S8.A9
M     $;6(J@:U/H<     ['9CJ33Q1L;A%[         $?3QP3>KQ39B^7
M   .2SF=:G*E8           QWKE(]FCKOOP   !.-.Q9[-M          "%
M;D%6M*H   ![N=NUC7MGC]@              "/+<%2MW.Y!ST#G(++8U^7\
M^T                   -=D\TRUZ.O^_(     ['9<JS3G2GWR"0
M   >/O(EM0P1>@TV6,     "1();A9-ST\Z        *I:=2';<    _0C"T
M>_G0                  !HDT=*]BB   )3K36\RK@         'Y\[N=YN
M\   V2/W/%*>L>C5   [';!4+%@J-COYT              1[/%3O6I^;O
M   /MV7ZDT\4I]UAD         &A3QP3=KQ-:B^'     !9//M3Y1L
M  #4)?%+=BCX>\     DVO+97.M;;%[           &G2^*V:-6-+$0    '
MT[;'+MRY5F           T&>.F6O2ZW   !R6YRKDJUI@        !JLGBDV
MS1\?>    6JS+<RU)P               (BT*M:-J@.0'.1T+3X.E)=*P
M               !@O?FF.O2UN3P    !R2[5FL7GV=FC]@           #@
MBZS%7/0K:=+&     )BJ3VMS+8        JEIU(=MP   #]",+1[^=
M             &B31TKV*(   E.M-;S*N          ?GSNYWF[P  #W\[U'
ME[P  9+SZMMEVY'KR@              :M)XI5LTL=WR    !(]>6RV=:W*+
MV           -2E\5NT*T7680    .2U69;F2I.       ,9ZY2?8HZW)X
M  &0YVS&;:F>I.             (HM0UATJN%]>0   !ZN=N;D7=XAD
M      KU?K5UOU@   ,IY]7=QKV>\>@       !T=Y2S7I:5-&   !+U6:V.
M7<                $"ZU*"-6ER.\Y .06]^<U=QK3
M #Q]Y3#8I:7+&    !M,?NTF9;D*"0              ?!!UVO7+0K>'O
M  +.YUJ<J5@       "J6G4AVW    /T(PM'OYT                   :)
M-'2O8H@  "4ZTUO,JX         !^?.[G>;O      !E?/JX^3=W.'V
M         !X.\I3LT=5D\    #V\[93.M3;3GY             (NLQ5?TJF
M!]^0   !WNW)R+N_P2       5(U:<3V80   !MT7NW>5<V:/V
M    ,3Z\U6U*D7V(@   !GO'J[F->ROGT          /@IMKTH\GB    D*"
M6Y61=^P       "M>C5@2[7    V+Q[N[C7LAYZ                *R;N;
M%NA5Y .>AR"[7RFUD/'H                 #@J1JTXHLP@    3;3GLQG6
MO5SH               &MR>*I:=309XP   !W.W5Q[NZ0R       "J6G4AV
MW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M  !^?.[G>;O      /0[<C(N[_!(               *HZE2'K4     VB/W
M;S*N;7%[              &,]<JSIU(ILP@   #,^?5W,:]FO'H     "%+D
M%6]*H    ),KRVURKGNYT               ?)7+0K0!>K<    $HUIK?95P
M          # ^_-(MFCB_7D   "Q-"S8:A9       $;6(J=ZU/Y<   '8[<
MW(N[]!(                !4+Z7(U.S"Z'( ,EX]76^3V\7ZC]//7KYZ
M              @J[7K+HU0   !W.VAS;4T4YP                !U.5HT
MJT&7*X    W.*2Z^-=[70      *I:=2';<    _0C"T>_G0
M      !HDT=*]BB   )3K36\RK@         'Y\[N=YN\      LWG6ITI6
M              !#MN&J6G3    $BP2VXRKF2\]               '!7F_6
MKQ?K<    $D5Y;C9-WD     UN3Q2#9H^/O    )2K36VR[??SH
M       $$7:]:-&KP    6GS;<T4YP          (JM0U&U*?    .QVY>1=
MD""0      8GUYI#LT<)[\@   6)H6;#4+(                '5WE(_K</
MI]<'(!SW@WNE8M5\WK\$'7,S>(;.]0V@               -/E\4HV:/G<
M  ]O.VYRKDDUY0                  ()NUZT:-;Y<    M7F6YDJ3@
M  52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE
M7          /SYW<[S=X     )$@EN5D7>0              # ^_-'=JAX.
M\    DJO+;O*N>KG0                (1N05@TJGR    6=SK4Y4K
M%/-:E&=B(   #>X9+E9%WU<Z                 ! -ZO6[0J@   9/SZO-
MBWLMY]           5@TJL'W*X   &P>/5W,:_D_/0    !P5#U:<6V80
M) @EN9D7?L                 U6S#47ZG&.#D Y'4R9%Z?L/2'4Y5K1P]O
MBL3Q3U/MT              ?!2W8HZ+-&   ![>=N%DW9 @D
M        A>Y!5O2J_#@  R_GU9;.M3%4F       %4M.I#MN    ?H1A:/?S
MH                   T2:.E>Q1   $IUIK>95P         #\^=W.\W>
M   =CMW<:]MT7L               5&U:<4V80   -TBDN=CW?;SH
M          $%7:]9=&J   ![^=O)BW\YX]    1;9BJ%JT@   ,QY]7=QKV:
M\>@                  *MZ52%+D    $X4[%G\VT          !YN\I1L4
M=0E\    2O6FMQE7     !!MVO6+1J@   9+SV[F-?V'QZ
M   $5:=.N?T&6.7 Z'(+'?/:LHYEP#%>HZA:/S^SQS6;H[>0Y[
M    @V[7K%HU0   .]VX&3<DBO*                    !"%R"L&E4X /H
MF>I/9/.M9/ST       "J6G4AVW    /T(PM'OYT                   :
M)-'2O8H@  "4ZTUO,JX         !^?.[G>;O     )CJ3VLS+8
M      C:Q%3G6I    9/SZN[C7L_X]                   5DT:L%W:X
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MVW    /T(PM'OYT                   :)-'2O8H@  "4ZTUO,JX
M   !^?.[G>;O    !R7@QK^W1>P              ."DVS1TJ6,   "V^7<E
MBK,                   .EREVQ2T>:,   ?;MX,:]MD7L  "'[<-4-.F
M !+U6:V.7<                    &D31TJV*7PX   )KISVDS;8
M    A"Y!5_2J    >KG;K8][;XO8   \W>4IV*.GR^    )HJ3VGS+8
M             JO]3B:7=K\CHX.09*/W<CXSZ$  5AN8<;2T\_XEM?3WLSYE
M            %=[]:O%^L   !.-.Q9[-M                      #Y*EZ
ME/<8O<_4;'?SH         JEIU(=MP   #]",+1[^=
M &B31TKV*(   E.M-;S*N          ?GSNYWF[P    2-!+<G(N@
M       "*+4-1]2F   !*E::W>5<                    &GR^*2[-'J<
M  $Q5)[6YEL  "D.S1TZ6,   >OG;TXM_-^/0                    %6M
M.I"MN    >GG;WXE_+^?0           J-JTXILP@   ;=%[NOCWO5SH  %9
M-&K!=VN   !M$?N[>->]G.@                 =?>4R^U^=\_K@'([P<DA
MYMNRGS&T  -=]0T]N_.=;FS>)[9U/H/?SV           /'WE#]NAC/7D
M;;%[NSCWO3SH                                  JEIU(=MP   #]"
M,+1[^=                   &B31TKV*(   E.M-;S*N          ?GSNY
MWF[P    6LS+<QU)P              !2K8HZ+-&   /0[>;%O[#'Z
M               K'HU8,NUP  !W.WLQ+^=\>@ ([L14TUJ0   $_P!&S9#/
ML@                    # >_-%MNAT.   "R>?:GRC8           &,]>
M:1;-' >_(   $W4Y[0YML  1?9BJ#JTN    =[MTL>[NT,@
M     U2W7JG]=A<] X.0.IV^>U9?Q=$  "M5C$BN6AP2!'<M16W?IT
M    ""KM>LNC5   'T70R+V^P2
M 52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7
M          /SYW<[S=X   !Z>=OSAZ'MYT              #1)HZ5[%$
M"=*5BS>=:                     &&]^:)[5#R]X   +$T+-AJ%D "I^I3
MB"U"   /5SM\,2_E?/H                     "JVG4AFW    -NB]WAQK
MX           $>3Q4VUZ?PX   .2VV7<EBK, ,+[\TAV:.(]>0   +)Y]J?*
M-@                  ")=G/@7Z+)'(< #BU/R._M5.P  !J7JO4&U\Z!.\
M.K.D.J          !1O:H:I)X   $R5)[5YEL
M            52TZD.VX   !^A&%H]_.@                  #1)HZ5[%$
M   2G6FMYE7          /SYW<[S=X   !)]>:X&3<               %6=
M.I"UN    =[M[,2_G/'H                     "K^E5A"Y7   &RQ^[TX
MM_D \7>4'W,_R]X   )MISVBS;8                      TB:.D^Q1
M O#C7]NB]@           5UOUJ]7ZP   &3\^KN8U[8/'H<%/-:E&EB(   "
M2:\MQ,F[]                   %=OI<:--2B' <#CCW>/=Q?C/H_IT   5
M#L_/:AVL.QVW%?Z';_-@         #0YXZ6:]$   =SMYL6_L<?H
M                           52TZD.VX   !^A&%H]_.@
M      #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   !9K.M3K2L
M            >;O*$;F?X.\   $QU)[69EL                      :E+
MXH]LT.    77Q[V\0R 1':AJ9J4P   +NXU_<HO8
M  %(-FAI\O@   6/S[5@*-@           #K*9Z]'0)XP   ) @DN7D7>QV!
MKM>M.C5    RWGU=[&O9OQZ                   %1OKOG<'/$X XX D//
MN63^<VP   (5DS*^RY#@;CYL6ZA^AY=         %8]&K!EVN   )BJ3VMS+
M8                                   %4M.I#MN    ?H1A:/?SH
M                T2:.E>Q1   $IUIK>95P         #\^=W.\W>    78
MQ[V[PR               1;9AJ%JTP   +IY%[?()
M    *5;%'19HP  !86A9L50L@54TZD-VX   !N<4EW,:\
M        *_WJ]<-"J   )%@EN5D70           !KTGFD>Q1QOKR   !8:A
M9E6M+2S8I>=P   <EO,JY*5:8                   8N2.GOUWS@X'  <3
MWAZTN9>B   !KO8::3?- .+,Q[DJ>;X         HCMY^O>_(   NED7M]@D
M                                    JEIU(=MP   #]",+1[^=
M               &B31TKV*(   E.M-;S*N          ?GSNYWF[P   ?;O
MZ!X6AZ>=               J[I5(2N0   #:H_=Y<6^
M      ()NUZS:-4   ;W#)=3'O 4,V\_!^_(   LEGVI]HV
M          !JLOBC6S0   'IYW] ,+0[G0           !$MJ&I>I3X   !]
MNYWQW7_?D   "<J=BSN;:                    CN_3K9]!B . ' MG\S]
M!LD$X    I?+\U@47 -EY-<B/Z/Z=        &GR^*0;-    ;/'[O1BWP
M                                 !5+3J0[;@   'Z$86CW\Z
M             -$FCI7L40  !*=::WF5<          _/G=SO-W@   V6/W>
MK%O@              "BNU0UJ3P   +$T+-AJ%D
M  :])YHEM9_   !VNW_PM#U\[K<GBBFU0    O/BW]HC]@
M         43VJ&N2>   !=S'O[G#[             JWI5(4N0        #;
MXO=U\>]Z>=                    @O8RH<U,T#C@ 96*2X/S/T6-YXP_(\
M-YBPW(\/R+#<CP_(\-R+#>8\1R+/7)L%)%P 6F\;TE<N@       "#[L%8-&
MH   )]HV+)9]H                                    52TZD.VX
M!^A&%H]_.@                  #1)HZ5[%$   2G6FMYE7          /S
MYW<[S=X   )(KRW'R;H              &$]^:&;>?P   "[V-?W&+V
M                  !1W9H:E+X   %T\B]OD$D26H:EZE,   >SG9\HV
M                     !$EJ'4I?    M1F6YGJ3@            >3O*3;
M-'5)/        ]/.W7Q[VWQ>P                   !5GZ#!TVU6<< #@>
M?-\XKYV/I<    ';-Z[['0."1>7+6<WP       !5#4J0_:@   %Q\F[)%>4
M                                    52TZD.VX   !^A&%H]_.@
M               #1)HZ5[%$   2G6FMYE7          /SYW<[S=X   )GJ
M3VHS+8              $768J@ZM(   >AV?Z%CD
M    BFU%ILL8   L_FVYPISUUOUJ]7ZP
M     G>E8LQG6@            !ILWBE6Q1\[@      %G<ZU.5*P
M             .KO*9?2_-='>!P<X' Q6#X\69X     ^_??1:Z X^W;LOI\
MJD        H_LT-0E\   =CM_L+0]O.@
M       "J6G4AVW    /T(PM'OYT                   :)-'2O8H@  "4
MZTUO,JX         !^?.[G>;O   !8*C9L;GV0              *_7J]<="
MJ                                 )MISVBS;=3=2G$5J$
M                        2K6FMUE7              (*NUZRZ-4
M 2E6FMYE7.0                    :A8K54W, !P '&"^7BZH>     ?7>
M^BWT.!P64;<O]T0      !UN?GWO9_0X  !M4?N\N+?
M                    JEIU(=MP   #]",+1[^=                   &
MB31TKV*(   E.M-;S*N          ?GSNYWF[P   68SK4[TK
M    %5].I#%N                                  297EN'DW:6[%'0
MIHP                                !NT,EV<>\             !P5
M"U:<7680    !F_'J[V->RWGT                    !$=[.@#3R  X ZX
M>8+YF(     <GHM>N !Q*G;]H/6Z       -=D\T2VL\   2G6FMYE7
M                                *I:=2';<    _0C"T>_G0
M           !HDT=*]BB   )3K36\RK@         'Y\[N=YN\   %K<RW,5
M2<              "F^M2CBQ$                                 -M
MB]WBQK]$]JAKDG@                                 9CSZOOAZ
M           Q/KS2+9HX/WY    'T[<3)N237E                     %
M==/&BZY0X' .!QX\_F+QHP!['K,=ES'J3,=ES'9,SV3,=ES'9,QZDI_Y^=Z7
M '&9[)=R3Z@       :%/'2W7H@  "<Z5BSF=:
M               JEIU(=MP   #]",+1[^=                   &B31TK
MV*(   E.M-;S*N          ?GSNYWF[P   6^RKLHUI0              *
M.[-#4I?                                  ]_._H!A:- MS/QOKR
M                               .]W]",'1               BZS%4'
M5I    "9JD]J<RV                     !4C8^=UJ6 .!P!Q*67?W:I:S
M'9<QV3,=D]O?8   %((OE\2C <"Z\OTV>[,      !%5F&HNK3   %B*%FP]
M"R                                    !5+3J0[;@   'Z#X6CZ.=
M                  &ASQTLUZ(   E.M-;S*N          ?GSNYWF[P
M7-R+TA02               4,V\_!^_(
M     Y+YXFA1+;H=#@                                 'Z%8.CVN@
M             "K.G4A:W     ,KY]7=QKV=\>@                    /
M)WS2_9^8^7!P!P!<?(^ER_F4     "E$/S& 0N. "U\OT$D>KH      $/VX
M:H:=,   64S[4]T;                                     %4].I#E
MN    ?H'A:/LYT                   1]/'3'7H@  "4ZTUO,JX
M  !^?.[G>;O   !=S'O[G#[               H!NYV/[P
M                   "S6=;K/HU?EP
M    "_V'HY'ST             ")+4-3-2GP     2+!+<?(N_8
M           -)FJU7TOG^  .!L7B>WN7]&      *30?+X#D0 %B9-F;Y-0
M     "%[D%6-*H   +,9UJ=Z5@
M  "JVG4AFW    +_ .'HY#ST                   1U8BIKK4@  !*M::W
M65<          _/G=SO-W@   O1BW]GC]@              ?GWNYWD[P
M                              #?89='FCZG   !=W&O]P
M                   -HB]=CH             U_P!^:1;-'&^O(     %C
M*%FP="R                    (=M9D!7<@<< #@EFMHV(I;(      I-7^
M7P'(> .!-,FI9";:       A>Y!5C2J   "R&?:G^C8
M                    JUI5(5N0   "_>'H93SZ                   $
M;6(J<ZU(   2S5FMMEW          /SYW<[S=X   +XXFAGO'H
M    #\_]W.\'>   "ZN/>]W.@                            #DI1L4?
M%W@   OUAZ&5\^@                                          !\%
M-->E'T\0      [7;FY%W?8)                    *Z7<6*;&>X #C@L?
M3VI3@T      !1^M\MA>1. !*DFA::?>       AVW!5+3J   "P=&S8S/L@
M                                    5>TJD(W(   !??$T,QX]
M               ",;,5/M6D   )=JS6RR[@         'Y\[N=YN\   %^\
M/0RGGT              !0?<S\1Z\@  "^&)H9_QZ
M           H=MY^!]^0  !>K%O[+'[
M              %>;]:NU^L       -B\>[NXU[(>>@
M "IE_P">U#W6 X' %QJ'TF=\S      "A]3Y/R/+@ ;_ .[EO+/T0      $
M668:AZM,   334GM-F6P                                    *T:-
M6![M<   7RQ-#.^/0                   BVS#4+5I@  "9*D]J\RV
M     !^?.[G>;O   !^@>%H^SG0              *+[5#6)/    O!C7]OB
M]@                             4DV:.ERQ@  "Z&1>W^"0
M                                 #09XZ9:]+K<        ERK-;/+N
M                   <%)]#Y;RO( <<&6Y)<ZC].      .MR@]/Y(  ;IZ
MLW(M?2@      :!/'2_7H@  "1H);DY%T
M         "NFA6KW>K   "\V+?VF/V                   (DM0U+U*8
M G"G8L_FV@         /SYW<[S=X   /T'PM'T<Z              !2[7HZ
M#/&   +C9-V2:\H                             %0M6G%MF$   6IS+
M<S5)P                                         !C_7*1;-'7??@
M       "T^;;FBG.                  ,-V*FEWYD .. 2/'=L]6W@
M !BN1T9J?*@ .MN]6;FV?I0      ->D\T1VL\   9KSZOKAZ
M                          $ WJ];M"J   +L8][=X9
M     !"MR"K6E4   $^T;%DL^T         !^?.[G>;O   !^A6#H]KH
M          %3=2G$5J$   6@S;<WTYP
M*TZ-6!KM<   6"HV;&Y]D
M   5-U*<16H0   )*KR[A%[@6[7    ]G.W9Q[VU1>P
M-#]U*K6?G^  .!/,.O-L6H      -/\ -:FE;YH  ;3ZL72L_3       =;G
MY][V?T.   "^&)H9_P >@                                   !"-R
M"KVE4   %R<F[(U>4                   0-=KUIT:H   L70LV$H60
M      /SYW<[S=X   /T-P=+Z               *YZ%:OEZL   )XI6++YU
MH                             "%KD%6=*H   )+KRW$R;H
M                                $,VX*K:=0   #+^?5WL:]E/':7;%
M+1YHP   -TBDNICW>_G0                !$DF=7.?% < "U-??W[S<
M  'RYB^>(MCH5LAQ  !MWJS<VS]*       *0;-#3Y?    M?F7)@J3
M                               "*+4-1]2F   +=Y5R5*TP
M           KO?K5XOU@  !:'-MS=3G          _/G=SO-W@  'T?H;@Z0
M               A^W#5#3I@  "0H);FY%T
M    #3)HZ1[%$   >_G;^X6C]@
M      &L2>*2;-'Q=X   .2WN5=E&M*-8D\4EV:/A[P   "=Z5BS&=:
M            $$2Y,'291P <#BZ]?ZC))!Y^></R/#<CP_(L/R/#\BP_F/#\
MCPW(L/R/$\CZW.1Z#ET ;KZLW%L?2       "JFG4ANW    )@JSVOR[8
M                                 CZ>.F.O1   %J,RW,]2<
M            5HT:L#W:X   MQEW)7JS          ?GSNYWF[P  #M=_0K!
MT0              !JLOBC6S0   'JYV_P!AZ'?SH
M          ZW*![N?X.\   %V<>]NT,@
M            Z7*6[%+2)HP   )SI6+.9UH 0W;@JIIU    .2W^5=D^M*
M              !6V7$BCWG!P. ?7EME&UA^1X?D6/YX     'UWO/0.<CH[
MOWJW;J?Z(       0C<@J]I5   !D>>KZX=_T\Z
M              !K,GBBVU0   %C\^U8"C8                   %4=2I#
MUJ    71R+V_02          ?GSNYWF[P  #T._H/@Z(               X
M*#[F?B?7D   70R+V_P2                              5 U:<7V80
M !8>A9L10L@                                       "MNA5@*]7
M   W"+W=;'O>GG0 *HZE2'K4    &7\^KO8U[->/0                JM)
M\_'WJF.!P!U1<\=/@      'WZ[STZ Y!)_J]:B;?       &L2>*+[5
M"V.7<EZK,                                   !TN?GSO9_P .   3
MA3L6?S;0                   IMKTHYGB   %\\30SGCT         !^?.
M[G>;O   /7SOZ"86B               !4G4IQ-:A   $^T;%DL^T
M                      !!]R"L&E4   &TQ^[S8M\
M      #Y/H               C>Q%3K6I_+@   ]7.W7Q[VW1>P !X.\I)LT
M=:D\    237EN)DW?H                J'[^<U#M8<  Z*_/-7X      !
MV^SH  3'[T[*2[8       %&-JAJ\G@   2#!+<[(N@
M                  "A^WGX#WY   DRO+</)N@                  "BF
MU0UN3P  !Z>=_03"T?H          _/G=SO-W@  'NYW] <+1
M     AFW!5;3J   #8/'J]N)H?0                       /D^@    #"
M>_-#MNA\.   "YF1=D."4                      #P>N4HV*,LU9I\HV,
MCYZ             ,3Z\TBV:.#]^0   +/9UN<:4X   T::.E^Q2Z7    +(
MY]J?J-@               "F'OYC H@' 'FK<Z8N       =LKD  $\>]:?I
M-@       "N.A6K]>K    73R+V^02
M      4XUJ4;V(@  ,_X]7PQ-                   #H[S\_-W/ZG   -N
MB]WAQKX          _/G=SO-W@  'NYW] <+1                Q7KS0O<
MH=+@   N'DW9,KR@                      >/O*4[%&4*TL_4;&4\^@
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MZ                  &DS1TFV*(   E^K-;#+N          #\^=W.\W>
M >[G?T!PM$                5"U:<6V80  !)=>6XF3=
M         K3HU8&NUQD.=GFC8GBC8]W.@  "([4-3-2F   /IV[6/>W.'V
M                   !H$\=,=>E\N #,^?5@J%B;:<_?SH          $&W
M:]8M&J   !G/'J[V->ROGT    /DIUK4HWL1    ;+'[NYC7O=SH
M      %''ROC>> !P)@BTM@39CU)F.R9GLN8[)[^^P   (9\YE<?&*!ST +7
M>_H)%[=        %,]>E'D\0   %P,J[)]:4
M           0S;@JMIU   !:S,MS'4G                  $#W:]:-&J
M +(9]J?Z-@          ?GSNYWF[P  #W<[^@.%H@               "++,
M-0]6F   .2Z61>WR"0                     #2)HZ5[%+K< &6\^K 4;$
MX4I_3SH  Z7*)[=#!>_(   DFO+<;)N@                    #Q=Y239H
MZQ)X   V'QZLOG6I7JS          :A+XI1L4?-W@   ^G;BY-R2*\H
MPGOS2+9HXCUY    F&I/:[,M@              45Y\ITN. .#Z+U>OJ^UT
M     5J\X<0^<T<]Z !<SU]-LW9P       !%EF&H>K3    V/Q[O#BWO7SH
M                                  &K2>*,[5    2?7EN!DW0
M            !2[7HZ#/&   +F9%V0X)0         !^?.[G>;O   /=SOZ
MX6B                .LHOM4-<D\   "0();G9%WD
M   \O>4GV*.I2^   ,]X]63SK4O59@ ! =ZO6S0J@   6QR[DO59@
M             *K:=2&;<    %KLRY,-28         >;O*4;%'4)?    $^
MT;%DL^T      (OLQ5!U:7    !:O,MS)4G              %%O/RGGYSAP
M 9=)=OW]2      !3;S\UJ_('0 '87H]?5]KH        ^2DNS1TR6,   ";
MZ=BT&;:                       KEH5M\@DE&M*          ."A.YGX?
MUY   ^W;T8M[9(_8                 U*7Q1[9H<   'H=O]A:'IYT
M      ?GSNYWF[P  #W<[^@.%H@                0;=KUBT:H   %J,VW
M,].<                    "L&E5@^Y7    M)FVYKIS@ #Q]Y17;H8;UY
M  &5\^KOXU[-^/0                   $06X:GZ=,   #<XI+M8U[Z
M     !6+2JP;<K@   ;O#)=+'N]SH      %9M&K!-VN   ![N=NUC7MGC]@
M             4;\?*>#G@'0-L6+CR?2@     #PO%'^?+?(  -B[-<Y],
M       (PLQ4_P!6D   !R6TR[DM59@                     ((NUZSZ-
M7DF*I/9G.M9/ST         "J6G4AVW    )NISVAS;8
M JIIU(;MP   "2*\MQ\FZ          !^?.[G>;O   /=SOZ X6B
M        !Y^\HOM4,![\@  #(\[=W%O[#X]                    13:AJ
M/J4^    ;7'[O!BWNQT  "#[L%8-&H   !(4$MR,BYVN@
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M           ?GSNYWF[P  #W<[^@.%H@                "&+<%5].H
M!O<,ES<B[W\Z                  !J,OBENQ1\'>    7"RKLFUI0  !UE
M)-FCI\L8   $V4Y[1YML                  8?WYI1L4=?]^0   )?JS6P
MR[@         PGOS2'9HXGUY    M1FVYGIS@       #5)?%)]BCX^\
MGRE8LGG6@            !36+YG5.5W X!)7J]:R7Z       0/W)@ED\]
M"<N:L]\UP         -<D\4@V:/B[P   #,^?5S<>[M,?L
M     "(+<-5-.IU.  "8*L]F\VSE//H        >3O*%[F?C^\   &]0R71Q
M[O8Z               .ERE>Q2TJ:,   =KM[\2_F_'H          #\^=W.
M\W>   >[G?T!PM$                 ?)2K8HZ/-&   !,=2>U>9;Y
M             ,7Z\TJV*6LR>    )5K36ZRK@    T.>.E^O2^'    +!4;
M-C<^R                 ,;ZY377I:9+&   !E//J\>->S'CT        !\
ME.M:E&]B(   "7*LUL\NX         (5N05:TJ@   'T[<+)N277E
M      J1%\[H'FGP "5?6A:*7>      %3_7SVA=J <] "S?C=E'E\
M    0E<@J[I5    !G?'JXF3=VZ+V                  !"%R"L>E5ZW
M !F?/JV67;D2O*        *P:56#[E<   ">*5BR^=:               %9
M-&K!=VN   !*]::W&5<           'Y\[N=YN\   ]W._H#A:(
M        &ES1TIV*74X   !/-*Q9;.M                 #P=Y3C7I:--&
M   ![^=O%BW\]X]     5JT:L"W:X    GFE8LKG6N0               #%
M>O-0-:GHDT8    MEEW)=JS         " KU>MNA5    V'Q[N[C7LCYZ
M      !4O4IQ):A    S/GU=[&O9CQZ            %8XL*)/&< =$J^[]H
MI=X     #J<I%)\MYGET  +D1_2['R<          "I6I3B6U"    ,GY]6W
MR[<BUY0                !UN5MT:T#W:_    !D.=NYC7MCC]@       #
M59/%'=JC\.   #DLQG6IVI6              ! ]VO6C1J@   "Y^1>D""0
M          ?GSNYWF[P  #W<[^@.%H@                 "NFA6KW>K
M "<*=BSN;:^@               #&^N5#U:<?3Q    "U&9;F>I.     //W
ME*MBEILL8    F6I/:/-M=_.@              :+-'4K5IZ_P"_(    F2I
M/:O,M@        #2)HZ6[%+I<   '8[<O(NR!!(          ,=ZY2/9HZ[[
M\    2;7EN#DW>0           ""8\JOL6. !*ON_:.;>      TGM6I<OSH
M#H#D]SW=J#ZGD           \/>4MV*.H2^    !VNV-S[,]T;'T
M        :_[\U3U*D>3Q    #DM=F7)@J3         "I^I4B"U    !R60S
M[4_4;              @&]7K?H5>    "2:\MQLFZ           !^?.[G>;
MO   /=SOZ X6B                  .IRE^Q2T6:,    2[5FM1F6_5SH
M            &E31U)U*FMR>    !+=6:VF7<      &L2>*3[-'']X    -
MZADMCEV]DC]@            #S=Y7F_7@6]7Z7    !N$7NZF/>]?.@
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M  #W<[^@.%H@                  :[)YI+L4<9Z\@   #=(I+8Y5O:H_8
M            Z.\K]>KU_OU^AP    ;5'[NMC7O?SH      $7V8JAZM/X<
M   'NYVQV?9G"E8^P           ?)$5N&NM^MK,G@    #+^?5U<>]L<?H
M        56TZD,VX    -_@DN9D7>QT           "O5^M76_6    [W;I8
M]W=H9           !A>14?K?+\.. )#]W+<6/HNMS%<CPWF/#\BP_(\-R/#\
MBP_(\/YCPW(L/R/SO/OT/7;,'+H =39%J3W#K@           #3)HZ:ZU/&^
MO(    'H=GJC8GNC8R7GH            $>3Q5NT:VB31@    "5:TUM\JY]
M@          KY?K5SOU@    -IC]VAS;4BUY0         !'<\57M.KJLG@
M   ">:5BRV=:            'Y\[N=YN\   ]W._H#A:(
M    C>Q%3W6I]3@    ]7.V)H69VHS]SH           X(FM0UTT*VJR>
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MQ;9AX     -OB]W7Q[WIYT            ?GSNYWF[P  #W<[^@.%H@
M              0G<@J[I5.     #:8_=B,^S+=6;[         !YN\B2U#
M]Z#3)8P    !Z^=N-DW=^@D         KIH5J]WJP     &UQ^YLI3R]5FS7
MCT      !\FASQQ!;AA^U#C?7D     #W<[<#)NR#!(         -=D\TCV:
M&.[P   "V67<EVK,             ,#[\TBV:.+]>0   )FJ3VIS+8
M     K+!AP]'F@ <<     #NF[D=+T'0'(Z%R:7TV;Y*             -,F
M\4\UJ6&]>0     .QV2*\DNU)I.KRYCQZ       'R:/-'%-J*'[<& ]^0
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M      #+^?5OLFYO4,@         ZRF6O1T&>,   "9JD]J<RV
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M)-OB][%'Z]'.@ ?)A/?G6I/.E31Z#/'']B/"^O(      &3\^K>95R0()
M        (.NUZRZ-;K<        ^G<CY[[./5SO3UY.\QWKG0X        !M
M\7NW65<V:/V         !7:_6KS?K    ;/'[NWC7O;SH              %
M8-*K!]RN   !D.=NWC7MDC]@         #HYYHW5^6QW/  V_P!6=0\U@
M ,IK>^V?H =<@DJ&]9BGN               8_URJNG4BJS"         !Z>
M=]#O9QT=YY>NMP         >KG;-9UJ:Z<X              C*S%475I^=P
M                   =SMLLNW*]68             #\^=W.\W>   >[G?T
M!PM$                     0M<@J]I5>IP       #Z=]_'M\]]?.]1X_7
M,?ZYYW         -JC]V[RKFU1>P           (WL15/U*F(]>0
M           )CJ3V?S;7MYT         "/IXZ:Z]+K<   '<[=''N[Q#(
M            /+WE*=BCJ$O@   #>X9+GX]WM=          %<(,6$X\L 6$
MEV( AR>EY'+N2[[S'9,SV7,]DS'9,SV7V>_5?]7'=#D= "?*FO,M;3
M         '!!=VO6_0K>7O                     -UADM=F6]LB]@
M          ".[$51=6GCN\                  'MYVVV5<DRO*
M      /SYW<[S=X  ![N=_0'"T0                     (]GCJ9JT\+Z\
M@                   2Y5FM)FV_?YZ            !A/?FK.G4C&Q$
M               ,OY]6<S;4N59@         !C?7*1[-#7O?D   "R&?:G^
MC8                &H2^*4[%'R]X   !8"C9L?GV0         !K?F"EE?
MYGX<Y!-LFI*?N_\ 3N8[)F.R]_>@ ".YJ58K^$'7(!R.K6YOT.Y160
M         !JTGBK^G5CF>(                   >_G;$9]F=*4_8Z
M           -4E\5)U*>HR^                 !LL?NW&5<W*+V
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MYN\   ]W._H#A:(                       B6U#6G1JX#WY
M      'V[,U2:Q^=9R_GT               !X^\@J[! ]ZOB?7D
M      ?3LK5I;%9]G;8O8           A:Y!5G2J    97SZN]C7LYX]
M              5%U:<5680   ,YX]7=QKV6\^@         -=Y#3"'YGH<'
M)=V;ZC-=E    J1J?.ZQ+7 =#D&Y16K5Y7T                   Z7(>MP
MP%?KZI)X               &1YV;*4\Z4K&>\>@                   -"
MGCK3HU=#FC              &U1^[)YUJ4JTH                _/G=SO-
MW@  'NYW] <+1                        \O>0;=@@2]7P_KR
M      /HE*M-8K/L[C%[                  \O>0W;AA.Y!I4T8
M     ]G.S%4FG:E8VN+V           !JTGBDNS1\?>   #DMUE7)4K3
M              #%^O-(MFC@??D   "4:TUO<JYR          0#XR('\9(%
MB_>S-?O4   &,]1TVV?FN!T.0.A,=+3GG/U@                  !P1Q8B
MA6Y!%MF+R=X            .QV0H))EIS2Q5F]G.@
M #@BZS% UZO'D\7            !N44D\T9Y@J3=CH                'Y
M\[N=YN\   ]W._H#A:(                        'F[R'K<,)W(-&FC
M          'KYV7ZLT[4;&WQ>P                   !J,OB)[4,8V8M(F
M\=;@        &2\^I)KR2I6FE2K+[.=             B>U#J$O@   #/^/4
MT4YP                  !HTT<8V8@   !,M2?8H_0         '0Y3R/YS
M5.5QMW;%QY/I   !&EJC6[3Q'0!T.N2RF5MR/5N@
M>+O(SLQ1?9BCJQ'KWOP         ,YX]2%!))=:64*TN6\^@
M           !JDOB'K<,568=2E\<         &P^/<IU99AJ3;U#(
M           (3N0=8  !W$U4YP                         !JDOB)[4,
M868M'F\=3@        &0YV2*TLJ5I95JS>[G0                      ,
M=ZYHTT>D31ZE+YU>7Q@)/.']<^7   /0[FX_6R1^MIC][G#[WF'WN$,GV
M                                                      :OR"GW
MGYSR/(MWZ^BWGMH  "O^ECQ)>SP'0 YZN)@?29;Q(
M   !@/?G29H].F\:M+YUR3Q@_?,5Z\^3O.  <F0YW*>/6<\>MCC];+'ZW&'W
MN<4FQ1^@                           ,#[\Q]8CT>:/3I?&LR^<#[\_#
M@   Y,QY];-%ZV^+WN\,F_P2;7%[
M                     \'>:-/'H\WC4Y?&K2^,![\X?WSX<   ]#N:\>MD
MC];1%ZW.&3>8?>Y0R?8                           /@Q_KGA]<Z'/CK
MMX]'.Y#SWV\[R
M             ",N4:M\POGJ1URUG=\  "I>Y\]K,\ #H 9N.6W_ ,_]&
M                       !TN>;TZG/IWOX]''VZ
M              !UN8KWS%>N>7O.CKY._CT\[E//<KY[Z.=
M                                             'P>#USP>N=+G7UV
M\>CG??Y[[N=Y
M                                                !#3,KFQA;=]#
MO2V !X/7BFOT?S7 ZY#KH"2J5VQ^+M
M
M
M
M                    "%V97?N/MBQ<#GT78Z -!MTZR;N('0Y'0$ZY&K,>
M9I
M
M
M                                                     13W/K9Z
MQ9TYJSKYU0!".MEPKJY@'/0 =6>^>W=YIV@
M
M
M
M                         !I7:M9/>)9?QM[SRT!6;Z##T&]4 =!T.2XW
MR7TF0\>P
M
M
M                                                           ,
M:\0-[R9M\Z>>Y,*>_6?.8J6,.N0!UFH9;>?)?1
M
M
M
M                               #2O57;_-GQ2>*>?7_ #CKD#H.A(>=
M<LE\UM@
M
M
M
M#3+M6KWU6$Z#H<]!U,F'I3?@:H
M
M
M
M                    B[6H5]^EQSHX ..!8;YK8D_*O
M
M
M
M                                       "$]W,A7=S#HXX X!:7Y/<
MW.E9
M
M
M                                                          $
M_0Y42:]  <#@<%P/C]_-P2@
M
M
M
M                "N'TF1&>G3<< .CC@78^+^A[>=
M
M
M
M                                    %;OH\F,M*F#O' '!Z?'JZ_QV
M^
M
M
M                                                       !6[Z'
M*B_2J#@ XX&5B]W.^2W0
M
M
M
M              *^;F;#VM2XX ''.C+Q>[G_ "FV
M
M
M
M                                  !#FI2KWN9PXX.@<&5C]W4^4V@
M
M
M
M                                                     -0LPU%^
MER.'1P!QP=G.WG^3V^0
M
M
M
M             <%,_IL?7IO X .!SMW/E]C*>/0
M
M
M
M                                 $0Z-6M>UGCC@Z. 6TP-*0*DX
M
M
M
M                                                   '!5;<SHTN
MU^'1QP!/^5<GC,N
M
M
M
M          #S=Y6?9H1-=@ XX&XUY;E8.D
M
M
M
M                              (YM0P;HU8\LQ=?0XXN-AZ&]5Y0
M
M
M
M                                                    /#ZYI<\6
MB6(XCN0;C!):C)N@
M
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M<O:4-C$3#0=8;E)[P,.&6#5+CI)"%"Z*D8@^MGU33$%Y13(3;IG@(3+A(ZC
M8E(M&P.)\%FX>ZKD8ZKD8ZKD8ZKD8ZKD8ZKD8ZKD8ZKD8HJ\]&T+"G0CIO5<
MC'5<C'5<C'5<C'5<C'5<C'5<C'5<C""_"J^HZ6NZA&BOJN1CJN1CJN1CJN1C
MJN1CJN1CJN1@A<LFH'L)Y0+)H"Y=+]U!5-JPN-#?BFC0A/9-7-<J.).1I*-U
MPZ847RLJ45UU"5:($<0O6G7 64^$ZZI46$U<(*].U""4 T+-R4U/A6?*LK1_
MG4AB5!5I-Q%9-A&N"EJL2G*J6KJIE72]FQ-O*.%EN>;>4:*Y"4[#<%T\W.86
MLWA'&IERX90#579*>!CN1U49%4$X^$ID=U6'8F(D*]T3IF9U1-*0FK3U@ZDU
MI5U#(4)+Q2EF>NNE]BP ?P;0^?JF"VWVG2F/D=[:^Q8')<<LG0I*II7,9B90
M4\:2"$TQ-U-==(=*S<=,385GXK*LYS\T]1174'4DW!5DR$:XB6J135*NG9:Z
MZ0Z5VY9(A"PX3ZZ)KD5U**#4A7&3U.)3E5+5+*2"MIRJF#(Y_#;=U>:6P7"=
M/*BF$J6$.&&PWPVZF:NYI7UVWWVL6?WW-=?*:B0M/Q45Y["BOA41H1;B)BI%
M-4JI:NZ7V+ !_!M#Y^J8+;?:=*8^1WMK[%W**B72BKH?AI<GH+9MOT0=155*
MBE=N213H67*H+U>N1G,HH5:%<@@HQ35*NG8G"\R#?DONT^X:MB;[Q4&_-OO!
M/<$M4^FMSXA.7A/ &)4$(SG+2XTW7.%<!;Z8>.C*)O#;EK<"7UCW"]9J]GA'
MA^B H\I6=Q7G:GM^E=?:DM;,ANI00*V^_D]:U=TOL6 #^#:'S]4P6V^TZ4Q\
MCO;7V+M<#C*MTHNN VX#6@::!4X58,.D$/3N%X$&])P/!0<%6Q(#M4&]4WGH
MGN"6O,F0B8#GN2(8BJJ==6R4U3HJ;%R1"\%C(1P'4W&:O"#84%:&05).4 50
MEK!1:00W>Y*G&IX6&UN>'M:X _50?"/"/"/"/"/#]6T<X] VY042R66<-RS)
MV*ZYB5;0WWVH(<(3D).$#472^Q8 /X-H?/U3!;;[3I3'R.]M?8NQT.DNVBBD
MIF%<WH*:9UU,]O2;R3IAQPRP3GN54+%==0E>R2G.F;8N0*3@J;!/ :Q<<!-O
ME7&ZCCC'VAO.<XW#" Y";B+:@P &: =3=$;BGA8+IY*=UER'3YZL**D#+BBE
MIH*01UJS_P!1V>$>$>'Z6W']5L[:YGV30H5UHXN&=K+&A20[8N2&9BFJ5=.F
MNE]BP ?P;0^?JF"VWVG2F/D=[:^Q?JZ', VR*@H#JAO0VU;?%FM,M+I1!*N5
MVFW(-M" Y#C=,MYSDW&7U3K>!=N J*D85C>U$SHZ>9:+V!7Z-0Y4 )Q)ALJ*
M1,X;=NKF!?5/1S2;R;55,2K!33.NIDMB3>3M<K_]5@M;7_M.UB"4 ANVXE1G
M<&@]A4"LJ:".E]+=+[%@ _@VA\_5,%MOM.E,?([VU]B_1?70&^GJRJ86CVA1
M4D5;4B!()-)Z5T.TLVP%15,K!O:BIL8B8:#Y"7*=0\WK0@ACCB&ALTI3JF3:
MBN?@G:U2&@"TY2F +:H@,!LQ$"E2V$BF*4-.HB:(G516VDD2!6,ABP8MBC#0
M:M-1!NVBR7@\C'DW045U!ULM^249ZBXC5YB6PE30I(PV7 $XDS4*2@"E$EQ8
M&75+#;=K>K7KW#7Z:#X1X1X1X1X=EK?^OVI24BZ24=+R-.(30%$\T?J*6]6S
M4%K3&*H+VJ3J(!MTAA10SD4.*&XE41)$3I1-&3YQ-OI=4"-1'%@1A(0D#VP1
MQ8,6F"G!JURJ#!QIK!")RG3/0-5VF&V83E(NK%-)=+[%@ _@VA\_5,%MOM.E
M,?([VU]B@^>!32CE<(SC4,)).-*0A&V:N:@M:8*446L2:8$M:DU0;M-*%&WR
MRGP*"(7KBWK;Y.FZ5XO(-O F3(IP?-*7C,FUE8_!.UJF/ %IRM, 6T108"9B
M(%*EL)%,4H:;1$T1.JBMM)(D"L=#%@Q;)&&@U:8.<&[9+!>#R(?3=!35.BIE
M/WC)Z9ZO2E"#%%K'$RI+$5E:2;:PF#">B$$J67_,*+02%2%*U$H56PIHV=CO
MOB=2_P!K<F.X6NX1&XIEC 9LOIW\Z>='<+1;=;C4P@J  M>[J_(VL%KO@[2M
MKA5 )N%QFG&;S);65%B$ZU$)[*1DZ***0Z<YQ*)J,E&V:2;A2MBIE8-D3! 7
M,UG.,VSI$\"I%='=+[%@ _@VA\_5,%MOM.E,?([VU]B_Q#\=?/#F!%;9]?$1
M+9D2, %PBH?<>3"BF'*VJ8&I:5YO*AO@CCB&1LJ0QU98DFVK*!0G(2>DRS*+
M3252%*U%$X56JJ(V=COOSZ5Y.ZANE1AJS N.BBH2M#MF=/21VDF(FE6&,E+$
M+=N5),E.4Z9Y&&]>.EIU @"J$EY%&0%+#;IU<$/IKB.GEQ;"2)BJ!INH03>3
M-@?POIMC!;(/P1=H75PLWR*VMF5X]D##J%K1;:J"A)'9*4CZ<T3 .A+%L2!N
M2RTE-#S-!V"MLT6,A' -%=+[%@ _@VA\_5,%MOM.E,?([VU]BN.Z># [Z**A
M:VO;;QD" &6"USO=@;;*&3 AL?'33.NI#MJ>49([/2T32K#)2EF%JVZBG2JI
MG15D83UXC1N=Q MQ..G1E$UC;C#/+LD-K)Z!1J%MIIR])PL-01,E-4Z:F*\.
M=@:=XMJEQIH@=00F%ANGGA'2.1>";R8;-BGC.&WC6Y85V&Y@OE1<%O0_(V]G
M65DNA$%Y>,N ]CE+QF@6Y/*<([<3T(/5?YA>MZG*\+C44&_5D8#MY08T5TOL
M6 #^#:'S]4P6V^TZ4Q\CO(&ZB!TR9$.&.Y/3C"J::C,+MT/7N-?!;J<H'QU0
MYC;C&/+\D)IIR!3J%IK)R]2X6 ?1LDI^$V&\>;A:!2404DBOK@[@4<1$@84S
M+8MT73=:Y;?DUF%5'-HIG$6,BDS#3<P3D(:>Y#5\984U1&23R&L KJ=HAAJ"
MP+L<5;C4\-OVMS@YL5T!_P!\#0 X=M[,;-A$"SI<HKD4,:$VSKA';K)(($M=
M712+0X[: F8.DATXQCMX[>-"T-TOL6 #^#:'S]4P6V^TZ4Q\C,F)IA7.-AL%
MVV3UY\\"FDW&OC.)1Q$R0Z@8;%N 2,2EX:QRL(FMPKHAQ#,X@!Q"PS/=(;D(
MYWZZ>=GL3>;)MQF4)OE&\5URFE%5@JZF,90,:(L#H2BEJ8"P1TU=%(E#T;-3
M=4<+,<U3=4:*Z1*-#<AT^N)A0449?4D\@"F$]BN*/ZJ_@3P.&(;+/]H?3MFN
M&L;4MX*HP5*@D@-A6V^27R[F9QQN5X@1JRXK3<-#B2M!=+[%@ _@VA\_5,%M
MOM.E,?(R@ "&AF@U@VV1V"X+IYL<Q(#=-N(TWVV4;I77*":652SK8AA"QI"J
M.BJ".K +:?EN*Z>7EL309@KB%)$0$XML%5,JZ7C;[T98F(Y^1*&G6T<%=3E-
M.&23V&V[JT+W<\F^GSG.J> ,.H6MG-JENINQNL?B7%WII?BE&% _)-"*F@3H
M.QW&=7" X@0:S K/8(:7LHH5 X;NM[62QM1P5MU5"%H'"SW2^Q8 /X-H?/U3
M!;;[3I3'R,MN&MP@.P7"=/*BF)I,\9R#IZ<72RNP3EXR>-O?"6)D.:;?4I3E
M5+&X%H- 2S9H4\9PLQFUN 4  ,L#L;W8DC4L5N'+S$GIWXUN>$<-%=05;-<U
M+B3<RJI@HY!95AEM0PVW:VR"B2"#&$F.-WLDMQ#CB<O&2XG&VD9;[N*K<MA=
M3@H;J4..(:&PDR8Q\RT6:"W0=G>;!D;BJF=%6&V@RA-*SW2^Q8 /X-H?/U3!
M;;[3I3'R,C(;O/U:4O"6O7%<)#3#QT92.86<SQ'&.6+!$B^QO9BTJ%,Y>6>&
MVSEXPOC?;CYXJX6DUQ7(>+%@B9?97\RY"TX4U0&2CR2I!+"?I[BM7@1\*&LC
M(*DFJ *J2R?XA]NCGI_"S6S4XE*BBD*C8W29X5OX+;%O,<_00.D8-TMVMOG6
MT^YAQ172+1KJJI44O!PS<*MA)DQE RTFF"VRNTO=D25::J9T5=R8DFU@PV[=
M%4S0W2^Q8 /X-H?/U3!;;[3I3'R,=%$Q*VLA4M](V"X+CYPJ86LVAG(?)DP4
M\KLK]9<C=&$B=%3CB*JA+:9AN X>3).%)2QED^CI("(G[/<%HR3!<-LW!PAW
M3F2P9PNYV^(W5/"PG3R0[DN,Z>" PIY 94.H2*"@INR7%,^FCX+>E?11OU4T
MT)6)*:<,DG6VZQT(0B? 4BVMN6XIE"N$$&LR*S6E0W2NUOQE\PH[)2\9MNVY
ME0A.3"J27T-TOL6 #^#:'S]4P6V^TZ4Q\C';5"Y@J; ^W#R-'PIJ>,JG4-&!
M04[9[AM&1*O#;9P< HX*ZY!T.A;FOK.%BM>2"G[08+AFP'2WZVZJX A:@1&Z
ML4KJ1IW.WPW$F&2PA,QAMTZN.+XG.X VZF&3(APQA8#6Y,2V6XYCSGL" 5X)
M%['J@<V3X0EXP@FDE6+K)35GC@2<355(574<+!:'*@-MN"SO2_5";)YPBMQE
M$6_+1W2^Q8 /X-H?/U3!;;[3I3'R,7^8:J/R-#U\YRID[ER:^M86 U^3$-H&
M!H,!.YNU-Q4P4U3HJ:ZU)>1N^Y2WR](PV[;G-5':G<WJ7$DU4S#JP6Q6N$4]
M1<5J\<!A+&1"9AKN$-QIF P8#* .APB.-3PV\:W,C6S/ SQ+A[TTKQJAW/A#
MY6I0C+(Z&<258!9)ZJZ*]BMTU..&VZJF5=+P98R6I-NV?A   98+272^Q8 /
MX-H?/U3!;;[3I3'R,3"2.:N'8+BK?+$7#;]N<Y5-J=*!0XDH4.H$3!;1:X!8
M[W8L\]7,!0J(=,HJ4$BINUW*;_ G\!<Q64,)*C0K)NH?C6Y&>PMAP"-U3*F0
MSA?ON,Z>,&PMQ"%<*F3)A$"NRB5R"#,C3,F.]BE.(7>Y?2:5I+$HJ"KA 71D
M$Z1/ J)74'#89 HI'Q%0_@;""(X54N7#* ?@UTOL6 #^#:'S]4P6V^TZ4Q\C
M%;%*X1%V!YK7.U[  !69'0$<-"2MKN:W^%-X A:@!4-3I64GM?BQRAOX;7H/
MJ"[8O)-"VDC UEQL%JU?U"^H4TX%6(K:.,A*.&W3JX QW/IT<A(3_?""#68%
M:3<H;B9LSI-<(@8+=E/*5[[@)'!*?Z-%RS0SE-4JZ=/=%:] G@E*=4V:WI-]
M)_![I?8L '\&T/GZI@MM]ITICY&$N!4:,$BM!$GKWJL<F;^&V"#Q!O;%A,#6
M$PR7$)F,%JE?]NVYBKQJY@*EJSAE+3PTI.VVYJ-P2M@:BIRA?U+T;-+B3JZ*
M@Z\+"=/.R78L*H**GJJF,L'\-MVMZ-&SW#,^0C@:Q3@T'O=27S9$_5@./QU#
MH5><KN"V[?YBI?A%TOL6 #^#:'S]4P6V^TZ4Q\C#;I.X]R;!=!5XI7P @UF!
MD1,H1DO;;H(W#*.!N*?)UO\ SV'3=! F:,UG#."V"-Q2EMSR2.=(&%IJ7-6_
MJ;D-7PGA3E 9*.H2R"O)OZ3G*F3X=$W H860V)N!1IIE3+9W\:]99[R1:9PY
M33*BG [$WE:[^@8E05;77)+J9I7NK<I;N (*H<5OH]"$D_A%TOL6 #^#:'S]
M4P6V^TZ4Q\C#:@EY$_7F1Z"I<^<K4#N"V:-QROMSJ2.=H6%EJ7-&W^MS%+@T
M#"T$KD[?V]VI7)U_!:A1\0=2('2*&\6U4W5+"S7-4W5(.ND6B+CNGAPL*6F#
M+!]&2041.VA<-<:K][%*<2NX;E)WG+?JU5R:&J2G*J6DNHI>JHX+:(O'K'X3
M=+[%@ _@VA\_5,%MOM.E,?(PLHGP+8U]QU+@6YA9*5REN[>]4KE+BP6H4?\
M5^MT#_$KN!H)7.'!N%UDWS X& >X%T:I>105]-4" R6=PVW=7A#K<5#<3!QZ
MS(V#_,,1K<B(;0J&N"3<%NR?D)87$1YBB=C 6^8)ND<"CS9:P,A)Y0WOPFZ7
MV+ !_!M#Y^J8+;?:=*8^1@IIG746!D6+:^Z9_P!96P-A*YRN;A=5-]0C@9![
M@'/^JV>YDKX+4IOD+;@Z4WFJ!@+CU%3 (LAPM4_VMSDEAHKJ#K65PVO&,-N6
MMQH^TOLUZ"%@;A/@43$O$^ 6?U;JM-%5J:I5TZ)W'^7-S VDWFZ[^%72^Q8
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M9+FB_P"KO32W!IWZ"& @8%<*8# KV1 H%N.CAP+=$E*!;J50+<]1J@6X:T)
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MD0 .&:!U[F=Q1N!+*X;7C6*WS4YJ:TCM<=#<3!AJS N"BBH6MFMFENINF4"
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M1+B(C)9BU#=(RM.-1M,;2.*<VDVFFH3W#FU!:6H;IY&VYU(6MJ&V6?#=4?Y
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M[1.)Q.)Q.)_5]5]PFN=(T+RP*+BKJ2?TNS=%$[2S]P4;1T:8947#)!V%L74
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M2</ZPTWB'1OM7Q,9[2/63(:9.>@8^X*+XFV?TRR_-%WK.TV;KHVKI&F&5$[
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MV;_2"".1U;+=P3.=)]RX)#.G9W/P-+.'6\,[0O/UR,73%PQAF,.,,1<$71!
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MW2:S29M]KB.$1<GE.#,Z J-42K#P]&E![8 F&'Y8YQ?B &)]DJ.Q4;4\Q_\
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MU3RFTT%:S22<:*E*"4C"3!1+TSSWY?D>UW01H_@K1\VQ>].&*3=.,A224J&
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M"QS=#^%UA.SWQOU?[OF%4S# O"=DCY8QX3+IU:P+E&S3FJDK02E232",D7Y
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MY](NI.@K/2.WGJ96DT)>I9/+@Z:,;<E'KE-U"]RK(8=E9A-JZV:#5"Q,TO\
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M,LC4SQTQ(V"NXXFEA-*64WSKFY3#;#* AIL6J4C(-JI27W*2L\O_ %42TO\
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M;WP!X8OY5A?&;$7;&2?]A/=&MDK_ &A&MLM_;$:V2G]D1>V.E$\#"8O)=I/
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M#9G35CG9$TO1 TSR;*)I^J+P<08;:3P8ZP!,E'@=R>(\?H+*9\<B$)PR5/\
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MP8S&TYOPPW!B3!%Q8C!,!2?+[*;&L/F:9#&-!N"\<-9N^0&3)E([K%7BIF5
M5."(Q$0TDJ<)#GL."BVG@F\EW\X'/),&)#GI* P<6>L=4Q/PKW *?O,ZR@<-
MC&Z+D)?0N:I]2YP24FW@P93L[^A(]Z&D<Q.AND'G )[-" O!!N:"5)-35Z.
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M$6>=/Z(_?1^1RD&P2<)R +R:#%.*8C?\?5R&SSW1#,6YU9S(O<@V)7$;$,%
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M 0]7'=F"0P/-,2.S+4Y$(I0:YS0P1U3>,^!ASV5@?-1]2O02.6O'--2F;W=
MAKM9B0@LYCKO.[0"^TU=-/!03'RP3LK+FE[:HABQV1U28ZQ;F5_*NO2<U_8Z
MJ8P: (!@P@-S'P$F@'U7H?HO0_1>A^B]#]%Z'Z+T/T7H?H@U1B"*2]V]ZM1
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ME1M1,5X-"C>M=!Z\#B#DFA1F#BR_,6GR*<W+Y,F4(W86 N>0/^U2ENRZY%N
MX31"1<47>DTA8,S!-\V3)]@X_P!KIPF6 /47Y.F^+)OPX0)*<R2>@_VNTAB$
MZ#N-^73ITZ=.G8$6QP .K_[7C.7HY>Z=.G3ITZ=.F'43:FZ-_M=Z^'&:.G3I
MTZ=.G4+F+G-K_P"US"FB'%[ITZ=.G3ITZ )D'@'^UX/$BCITZ=.G3KW'Q_VP
M)Q9$NG3ITZ=.A!>07+_MB#<'#41TZ=.G3IUX;1_M@XX.\FZ,KITZ=.G3H!"
M(/#_ +8/Q.1/L!&J=.G3_D=&'3#P% $$08C_ &N @(<&!!1?@AP7E'DZ?D=/
M^#IT9)QQ8/\ ;!H-H G_ &1R)_(Z=.G3IL$OI X<P_VP< ! Q!D4:;$XK5X7
M)TZ=.G3H9- *]_HX_P#;+>B%P!3IK"-4*C'C>G_!T_X=LIO?0L=/]MDOQ9'$
MX)T8HX/#4\+!U,J0T(T^ #7[YB0EJ#'-_P#;GC7"NG$N+_'.W)'U[N04^0!>
M'TC*KS)PF;CF?\5__]H # ,!  (  P   !"2222222222222222222222222
M222222222222222222222222222222222222222222222222222222223E;V
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222220S_\
M_?DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MF_\ _P#_ .DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDD?_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD7_\ _P#_ /<DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDW_\ _P#_ /TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD_P#_ /\ _P#]))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))?_ /\ _P"#))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))U__P#\F22222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222223C?\ X$DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDUIPDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDG%DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDE)OCTDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC_L:DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDB(Z+D*DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDHB\DDDDDDDDDDDDDDDDDDDDD-,X:DDDD
MDDDDDDDDDDDDDDDDDDDDDDDD@%XK_P#_ /$[:R2222222222222222222222
M22222222222222222222222222222222222-?_@R22222222222222222222
M22222222226H/_\ _P#_ /7FB22222222222222222222222222222222222
M222222222222222222222222222222222D)?\:*22222222222222223(L9_
M_P#^!49DDDDDDDDDDDDDDDDDDDDDDDDYN_\ _P#_ /\ _P#_ /7MDDDDDDDD
MDDDDDDD0    !DDDDDDDDDDDDDDDDD@    'DDDDDDDDDDDDDO\ _P!Z2222
M222222222222222222222220N?\ _P#_ /\ _P#_ /\ _P#WG)))))))))))
M))))(0   %))))))))))))))))))))0   ))))))))))),   !)))))]_P#_
M /\ ^])))))))))))))))%U__P#_ /\ _P#_ /XW$DDDDDDDDDDDDDDDDDDD
MDCV__P#_ /\ _P#_ /\ _P#_ /Q@22222222222221/_ /\ _P#C22222222
M222222220?\ _P#_ .&2222222222223?_\ ]$DDDDDDDDDDDDDDDDDDDDDD
MDDDDS7__ /\ _P#_ /\ _P#_ /\ _P#&,DDDDDDDDDDDDDDB_P#_ /\ ,DDD
MDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -))) ]__P#_ /\ _P#]
MR222222222221&/_ /\ _P#_ /\ _P#_ /\ _P#'"222222222222222222)
M[_\ _P#_ /\ _P#_ /\ _P#_ /\ _P"1))))))))))))()__ /\ _LDDDDDD
MDDDDDDDDDG__ /\ _P#$DDDDDDDDDDDDDO\ _P#]R2222222222222222222
M222221Q__P#_ /\ _P#_ /\ _P#_ /\ _P#_ /O)))))))))))))(O\ _P#_
M #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#222#?_P#_ /\
M_P#_ /)))))))))))) )_P#_ /\ _P#_ /\ _P#_ /\ _P#_ -BDDDDDDDDD
MDDDDDDDD@_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /ODDDDDDDDDDDDD'_\
M_P#\"222222222222222G_\ _P#^I)))))))))))))&;7WZ)))))))))))))
M)))))))))))*O_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ ^22222222222
M22+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ TDDN
M_P#_ /\ _P#_ /\ CDDDDDDDDDDDG?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ I)))))))))))))))+=__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#^J9))
M))))))))))O_ /\ _P#!))))))))))))))S_ /\ _P#\))))))))))))))(=
MMA69)))))))))))))))))))))))]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /[\DDDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]2222
M2222221__P#_ -)(5_\ _P#_ /\ _P#^<DDDDDDDDDDA2_\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ VG))))))))))))))1_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#[LDDDDDDDDDDDE'__ /\ ]B22222222222223_P#_ /\
MOR22222222222222 5]*&2222222222222222222222!_P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ )))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#22K__ /\ _P#_ /\ ^I))))))
M))))-_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ +I))))))))))))-
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ "))))))))))))*__P#_
M /ZDDDDDDDDDDDDD>_\ _P#]6222222222222220Q+T]6222222222222222
M222222,O_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ ,9)))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#2
M4_\ _P#_ /\ _P#_ /B22222222220?_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#\R22222222222$?\ _P#_ /\ _P"B6[[:C3/_ /\ _P#_ /\
MZ4DDDDDDDDDDDD__ /\ _N2222222222220__P#_ /W)))))))))))))))&(
M?W Y)))))))))))))))))))))/\ _P#_ /\ _P#_ "[,H3@,DU__ /\ _P#_
M /\ Y$DDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ - __P#_ /X^)K'LDDDDDDDDDDG_ /\ _P#_ /\ _G-UDGWO_P#_
M /\ _P#_ /\ .22222222222S_\ _P#_ /\ >5DDDDDDDUO_ /\ _P#_ /V)
M))))))))))('_P#_ /\ [9)))))))))) _\ _P#_ /O))))))))))))))) ^
M9GVY)))))))))))))))))))(C_\ _P#_ /\ _P!?TDDDDDDD^E__ /\ _P#_
M /\ :222222222+_ /\ _P R2222222222222222222/_P#_ /U)))))))))
M)'__ /\ TG__ /\ IF220^2222222222"?\ _P#_ /\ [Y4DDDDDD&O_ /\
M_P#_ /\ LR222222222,?_\ _P#_ -!2222222220:[_ /\ _P#_ +,DDDDD
MDDDDDD __P#_ /B22222222220?_ /\ _P ^2222222222222220Y8"GV222
M22222222222222222'__ /\ _P#^""2222222222=C__ /\ _P#_ (,DDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ -?_
M /\ ^UDDDDDDDDDDDDDDD>__ /\ _P#Z5DDDDDDDDD@G7_\ _P#_ /\ ))))
M)))))$?_ /\ _P#^1))))))))))))K__ /\ _P#]I))))))))))()_\ _P#[
M\DDDDDDDDDG_ /\ _P#_ '))))))))))))))))"(!W;I))))))))))))))))
M)))M_P#_ /\ _P#GR2222222222221#_ /\ _P#_ /PDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ "__ /\ QDDDDDDD
MDDDDDDDDCG__ /\ _P#VDDDDDDDDDDDDF_\ _P#_ /\ W)))))))(-__ /\
M_P#>)))))))))))))(;_ /\ _P#^W)))))))))))+_\ _P#_ $I))))))))+
MO_\ _P#YDDDDDDDDDDDDDDDDDF5-BUDDDDDDDDDDDDDDDDDDDT__ /\ _P#]
M4DDDDDDDDDDDDDDB-_\ _P#_ /YDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDD
MDDDDC_\ _P#]22222222221__P#_ /\ _P#ZDDDDDDDDDDDDDDDD1_\ _P#_
M /NDDDDDDDDDDDDDDG__ /\ _P#@DDDDDDD!_P#_ /\ _?DDDDDDDDDDDDDD
MDY__ /\ _P#[DDDDDDDDDDDT_P#_ /\ ^4DDDDDDDD/_ /\ _P#@DDDDDDDD
MDDDDDDDDD5/X@4DDDDDDDDDDDDDDDDDDDO\ _P#_ /\ V9))))))))))))))
M))?_ /\ _P#_ "R2222222+_ /\ _P R2222222222222222222/_P#_ /U)
M)))))))))'__ /\ _P#_ ,"2222222222222220?_P#_ /\ R22222222222
M22220?\ _P#_ /TR222220?_ /\ _P#E2222222222222222)/\ _P#_ /H2
M2222222222)?_P#_ /S)))))))(]_P#_ /\ !))))))))))))))))),[0MI'
MI)))))))))))))))))__ /\ _P#Y9)))))))))))))))))'/_P#_ /\ XY))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /\ S))))))))))))))))/\ _P#_ /Q)))))))))))))))) W_\ _P#_ &))
M))))7_\ _P#_ ,9))))))))))))))))(W_\ _P#_ #)))))))))))"__ /\
M_P I))))))&__P#_ /[DDDDDDDDDDDDDDDDDE]Z6)4F4DDDDDDDDDDDDDDDD
M4_\ _P#_ +\DDDDDDDDDDDDDDDDDDD>__P#_ /N2222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ _P#_ "22222222222222
M237_ /\ _P#^R22222222222222221/_ /\ _P#F222227__ /\ _;))))))
M))))))))))))%_\ _P#_ ,Y))))))))))(/_ /\ _P"9))))))%__P#_ /RD
MDDDDDDDDDDDDDDDD@!I?8TF$<DDDDDDDDDDDDDDFO_\ _P#]J22222222222
M2222222225?_ /\ ()))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#_ /2DDDDDDDDDDDDDDDD'_P#_ /\ FDDDDDDDDDDD
MDDDDDDDG_P#_ /\ YDDDDD7_ /\ _P#!DDDDDDDDDDDDDDDDDDDC_P#_ /\
M\DDDDDDDDDDDA_\ _P#_ / DDDDDE_\ _P#_ +TDDDDDDDDDDDDDDDDDB&;L
M6DDN^DDDDDDDDDDDDDDE_P#_ /\ XLDDDDDDDDDDDDDDDDDDDDDS_P"R))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_
M /TDDDDDDDDDDDDDDDG_ /\ _P#^4DDDDDDDDDDDDDDDDDDDW_\ _P#\2222
M9_\ _P#^Q)))))))))))))))))))(1__ /\ \,DDDDDDDDDDDS__ /\ _P"D
MDDDD3_\ _P#_ *DDDDDDDDDDDDDDDDDDD-+^ 4DAF,DDDDDDDDDDDDD0_P#_
M /\ ;DDDDDDDDDDDDDDDDDDDDDDD_JDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDD
MDDDDDDDDC_\ _P#]22222222221__P#_ /\ ^2222222222222220#__ /\
M^9))))))))))))))))))).O_ /\ _P!)))(/_P#_ /\ 9)))))))))))))))
M)))))'O_ /\ _P#)))))))))))(O_P#_ /[TDDDE_P#_ /\ _,DDDDDDDDDD
MDDDDDDDDCZ![2$DD,1DDDDDDDDDDDDD__P#_ /\ $DDDDDDDDDDDDDDDDDDD
MDDDDYLDDDDDDDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222
M221__P#_ /\ R2222222222222222_\ _P#_ .222222222222222222222:
M?_\ _P"I))!/_P#_ /XDDDDDDDDDDDDDDDDDDDDDA_\ _P#]>22222222222
M ?\ _P#_ /V222+_ /\ _P#Q2222222222222222222T;*TN221&NR222222
M22222+?_ /\ ^[))))))))))))))))))))))))))))))))))(O\ _P#_ #))
M)))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#_ /DDDDDDDDDDDDDD
MDDO_ /\ _@2222222222222222222223?_\ _P"-))#_ /\ _P#U))))))))
M)))))))))))))(A__P#_ (DDDDDDDDDDDD+_ /\ _P#_ ))))_\ _P#_  9)
M)))))))))))))))))'@+7[))))WT9)))))))))))_P#_ /\ W)))))))))))
M))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\
M_4DDDDDDDDDD?_\ _P#]:222222222222222?_\ _P#_ *22222222222222
M22222220O_\ _P#[))+_ /\ _P#_ "2222222222222222222222?_\ _P#Y
M))))))))))))]_\ _P#[LDEG_P#_ /\ $DDDDDDDDDDDDDDDDDDDD@))8DDD
MB]IDDDDDDDDDDD%__P#_ -222222222222222222222222222222222222+_
M /\ _P R2222222222222222222/_P#_ /U))))))))))'__ /\ _DDDDDDD
MDDDDDDDDDA__ /\ \622222222222222222222223_\ _P#])(O_ /\ _P"Y
M))))))))))))))))))))))+_ /\ _P#U))))))))))))-_\ _P#_ %I!?_\
M_P#[DDDDDDDDDDDDDDDDDDDDWK+/#DDDDC8DDDDDDDDDDD'_ /\ _B222222
M222222222222222222222222222222+_ /\ _P R2222222222222222222/
M_P#_ /U))))))))))'__ /\ _<DDDDDDDDDDDDDDDM__ /\ ]22222222222
M222222222222!_\ _P#_ .2;_P#_ /\ J22222222222222222222222?_\
M_P#U)))))))))))),_\ _P#_ ._/_P#_ /\ X9)))))))))))))))))))&63
M[3))))"6F9)))))))))-_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDB_P#_ /\ ,DDDDDDDDDDDDDDDDDDDC_\ _P#]22222222221__P#_ /W)
M))))))))))))))'_ /\ _P#Y)))))))))))))))))))))))#_P#_ /\ I(O_
M /\ _$DDDDDDDDDDDDDDDDDDDDDDDF__ /\ \2222222222222!?_P#_ /U1
M_P#_ /\ _))))))))))))))))))))V;_ &_R2220$EJ222222222 _\ _P#_
M "222222222222222222222222222222222222+_ /\ _P R222222222222
M2222222/_P#_ /U))))))))))'__ /\ ^,DDDDDDDDDDDDDDD_\ _P#_ )$D
MDDDDDDDDDDDDDDDDDDDDDD?_ /\ _P!D#_\ _P#^22222222222222222222
M2222'_\ _P#UY))))))))))))$__ /\ _P ?_P#_ /XDDDDDDDDDDDDDDDDD
MDDDD]OM]\DDDD@6R,DDDDDDDDF__ /\ _"22222222222222222222222222
M2222222222+_ /\ _P R2222222222222222222/_P#_ /U))))))))))'__
M /\ ^DDDDDDDDDDDDDDDDW__ /\ F222222222222222222222220/\ _P#^
M'+__ /\ _P#))))))))))))))))))))))))-_P#_ /\ )))))))))))))(__
M /\ _P#_ /\ _P#^9)))))))))))))))))))(&S_ .JT?."YM^T222222222
M#_\ _P#_ "222222222222222222222222222222222222+_ /\ _P R2222
M222222222222222/_P#_ /U))))))))))'__ /\ ZDDDDDDDDDDDDDDDE?\
M_P#_ *DDDDDDDDDDDDDDDDDDDDDDDDC_ /\ _P#$W_\ _P#]MMMMMMMMMMMM
MMMMMMMMMMMMMO_\ _P#_ .2222222222222._P#_ /\ _P#_ /\ Y2222222
M222222222222228+286VVVVVYLWR222222223_\ _P#[))))))))))))))))
M))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DD
MDDDDDDDD?_\ _P#B222222222222222+_P#_ /QVVVVVVVVVVVVVVVVVVVVV
MVVVV/_\ _P#47_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /[DDDDDDDDDDDDDD$__ /\ _P#_ /\ F22222222222
M2222222220$!._2VVVVV\DO"22222222/_\ _P"M))))))))))))))))))))
M))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDD
MDDDD?_\ _P#R222222222222222;_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#\O_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))_
M_P#_ /\ _P#]2222222222222222222222[!(!&VVVVVJ!OZ22222221S_\
M_P#9))))))))))))))))))))))))))))))))))))(O\ _P#_ #))))))))))
M)))))))))(__ /\ _4DDDDDDDDDD?_\ _P#N222222222222222#_P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,
MO_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ I))))))))))))))%_P#_ /\ _P#]R222222222222222222221;2
M:0VVVVVVLVW:22222220?_\ _P#I))))))))))))))))))))))))))))))))
M))))(O\ _P#_ #)))))))))))))))))))(__ /\ _4DDDDDDDDDD?_\ _P#V
M222222222222222+_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#<W_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ )))))))))))))))._P#_ /\ _P#.
M2222222222222222222223":6]6VM61K5:!422222222?_\ _P"I))))))))
M))))))))))))))))))))))))))))(O\ _P#_ #)))))))))))))))))))(__
M /\ _4DDDDDDDDDD?_\ _P#R222222222222222/_P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#,7_\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /XDDDDD
MDDDDDDDDDD@__P#_ /\ $DDDDDDDDDDDDDDDDDDDDDD=+=FI%\DDDDP 2<DD
MDDDDD_\ _P#_ +DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDB_P#_ /\
M,DDDDDDDDDDDDDDDDDDD@_\ _P#]22222222221__P#_ /I)))))))))))))
M)(__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ -L?_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#<DDDDDDDDDDDDDDA__P#_ /\ 2DDDDDDDDDDDDDDD
MDDDDDDFS=O\ ?))))))$7^Y))))))))__P#_ ,DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDB_P#_ /\ 4DDDDDDDDDDDDDDDDDDDF_\ _P#]22222222
M221__P#_ /))))))))))))))))?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /A?_P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDS_
M /\ _P#_ .-))))))))))))))))))))('_;_ "2222223[:322222220_P#_
M /\ N22222222222222222222222222222222222223_ /\ _P 222222222
M222222222227_P#_ /Y))))))))))'__ /\ _DDDDDDDDDDDDDDDG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_!__ /\ ^                              \DDDDDDDDDDDDDB7_ /\
M_P#_ /[))))))))))))))))))))(2?R:)))))))&;?\ 22222220_P#_ /\
MZ2222222222222222222222222222222222222?_ /\ _P!R222222222222
M2222222/_P#_ /\ R2222222221__P#_ /I))))))))))))))(?_ /\ _P"
M                             7__ /\ [DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDD2__ /\ _P#_ /Q))))))))))))))))))))(2V2_
M9))))))+>VQ)))))))#_ /\ _P")))))))))))))))))))))))))))))))))
M)))))_\ _P#_ #))))))))))))))))))))/_ /\ _LDDDDDDDDDD?_\ _P#N
M222222222222222#_P#_ /\ 2222222222222222222222222222221__P#_
M .Y)))))))))))))))))))))))))))))))))))))))))))'_ /\ _P#_ /\
M_P#!)))))))))))))))))))($!-L9))))))/6VQ)))))))/_ /\ _P"9))))
M))))))))))))))))))))))))))))))))(?\ _P#_ -))))))))))))))))))
M))__ /\ _4DDDDDDDDDD?_\ _P#^222222222222222;_P#_ /\ 22222222
M22222222222222222222222?_P#_ .))))))))))))))))))))))))))))))
M)))))))))))))()__P#_ /\ _P#_ /XDDDDDDDDDDDDDDDDDDDA[)?(DDDDD
MD@MDD<DDDDDDDG__ /\ R22222222222222222222222222222222222223_
M /\ _P!R2222222222222222222;_P#_ /Q))))))))))'__ /\ YDDDDDDD
MDDDDDDDDG_\ _P#_ ,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDW_\ _P#^2222
M2222222222222222222222222222222222222203_P#_ /\ _P#_ /\ _F22
M22222222222222221<DOVR222222 ?\ ]DDDDDDDDG__ /\ F22222222222
M22222222222222222222222222+_ /\ _P!R22222222222222222223_P#_
M /\ R2222222221__P#_ /Y))))))))))))))(__ /\ _4DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD/_\ _P#B222222222222222222222222222222222222
M2222222__P#_ /\ W_\ _P#_ .R222222222222222223/VEO2222222#_\
M_DDDDDDDD8__ /\ ]2222222222222222222222222222222222222;_ /\
M_P"R2222222222222222222?_P#_ /[))))))))))'__ /\ \DDDDDDDDDDD
MDDDDD_\ _P#^R222222222222222222222222222220__P#_ /9)))))))))
M))))))))))))))))))))))))))))))))(_\ _P#_ ."U_P#_ /\ P9))))))
M)))))))))))%),D/)))))(1__P#_ $DDDDDDDC__ /\ \222222222222222
M2222222222222222222222'_ /\ _P#R2222222222222222222?_P#_ /\
M22222222221__P#_ '))))))))))))))))/_ /\ _4DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDD/_\ _P#W2222222222222222222222222222222222222222
M21W_ /\ _P#R3G__ /\ ^Y))))))))))))))))))N2;W(UK*U[:[0EO)))))
M)))O_P#_ /$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF_P#_ /\ \DDD
MDDDDDDDDDDDDDDDDA_\ _P#^R2222222221__P#_ !))))))))))))))))?_
M /\ _=DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDY_\ _P#^R222222222222222
M2222222222222222222222222??_ /\ _P#22?\ _P#_ /\ $DDDDDDDDDDD
MDDDDDD!+?IDMMMMMMJV[(4DDDDDDDB__ /\ ^62222222222222222222222
M22222222222222?_ /\ _P!222222222222222222223_P#_ /Y)))))))))
M)'__ /\ $DDDDDDDDDDDDDDD@7__ /\ B222222222222222222222222222
M222+_P#_ /W)))))))))))))))))))))))))))))))))))))))))_P#_ /\
M_P"R22?_ /\ _P"&22222222222222221DW:6VVVVVVVKVP#R2222222?_\
M_P#_ *222222222222222222222222222222222222-?_P#_ )))))))))))
M))))))))))/_ /\ _4DDDDDDDDDD?_\ _P!R2222222222222223_P#_ /\
M^222222222222222222222222222222;_P#_ /R)))))))))))))))))))))
M)))%)))))))))))))))+O_\ _P#:DDDV_P#_ /\ [DDDDDDDDDDDDDDDDDR6
MP#MMMMMMMKM__P!))))))))!_P#_ /ZDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDD?_\ _P"R2222222222222222222;_P#_ .I))))))))))'__ /\
M,DDDDDDDDDDDDDDDD?\ _P#_ -DDDDDDDDDDDDDDDDDDDDDDDDBDDDDD@W__
M /\ ^22222222222222222222222"@22222222222222=_\ _P#_ .2222,?
M_P#_ /\ 22222222222222220X!)*VVVVVVVUM__ ,DDDDDDDDG_ /\ _P#D
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD?_\ _P!R2222222222222222
M220C_P#_ /Y))))))))))'__ /\ LDDDDDDDDDDDDDDDDX__ /\ ]2222222
M22222222222222223MN22223_P#_ /\ B22222222222222222222222#_;2
M222222222222;_\ _P#^I))))%__ /\ _#DDDDDDDDDDDDDDDD>V2DMMO>A"
M>Y)OT$DDDDDDDDC_ /\ _P#TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
M/_\ _P!F2222222222222222220__P#_ .9))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDB__ /\ ^R22222222222222222222222_FZ2221?_\ _P"I))))
M))))))))))))))))))!O_P ,R22222222222_P#_ /\ ]N22222?_P#_ /\
MY2222222222222221+2;+2A"2220KX$"222222222#__ /\ ^)))))))))))
M)))))))))))))))))))))))))'__ /\ [DDDDDDDDDDDDDDDDDDD?_\ _P#J
M22222222221__P#_ +)))))))))))))))))__P#_ /<DDDDDDDDDDDDDDDDD
MDDDDDC7_ / 9))&__P#_ /8DDDDDDDDDDDDDDDDDDDDDBW__ /R9))))))))
M)(O_ /\ _P#K))))))1__P#_ /TDDDDDDDDDDDDDDD 26XDDDDDDD'X 7TDD
MDDDDDDG_ /\ _P#\LDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_P#_ /\
MYDDDDDDDDDDDDDDDDDDD_P#_ /\ _DDDDDDDDDDD?_\ _P"R222222222222
M2222;?\ _P#^I)))))))))))))))))))))+_ /\ _P"])))/_P#_ /\ I)))
M))))))))))))))))))/_ /\ _P#))))))))))#__ /\ _P#Y)))))))__P#_
M /\ Y))))))))))))))*O^O))))))) @)MQ)))))))))!_\ _P#_ )))))))
M)))))))))))))))))())))))))))))/_ /\ ^LDDDDDDDDDDDDDDDDD@_P#_
M /\ !DDDDDDDDDDD?_\ _P"R22222222222222220_\ _P#_ ,R222222222
M222222222220?_\ _P#Y)))A_P#_ /\ C)))))))))))))))))))))__ /\
M_BDDDDDDDDDD'_\ _P#_ #DDDDDDDB__ /\ _GR22222222222222_Z!2222
M222423;22222222222?_ /\ _P!V2222222222222222222222?M22222222
M222;_P#_ /\ R22222222222222222+_ /\ _P!222222222221__P#_ +))
M)))))))))))))))"_P#_ /\ SI))))))))))))))))))))7_ /\ _P#7)))!
M_P#_ /\ XY)))))))))))))))))))?\ _P#_ .W)))))))))(_\ _P#_ ._)
M)))))))9_P#_ /\ \Y)))))))))))))+V!+)))))))$A(E9)))))))))(?\
M_P#_ .S)))))))))))))))))))))!O\ GR222222222'_P#_ /Q)))))))))
M))))))))"O\ _P#_ +)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDG_ /\
M_P#],DDDDDDDDDDDDDDDDDDDA_\ _P#_ (DDDDV__P#_ /\ $DDDDDDDDDDD
MDDDDDDD-_P#_ /\ YDDDDDDDDDD*_P#_ /\ YDDDDDDDDDK_ /\ _P#YDDDD
MDDDDDDDDDD);_P#))))))(, $DI))))))))));__ /\ _#DDDDDDDDDDDDDD
MDDDDDDD'_P#_ !R22222222,_P#_ /\ ER222222222222222??_ /\ _+))
M)))))))))'__ /\ LDDDDDDDDDDDDDDDDDD__P#_ /\ TDDDDDDDDDDDDDDD
MDDDC7_\ _P#^222221?_ /\ _P "222222222222222220?_ /\ _P!&2222
M222223__ /\ _P#R2222222227__ /\ ^M)))))))))))))*[;1))))))(]L
M -I))))))))))%__ /\ _P"]))))))))))))))))))),O_\ _P#MDDDDDDDD
MD'__ /\ \R222222222222222;__ /\ _))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDD(_P#_ /\ Y$DDDDDDDDDDDDDDDDDS_P#_ /\ ]TDDDDD/_P#_
M /\ YDDDDDDDDDDDDDDDDD=__P#_ /\ 4DDDDDDDDDB__P#_ /P222222222
M2!__ /\ _P"62222222222222VT R222222923;F22222222220/_P#_ /\
M_&222222222222222221E_\ _P#_ ,V222222223[_\ _P#VY)))))))))))
M)))/_P#_ /\ _I)))))))))))'__ /\ LDDDDDDDDDDDDDDDDDD@_P#_ /\
M_$DDDDDDDDDDDDDDDD@W_P#_ /\ _DDDDDDL_P#_ /\ _P 9))))))))))))
M))(C_P#_ /\ ^I)))))))))'/_\ _P#6DDDDDDDDDDD _P#_ /\ Y$DDDDDD
MDDDDDDG_ ,+))))))$7[>X))))))))))))G_ /\ _P#^))))))))))))))))
M))A__P#_ /[DDDDDDDDDDD__ /\ _P#TDDDDDDDDDDDDD&__ /\ _P#<DDDD
MDDDDDDDD?_\ _P"R222222222222222222,__P#_ /\ VR22222222222222
M2K__ /\ _P!B222222,__P#_ /\ FR2222222222222&#_\ _P#_ -N22222
M2222)?\ _P#_ -R22222222222"?_P#_ /W))))))))))))+LME))))) .?[
M21))))))))))))!?_P#_ /\ ^')))))))))))))))(?_ /\ _P#^9)))))))
M)))/_P#_ /\ ^')))))))))))(S_ /\ _P#_ )2222222222221__P#_ +))
M))))))))))))))))))O_ /\ _P#QY)))))))))))))"I_P#_ /\ ^=))))))
M))O_ /\ _P#S5)))))))))))(HO_ /\ _P#_ "22222222223_\ _P#^_)))
M)))))))))+__ /\ _EDDDDDDDDDDDD O_,IW<H7UEH"4DDDDDDDDDDDDDEW_
M /\ _P#_ ()))))))))))))).?\ _P#_ /\ ^*22222222222_\ _P#_ /\
M)DDDDDDDDDDDY_\ _P#_ /YDDDDDDDDDDDDD?_\ _P"R2222222222222222
M222$?_\ _P#_ .>2222222222200_P#_ /\ _P#3DDDDDDDDC_\ _P#_ /\
M_P 2222222222&__ /\ _P#_ /ODDDDDDDDDD7__ /\ \R22222222222233
M_P#_ /\ C2222222222223_]&6VVVVE9MFV22222222222221S__ /\ _P#\
MQ2222222222283__ /\ _P#_ /LDDDDDDDDDDD=__P#_ /\ [0DDDDDDDDD>
M_P#_ /\ _P#W9))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDD3__ /\
M_P#X2DDDDDDDDDDOG_\ _P#_ /\ Q)))))))))!__P#_ /\ _P \R2222221
M2;__ /\ _P#_ )4DDDDDDDDDD/\ _P#_ /4DDDDDDDDDDDDDB7__ /\ ^222
M222222222;_VVVVVVV]^WLE222222222222220?_ /\ _P#_ /Q9DDDDDDDD
M33__ /\ _P#_ /\ 6222222222222 ?_ /\ _P#_ /D,DDDDD#.__P#_ /\
M_P";)))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDE__ /\ _P#_ .DI
M))))))),M_\ _P#_ /\ _F2222222222+_\ _P#_ /\ _1'!DDBWG'__ /\
M_P#_ /PY)))))))))-__ /\ _P")))))))))))))))&__P#_ /\ ))))))))
M)))(N  +;;;;:/;V7)))))))))))))))+_\ _P#_ /\ _P#Z#Q%DDCWNW_\
M_P#_ /\ _P#AR2222222222223?_ /\ _P#_ /\ ^*I1'#;_ /\ _P#_ /\
M_CDDDDDDDDDDDDDD?_\ _P"R222222222222222222221O\ _P#_ /\ _P#Y
M3;))(M^?_P#_ /\ _P#_ .4DDDDDDDDDDD*__P#_ /\ _P#_ /Y.P3__ /\
M_P#_ /\ _P#OR2222222223_ /\ _P#_ "DDDDDDDDDDDDDDD@__ /\ _FR2
M222222222>VVBVVVVVJ3: *222222222222222 ?_P#_ /\ _P#_ /\ _P#0
M57__ /\ _P#_ /\ _P#[DDDDDDDDDDDDDDD@G_\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#BR22222222222221__P#_ +)))))))))))))))))))))(
M9_\ _P#_ /\ _P#_ %75!_\ _P#_ /\ _P#_ /R9))))))))))))1_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ -I))))))))))E__ /\ \<DDDDDD
MDDDDDDDDDE?_ /\ _P#ODDDDDDDDDDDUM[UH%#Z"G9+?DDDDDDDDDDDDDDDD
MG_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \)))))))))))))))
M)"?_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ :DDDDDDDDDDDDDDD?_\
M_P"R22222222222222222222237_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#\22222222222220W_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
MPI))))))))))(?\ _P#_ /I)))))))))))))))),_P#_ /\ _)))))))))))
M'*6^OI))/_3^S)))))))))))))))))&/_P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ //<DDDDDDDDDDDDDDDDE?\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ ^E)))))))))))))))'__ /\ LDDDDDDDDDDDDDDDDDDDDDDGG_\ _P#_
M /\ _P#_ /\ _P#_ /\ _P#_ /\ ^K))))))))))))))()__ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#U?))))))))))('_\ _P#_  I)))))))))))))))))
MO_\ _P#ZLDDDDDDDDDDE"0DDDDD'_M_&DDDDDDDDDDDDDDDDD@6__P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _"LDDDDDDDDDDDDDDDDDDPW_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#DDDDDDDDDDDDDDDDD?_\ _P"R2222222222222222
M22222205_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _HN2222222222222222?
M+_\ _P#_ /\ _P#_ /\ _P#_ /\ _P!9))))))))))))?_\ _P#^$DDDDDDD
MDDDDDDDDDD@G_P#_ /\ ?DDDDDDDDDDD,E<DDDDQ_M;$DDDDDDDDDDDDDDDD
MDDG]_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ KTDDDDDDDDDDDDDDDDDDDD!_
M_P#_ /\ _P#_ /\ _P#_ /\ _P#[I))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDLG_ /\ _P#_ /\ _P#_ /\ _P#_ /\ M:2222222222
M22222222%;__ /\ _P#_ /\ _P#_ /\ _P#\2222222222221_\ _P#_ -N2
M222222222222222223__ /\ _P#Z22222222220F]R222.:ULV2222222222
M2222222222"U_P#_ /\ _P#_ /\ _P#_ /\ _H?222222222222222222222
M23!__P#_ /\ _P#_ /\ _P#_ /QW)))))))))))))))))'__ /\ LDDDDDDD
MDDDDDDDDDDDDDDDDDDH__P#_ /\ _P#_ /\ _P#_ /\ [.DDDDDDDDDDDDDD
MDDDDDDDQ*_\ _P#_ /\ _P#_ /Z\4DDDDDDDDDDDDDK;;;;,DDDDDDDDDDDD
MDDDDDDDG;;;;;DDDDDDDDDDDD 4DDDD]MV@$DDDDDDDDDDDDDDDDDDDDD1D_
M_P#_ /\ _P#_ /\ _P#7Y))))))))))))))))))))))))!&__P#_ /\ _P#_
M /\ _$Q))))))))))))))))))%MMMA)))))))))))))))))))))))))));1_
M_P#_ /\ _P#_ /\ S^I))))))))))))))))))))))),][O\ _P#\V".DDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF &DDDC$
MTFP4DDDDDDDDDDDDDDDDDDDDDDD3(L;_ /\ E)7@22222222222222222222
M22222222871?_P#_ .[W:)))))))))))))))))))))))))))))))))))))))
M))))))))))))))%<KU__ /\ $%14DDDDDDDDDDDDDDDDDDDDDDDDDDDF@]>4
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD2'DDDB 0&RDDDDDDDDDDDDDDDDDDDDDDDDDDDGCC<DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD=C6Z5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDP#K6DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDE ,DD5]:"5DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDD_0DD:TR"2DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDEHDDO_ "W[))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))+E)'?[[7I)))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))F9-_2W;))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))(0_2S[_ "2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222-EWEFR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222<@0'M22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222@;&UR2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222238")\R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222220+T#>22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222"T;*Z22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222+" _^22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222228;$Y*22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222,GY*"22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222229X0/R22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222223Y2FI22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222204_"0R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222221(P;+R2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222228Z'O22222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222*X#&2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222UZ2222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222223_Q  N$0 ! P($! 4%
M 0$!       ! !$Q(3! 05!A(%%Q\!!@D;'!@(&AT>'Q<+#_V@ ( 0,! 3\0
M_P"1RQ%09213H"@J2JJ-!^MG<*)>IXR<B@7J/K68YEIH_6K  DC&*W4?K48W
MKC1?6H.D7#8/K4CZ?7 (KAYW+ZU'\7&2+/ZU:D(-HH 0  8?6J,7(@QL$-D&
MUG]:X!9*I4.*K0$$8?6U!D7!\ 9Q4&/_ &^=] N1 @P?I<) E-R0MIX#:+;(
M&@^?*!S\1"*!FJIQIY%("2B/(B+-;_!!O+=0,@ P?^)D@2F<G@ 6"$"#&F$@
M2FY*VG@-HML@:#K9D%!9NCRA$D41(A))L@<% 6: Y" YA9@@0:CSJ_\ $@$-
MI.O2!0<!$T!$F:)I-P"@H S0%(1<AE#'_A1( <J.JB>12QX02(6:+DE%G0R$
MBLT=$<@B2*(FS1))L@4% 6: 90',+,$"#&HSY!R+-%.#!(J%FCHJ"E6/CCK:
M6TMI;2VEM+:6TMI;2&PT, .6TMI;2VEM+:6TMI;2VDP8,6\<1"<(([ZR2!4J
M.JB>12+#29!0=9HR!>-!=0+:6TMI;2VEM+:6UI0C$MI;2VEM+:6TMI;28 88
MBR6TMI;2VEM+:6TB 9-H .2R115RN;F%1L\=-D'(LT3O.#!(A9@Z*@I%I9+2
MN?%GK8H%H4]54LTQU<$&U.0IT)VR!:,T@  PQ8U'&.T0! :M-%&<BJ!8R5(X
M@HLX_P!JR(TF;'ADV/S+(Z*BBKE? DP30,5"IPJLY;%0IBJIYIH\*@5*88^.
M*H]!Q@W",\M?':"S9)M $F"$QC =W*Q.>J4:2MK&A9^X5/-,;[5D1I,V/#)L
M?F<8!=*0*# LA^*HE14XQ\\5$H.B43-2$:' 0H"<77!(M M4+JV/ X1"<VFS
MYQHN5AGU)(2J' T:&*H9H<7[5D1I,V/#)L?F<0!RB#G T#) -08B0E2$:' 0
MNJ: 2 <HYIH\XHH(!QBFRVT5@@"S&DM4KHEITY@8ZKI>#\+ITT'3P"Y(E%*G
M2:%(01\2]JR(TF;'ADV/S.$8[HIO@4J@9X<D .4]19T8]"@@'&- .AVL:25H
M@CC$D ABC-96G;H.-^>M'8(33'2]$Z=.G3\!OIVD"I1QRTP$DX0S3$?:LB-)
MFQX9-C\S@&+YHAN<$Z7X<0Z&:QI)1P@M,6(=T0WTL0G"#09Q(F"@),;39\XN
M,E3:G)./EZ<+ITZ=%6-],):I3NH):#"! .,-[5D1I,V/#)L?F>('"CF[!' "
M ###"'='-]+ DG"#1+$CH2B22YP$ $7)9#.* D )M%MA;(3^1$V2)$1R* BJ
MA& A;QQ+;.M DG"$YB0"Y%<6G] C;H%/XNG3IT^F  NE(RP(@! V2!YE#/*
MLDPC.1;:VELD2(2Y(DA$<BB&%(#!&/9 %\*]JR(TF;'ADV/S/  .49XVJ "(
MFB YE=9'>7-+('1!%#X59)PP082B23G 0P1,T0SB@! 62VB9R"VPG\B)LD2(
MCD4!%5 -(COA$O4WLI9!2=0J_)A<TI\7WL2NV0;1GD""'&(=L@6BM9(!@PT
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M]E65.3]:$)Q$DES:(3! !S.D;QME0(I@/:LB-)FQX9-V8@:"$A(A.;1#<P@
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MOCM+;YLOZ?[8V!'O?_*>_%]I?. CZV8>3$?2S%I,^/#)LP]- D;)0!UT
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M</3)**7#I?BS)L2&DM'$HAJ&V"2<(1HH((<8JC5&Z@AL0&!@MU7894<T.&)
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MOK9YL$W%1^[];( 8PCYD)DR9,F3(?K;K H5&ATQ%#X-X,#R/K<@#HER5<#H
M*(L#/Z*__\0 +A$  0(#!0<% 0$! 0       0 1(3 Q0$%046%QD:&QT>'P
M$"!@@<& \7"P_]H " $" 0$_$/\ D96&&:BAOP5/$P5%"LE*/5&?]LP]')
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MG"40"&*+!JI/$:Q03*OW>F"$ %Z$(+O1DR9,F3+;EAQZ>MY*XJ-5&!%!<O0
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MBF,RF=^:X4QY!/Y^^\!TZV[MNA+!<)_4'%D\PI\4MK;>DFHXE*^T6:A)<NF
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M!G?BDHXI%&9V<AX('$>U@ +YFTT4R9,F3)DR*!G@#B6*N4YK,PW+1"TFY:2
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M&;@9<*<V+5R96]7H-0*N'+[)P$$A!-7$:(UCT%O:[60PAN)A,*$2R)2JV^L
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M:".*NF,U]HRP<*"71U$3.$(1,(TY.SX!%>743EJ$7H98\,0X@=6 -TI1=X1
MO(;SJ);6#I*-C-H:I@)N@&K6+T0]DD2SN(:*"@   "P'K,HYB'S(//=45751
M18W&MVKF$&W30#XD)2//(V21LTY)\W.6)O94V94Q+Z?% Y$L!#:W#L+I19Z=
MX@=4*-FLM5L&'<BV=16$]''(E88J.P#4N)M,7+AB8-C(@Z47&]FBQ UMZ#J#
M#V(+]#O$_P#'VO/IE2L\R)G6'?@^SMT<_8ORJP 75 NU-$EC%;F6816D L.I
M9;++&[-X8F6T2@I)A$G6S!YO<X6]>LCX]@A19$T:GVTJI,N9;NG$(U"+Y$FP
M<)H%$N+U,.[W &1R!;9W2^J:_NMG\(CP?N=_7AY,P'[ KK_:A0L8H>7YQCR9
M7V!9[WY@L!JB U4-:>B6%*9;D\ZCL '2O=\+-UT#*H NI4=8:[3.6#9MO:QH
M&Q@! &QZP.4M^'O5=BZ713Z>C8QHK#%K))(-NG,;T4R0=Q* 8,L-('S&X-I/
M64"K 96GTCAFGDW.'@'2M+;,\#G,&[K!*3L!"B7P@O L2VE5]=<,V!$&Q;EN
M/&%*1V-M%L"T: N<B0>E*>E8%IVJ%G1$7"K!L<$6Q]&D3BTB/IR6*:%0!LB*
M(TI,7S),NY2%RANV=$6$'3E@G*R&4,V"S8H*E!9$1'T5RXUB.D4U8>$+3GHM
MH"GR>/"D U0UH* >L=5:HJ=57V.^0]EA"_'P%%3Z9]O_ ,6+O_$]F%L940!N
MTS9<MDH=XW#M*NAU$0="3E!UM\6((HQ7[%[&5RK=;M_8G2R6CVL&-U*@D8*N
MDJ@(MK_ANK160Z4D2"S)1HB#2$@]KA,6A=B\E7JFO[K9_"(\'[G?UI,E"F0!
MWH;%-TFL7\W(Z#V"0D?>#R2ZW]!<@PZ0B2$!&ZK57@W> 4%02C(6[HN#8Y97
MUUZX:5](UREA!J-2+= V(CA V63TLD<XR<;4+<62$&K527"+$T3Y(2R/6R/#
M8&UF#MN3;2=,(\0"#MY[?*87;%M7V@;IRF5*K=7V%Q/BB1"(V1-*M+T9!D.7
M4Y&XLQTA26QM8MC'9-XE 2"$B-D]/FJM@Q[D6YJ(PM29XCYB=4 =GI1KD>1%
M5\_^(]"KC"J+@-\)9W%#D,.D&55RKT4M#$5  NJH!0X&BS:O.1)U2P@>QE-$
M!TK';]@@KLKLH WVX.?A?H5;?CHUPO*26;)02F2*VX[)J-S7V2S8[=!2%,$S
ML?CTE^6*;8 75J"@2*7D70-\FI#V4E7AI,A19'9J%&A+DE,AW<"4Z5D9KS,X
MFK_ R!5$7) P0U$1]2U_=;/X1'@_<[^M?A0N!+Q<%8V^/V"3F7KF#+2YJ!@9
M/220#"S79;.^X#++")(%I?4==M4J^PGY%"D#D34IJ1D<1D'Y?_.B,"#")<>E
M)ZM%<,S>40RG*4! QT0;B)DZF+O"$#!Q(J,(TI9<V75-M@P!8 "QTACOPLD7
M0>'!>6A\6@ED &#V0"5LD.0,:T<RE&!!A$A'I1#6LX0.2IW,X7J"BMH,<\D7
MY>2(P(&$<G1>*815*"XB"-12':)1!.%D, 8B>M+Y5L3;'U@!WE@%J7A?8BMP
M3Y96Z]*)?'9"XH^?_4>R<+Z,0GX*<R5#=2_+T&=I&6V(S^E" J!(CD2B.\6%
M5L;TP"%L""5@Q)T+5MQUP%[(3[%)E\U@,(S'/8"1%,YY:7)3NO2":B8+OL 2
MJ@ 50* ^/E)1>7!HVO M[1++8$)R'&JXYD4)/\T"81&XCITB!?O=:K6#8D6)
ML!ZAK^ZV?PB/!^YW]57JMPUOS!G\F*" 8 @ P![ @YB"L'*670%@:< ,\2X#
M0 !H :=)0X02!W6WB-@F5"CDY@B:&[JK=565]D-0*&"R#34E1;X@X49$T>EI
M'X4LR<V8YXA]3.?'$^.:4DV$B72 &6!"9"-F'PE:"3/3("6.756ZJMWV: @K
M)Y!-.2PG ]) OR3!C<(0V52U03,@MPDG;U&+8KH6DP^=NV'1<=;".'9(2.@6
ME&3$9RX#H!1N/5,L"5, 5*4JWJ%;Y=TVF'1DFBD0F\X64P%F)*"005 "P  '
MLD.SQS>66<Y>.B_R#:N&J./C\_4Z3"!4(.1&F!7@4'DC(M!.2#=DJ1T8 N>-
MFZZ#8^/<) 61-3UY\KE#DJ6P +-#SWA!%N&B$M0"](<09$INN "55@%4"K<5
M12#F]<#ELLEP/:B*=B !AH U[6\-.)^D"81&XC:/OC( QQNI'*1L2VJ?$+,>
M$K6S&P2: @ ( P>I:_NMG\(CP?N=_4GV28- &JJ%'QA<(I&=1#BEE?8930W\
M%2"+7L(Z6851+$;3V84&EUL-$R4'8-5RIE5NJK=]FD;)A22)IR#&^'2*+(3$
MF0U"4:BFM0H3%QY(@2=2'#TKK_:*+' PC;S,NE?ZV!A7?I(7X)4*PKK05YJ?
M! 6 ]GS5E]5^JP&4V,6+ '1NBG;!N.Q [(NO4#Z;^0H3CA+C<J_LQ%D;"XTS
M>&('2>?WH1QP5;A-@@!$1N)KU+ "-@2TC!9V[:=%TA'DBM *= :)4)M P\I
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M>XB#=C!M$'=/U.+8K(6DR>=^V/16TV\)2//(V2S5B1V+@70SKFTDRNBQ%?X
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MGL^EB,W4G'97C[L]OU,L+(OAW"GH+BF0K& XCW5VU/-245 *["6!W+ ,[F@
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M'6XH$(W1=2_#L#VN(8P!L!GY_''0&:8I[15\?SUV?8P):EI_S;EP_>OH)?\
M]B?^/1OM_LE_#$>Y'X_].CR:/:>*_P#W/_.C)MS^1_OIOW._HV-C\2'L'_S[
M.C/U$*J8?S[\************************************************
M************TEL+^X/\Z-Z)N6\O_?XR $@@J4-@ 5:DNB@0FTX2!P!F9ZR-
M&L+!081!&B #%"Q9<2\ :"^TW\T1LB_"D_;)4E8)0O!.N8GLGSX_W[!*I:PJ
MM.\>@Q2"1_BS_O1!!LAPQ_#"*#AEV_\ 3H\_KVE@_P#]I_SHR7<?@_WTW[G?
MT;4Q:>Q^P);"_N/_ #HW"E7[LWY]^LA 1V".C>26<[J7Y/XSEL=$"R*>/_$>
MA?(F?)QYT".@6E'P#P!H+1!1HB>TPC!@FQ*GR_/T2U+]LP3)!$==4N+-UWD?
M[4E0^I*E(L?-H?P] L=/B9Z(M,&3>%_'\,+?ZMV7HR92'>%O:8+^X?\ .BNB
M2G*?^^F_<[^B)A 5X]@+(0(3@_HKPS^$^_6N)PZ+K+"_A#XOS_&#P-%FU:<@
MQJAA42T,14J&ZJJOHL*N(9L2=+>S%B&<^S@"$HP!K2**X.9=?W4E0^P2TKD(
M>R$_$GBL=8UL/SP+_E(BLJRK]D5#28*?D!_OH)VQK@1?DZ-QG=O//\,MM<P]
MS_UT;R3[2.KXQYF.C]GL,NX]-_<[^CPD?Q]@@.#QO+OZ+=&ZYW['>">_*Y :
M\+G]/'1OS)[ +\/XN/@GD+06J(#50I) 463SX4JNJ6OI.+BP*+G(0.K!O"]G
MA23+MOS'UDJ3[!=)04M(/),SMQUV"A8_K8J%05'V<X?($_WT$:P<.+_B.B,D
MGC!,%X9'\,LSJG=='>"?:7E?6&,W!?YZ-NM4[OTW]SOZ/&!_#V![ V(5?\#\
M=&?X #8;Q/Y/?HKRCL2?ET3NW*>)O^F#^+Y%63Q9D:W]R;@D=$G.!1#([Y0Q
ML:  0.5@18L[$&\HZ.<YD@.IJ-Q&R*-FK<%BDB')+)J.XA[+>06SN14GFI/L
M$JEJXO-NDP>?P=?4$Y?>M$90^(SZ >Y/-P1_#1'P);*7Y.CD$Y)M?PW^%V0F
M">TGHI.90_.?A/:;KZ?VW1JR7$Y#?37[G?T>$@_'L%__ (B@_P"V.B;44F>9
M6_A[\DTB8PM?C^>C<N9S9LGD7G^+7QKUQ!N8N!J265=+%=7,2[])"]H)4*Q<
M605?DE^" L%1FK2,0&HBE926KOW;>0=QL6=)&)->O8L2KY) J0RRTF2'<?98
M=@M-Y ^?B^DU)4GV"R3:C,B^>KU8YD@/+7.B$-\-!>3 H:E(@3K]^N$?!+_G
MH8ZVE  8X@]&+:/*]U^2?PM8N;MM/1EY)\3)]I[9< O@=%:6%)[^F+^YW]#G
M8'L,SV+6&?[L=&P4ZF+D'Q^/OUEG %\!Y1'GHR'0CDL#YLH!&*0"1.X_Q36;
MU@L>V(4T#K ZN>HS0- 0 6  L=%RSH E7:H5A4=&+9QV1>+]=>A^0Q[ZE#5.
ML)HX2C&$=40B61$STKG0ML=*EPC.QIQ]DML<[2_4,U)]058"]8W3.4.ZB_4U
M2S+_ &0J> >0?Y#^*G01I*^6*FK?NRH]N/<Z?&!-GX']U$&VISS%^*G+OPWP
MK/7*B4U*L_"C&N>H1_+]J&H?J:U1\U?YZ'" )_X Z-=+W&!D9\0<C^%PF2P;
M3GX'HRLD\;.GY/:125XS:,Z*TL7;>'TT_<[^APH_R>PPM;YS"@Z(2"5DQ!?S
M"N'"BLGPGOI[,&02![BU+4JJ99'S=T4W"A61DO/\3$BT:D8J- !:Q>M7?N6\
M"[!<NZ5Z8BV(O!RV-SS'[+PUZHRD&;CJ<AATD@,(0B81J2E+?9F:N(<0;1/9
M+[!Z;.OQ]F:DJ%%8B1*5()J6J<!+_P#8*_*IJZY#ORISH%W^2E4JRN5Z@D?M
M""H*2(95L$7Y3T*1]2&^KQ%\.C<AG/!'3X CPM!5,O2$^$_A4$\F(Z^#HS6X
MD[Q_3VF&;@[$?X^#HP@FCN//3#]SOZ'&R_#V$+Z04@;(T58E.ICS2>>BF+M2
M9N#YOS[];/E387><[=^B$,,J<X_?S_$[O0K(1(IHXX06E/1L&N?@<#C3-Y8A
M415/X @#_P!;OW3,C;9-+$Q=T!P%W1RU13.L?60/>2$&I?,<Q%\D^2$LGL=Q
M9\!-/+4_;")RAZ ?5%0_4L!/C9]#,$2+*QGY)YZ5X 0*5*O#'L'^%?F>!2_N
MI4&JT#"="98#!N_UR_/M(2!8[D=$2%#;QG>67TW[G?T.%E^/L4;5@D0O(A71
ME'S9020&ZH[+WZ\&I&"+KL .[HLOEM-LJFL(.10$@A(F'W$,4* 12@C,*B>'
M;V!\F>H7";NB689*$W68),JKE77HAZ;^4H#CNV"[5KIB+H7!SIFQ,2OORBVH
MAPFB '(@Z4(Z6$68N;(-$+Y>B7;6TIA-\(9EEH#?8@D2(ED37V*^<P?48EKN
MKNJ%=V,^@,#[[<23FRS_ %Z*)+DBV/-X-W'HX<S*@!)H1-=%O_A<*00>?_#H
M3)^UQ*!Y%W3VF$.5!^&SH2RVFS)C^Z+$03 ! >F_<[^@8+A#V(L/H1Z+\+\^
MBK@L92^\8/,4)!#LH)$=1/<9U:9H,T69B;3U"0EB2=S_ /!4)M8X$PB;B=&?
M:N$P$^K+-U&SW )6H$A@-40&JAK5R)$$+*(D $;*5+M::;%CR,')APZL9UNC
M_P#Q('CULTEW!-L?5 '>\ M2Z(+"#X)\LK=>EBD*T)>#@\;=\.@2C[)B%QM
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M<B:4>ZZLHINW<9:QTA((3UR*NKHO8M$R" HA(CA'V::H LZ<:JP?T2TD*[*
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M2\#410H5"C>$+/L$"9SA3B\[B2Z&&">J95=U]C$K*BZO32!G;PTA&JPZ&%Q
M])E^>NS<MI%W6Q=4D3$C%1JJKT6@D$50 NJH!4$T4F47G*RF4L1'IC2,8.HK
M0 '1"G%21).?*A$T TZ5H5 IP#.+$<W70H#YDY W$=3U5D3E2)^/ROW/K*6<
MM$Q@/Y/%0_8(5!447"FHTN'YH_!0%@,'J'\VU(<(Z!!!<03%7;->$G#H2!H,
M. O2>FY MD!<1O)0K9$1H@)\"[@5.?XHD2(ED37V(2L)'*W4Z)6!)*5D,VI0
MV)&X&Q!-W2!0!*X"HHB%RT(S2RZ@+#=Z1T,P;R6T8$Y79TD@,(0B81K3G;&@
MEC2*VPW]86"DH(E#2"SI1;<;T<LB5,J[])%M+9"M[2S*.?5/]SO]O@0HR0,0
M-1%*8NEY3*YY@=QL3!TEF7X4QR?.YF=5 J%%>(=]$R(C<]@4@2$<+7N:B\,$
M)2-T))1W.<2I4$MB.D)2&XRA.=K=DU(   @-.L$@)O QAW6-1.&$6@3"3HFH
M($LB.O3-7C8$N;[O@CH8((A,6C6DN-A*BRP^M@ 1J#E?@-6IYC,'/6%;QY60
M&GM_1+Y0JKN],C$A<G@6S"@WEPH! <EC_M;JMU5;OI-'K48T#5, %U0+M:M'
M\EGOJ5-4T@.C,MAJ@W%'S_ZCU(@&BA:N. )T"P(NJ>0J0#<1$3I7$&M\-*UR
M(NXI:,^I:14Z&!5^H[OJ:J.\/\"ZB@50#*U.[@L_P47SY4P:J3%OMO45#4OJ
M0J"K*OR,3+X]4YA#;"43<%X=!2UDE56XKUWR#N(C"(=-$JN22MTS+7)7L+"$
M-L-Y-<TD>7KWH0, $JK@-Z$FT27=(NSLPNN4SW,U!H!8IL &AU+I^%)V)UBS
M0G ],LQ:268EK V8R#6LX35V@<DF=2_3B7".U!Q;K&2!2/!EI_\ $PC<1$'U
M,?#/3_ZK8"ZH M+5,2&-3G\#(%Z:7Z,90 ,JH!6I%=81(=1 [R<KU7[G?[A
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MXL-'P"X+)U;'/)L6QCB$=J$.$!G?835>!0B;0$3VI.8C9?3M-41.RJV"IJB
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M&G*2(M( O"=].6V8$+IB/ #K'5$===5< 2J@ 58*M&R*5@W[@0ELLE@/2A_
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M[?)^UL#9$#RU+V+-H^"N;:F_HG228P?F2@^(@^3:VOZ03'O(>85?*<#N@$[
M/0S&6YAY-1=L&(0H;W&EH L $ >L0$:> RJ7FP\A9"FI<>+H[[B61$L^@@0K
M,L]RR\E:!=?+$7FAH!R(?%/=FUY+;ZA3S"H[S*_IU^(]?V*'=K1#^5=B1>:8
M!HDH[@G\U!\H&VX$O#-130+CM*'@] ]8*+: #*M'\&1; FH)A#(-!ZW]SO\
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MSW+)<Z5H1-@(RBZ*>ZN@/3,H&+V03H*2:!D]F@3"C1$BH*CZ6U7HVO8<I/\
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M>O#O1PA8 +JU8MM>4D/<H9AJ7AVKN<8+LCCU/C>\ 9& D-23:3I1V&1G7MT
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MT:8T"NTK<&JV=DPJA#A.4(.HB/VW:9IF\#R;S4-0_8(*@^EYV8-)2._XS_M
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AJ%]B3[-FBNRD!C@S_-8SSKW\"LFT_$?(B @.Q:_\5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pipeline072819.jpg
<TEXT>
begin 644 pipeline072819.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *Y"B,# 2(  A$! Q$!_\0
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M_P"@)9_]^Z/^%;^%_P#H"6?_ '[H ^5**^J_^%;^%_\ H"6?_?NC_A6_A?\
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M_?NC_A6_A?\ Z EG_P!^Z /E2BOJO_A6_A?_ * EG_W[H_X5OX7_ .@)9_\
M?N@#Y4HKZK_X5OX7_P"@)9_]^Z/^%;^%_P#H"6?_ '[H ^5**^J_^%;^%_\
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M_P"":O\ R6OQ!_V+TO\ Z4V]?)5?6O\ P35_Y+7X@_[%Z7_TIMZ /"?V@_\
MDN_Q$_[&&_\ _2AZX"N__:#_ .2[_$3_ +&&_P#_ $H>N H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OK7_@FK_R6OQ!_V+TO_I3;U\E5]:_\$U?^2U^(/^Q>
ME_\ 2FWH \)_:#_Y+O\ $3_L8;__ -*'K@*[_P#:#_Y+O\1/^QAO_P#TH>N
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^]?V3?^3'_BM_W&/_
M $W15\%5]Z_LF_\ )C_Q6_[C'_INBH ^"J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN@@^'?BNZ@CFA\,ZQ-#(H=)(["5E92,@@A>0
M1WH Y^BK&H:;=Z1>26E]:S65W'C?!<1F-UR,C*D C@@_C5>@ HHHH **** "
MBBB@ HHHH *^M?\ @FK_ ,EK\0?]B]+_ .E-O7R57UK_ ,$U?^2U^(/^Q>E_
M]*;>@#PG]H/_ )+O\1/^QAO_ /TH>N KO_V@_P#DN_Q$_P"QAO\ _P!*'K@*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_M'I0!\'45H^)+>.T\1:K!"@CBBNI41!T50Y %9U !1110 4JJ78*H+,3@
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M0 5\H_$3_D>=<_Z^Y/YU]75\H_$3_D>=<_Z^Y/YT >^?!O\ Y)OH_P#VV_\
M1ST4?!O_ ))OH_\ VV_]'/10!\]^-O\ D=-?_P"PA<?^C&KZ*^%7_)/M%_ZY
M-_Z&U?.OC;_D=-?_ .PA<?\ HQJ^BOA5_P D^T7_ *Y-_P"AM0!UE%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^P&: *%%?8G@/_@FSXJUJQBN?%/B2R\-NX#?8[: WDJ>SD,B _[I85TVK?\
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MD8/H17ZE_ SXL6?QL^&>D^*K2,6TEP#%=VH;/D3H<.F>XSR/566OQIK]"/\
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M)6(D=-[EB?\ 95L8.*_27X@>/O#WP7\ W6NZMML-%TV)8X[>VC 9CPL<42#
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M6"-DKC! 7 Z9R"!V?[.W[5_AK]H!KJQM[2;0_$-M'YTFF7,@D#QY +QR #>
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MKC!P  1C)P: /#]5_P"";OQ(L[%IK35_#NH3J,FWCN)D9O92T0'YD5\W>-O
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY1^(G_ "/.N?\
M7W)_.OJZOE'XB?\ (\ZY_P!?<G\Z /?/@W_R3?1_^VW_ *.>BCX-_P#)-]'_
M .VW_HYZ* /GOQM_R.FO_P#80N/_ $8U?17PJ_Y)]HO_ %R;_P!#:OG7QM_R
M.FO_ /80N/\ T8U?17PJ_P"2?:+_ -<F_P#0VH ZRBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_0Q0!^Y-?'G[3G[;4WP@\63^#O!>E6-YJ=F ;Z\O59H(7<;O+1$*[FPP)8G
M)Q@G-?8=?C#\=[R2_P#C=X_GE8LS:_?#GL!<. /P  H ^X_V3_VSM6^,WC)_
M"/BK3;&UU*:!Y[*\TU71)"@RR.C,W.W+!@0/E(Q7KG[6'@VT\:?L^^,[>YB5
MWL;"34[=R.4D@4R@KZ$A67Z,1WK\_/V&W*_M1># #PPO0?\ P"GK]+?C4 WP
M;\> ]#H%_P#^D\E 'XV^&] N_%7B+2]%T]/,OM1NHK2!#T,DC!5_4BOV6^%/
MPSTCX1^!=,\,Z-"J6]H@\V;;A[B4CYY7]68_D, < 5^7O['=C%J'[2W@6*8
MHMU)*,_WD@D=?_'E%?K7=VHO+6:!F9%D1D+(<, 1C(/K0!\'?&+_ (**:WI_
MC"]TWP%IFF2:/9RM"-0U*-Y7NBIP715=0J$YQG)(P>,X'N_[*?[4D7[0FF:A
M9ZC90Z5XFTU5DGM[=B89XF.!)&&)(P>"I)QE>3GCF_\ AW+\*_\ G\\1_P#@
M=%_\:KNO@W^R7X,^!OBJ?7_#MUK#WLUH]FZ7MRDD9C9D8\+&ISE%[T ?._\
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M^%_AV/'=];*^NZZ76VD=?FM[16*@+Z%V4L3W&SWS\G?MK_\ )SWC?_KI:_\
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MHI.0GB"X4>P\BW/]37'?\%.-3EB\.^ =/#$0SW5W<,N>"T:1*I_*5OSKKO\
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MFOK#P5_P33\0:A#'-XJ\5V.D$@%K73[=KIQ[%V**#]-P^M>K?\$Y_!.GZ/\
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MXP6$-M=1R.0.IP"36E<7$=I!)-+(L4,:EWD=@JJH&223T % 'XI_\*T\7_\
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MV++=VLD2LV"< L ,X!X]JR:_1K_@I)>07'P;\/+%/'(PU^,X1P3C[//7YRT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7UK_P35_Y+7X@_[%Z7_P!*
M;>ODJOK7_@FK_P EK\0?]B]+_P"E-O0!X3^T'_R7?XB?]C#?_P#I0]<!7?\
M[0?_ "7?XB?]C#?_ /I0]<!0 4444 %%%% !1110!^H/_!/;_DW>W_["=U_-
M:\T_X*>_\@OX>?\ 7:^_]!@KH?V&?BIX*\(_ >#3]<\7Z#HM^-1N7-KJ.IP0
M2A25P=KL#@^N*\^_X*)_$#POXVT_P*OAWQ)I.OM;2WIG&EWT5R8@PAV[MC';
MG!QGK@T ?%-7_#__ "']-_Z^8O\ T,50J[H4B0ZWI\DC!$6XC9F8X  89)-
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MSVEGG@N'Z2..P7*YY)XP0#\_/'VAZIX7\9:MHNM7J:AJFG3M:W$\<YF4NG!
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M_"WXW?#JQ^&?A*TNO'_ABUN8-(LXI8)M9MD>-UA0,K*7R""""#0!^?G[:_\
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M6>=8;A/9HGPWMG&/0FMV^\8>#_!]K)-=ZUHNBV_WG>:ZA@4GU.2* /%/$/[
M?PAU6)C;V&I:$=OS2V.H.<>I_>[P/RQ7YG^*[72['Q1J]MHD\MUH\-W+'93S
MD&26$.0CM@ 9*@'@=Z^V?VKOVX-)U+PY?^#_ (>73WTEZA@OM<12D:1'AHX<
MX+,PR"^, $[<DY7X1H **** "BBB@ KZU_X)J_\ ):_$'_8O2_\ I3;U\E5]
M:_\ !-7_ )+7X@_[%Z7_ -*;>@#PG]H/_DN_Q$_[&&__ /2AZX"N_P#V@_\
MDN_Q$_[&&_\ _2AZX"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?VL_!'QHTVVB&H0Z'XE*@3:-?2A'+]_)8X$HZXQ\V.H%=WXB^"W@+Q=J_\
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M\1[3_A!?!ER;G0$E634=27(2\=3E8X_6-6 8M_$P&.!EO"?V9?\ DX'X??\
M89M__0Q7F=% '[FZM_R"[S_KB_\ Z":_#*BB@#ZP_P"":_\ R737/^Q<G_\
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M_BF\OA%'!(/S'L.X^5?VAOV%M:^'/]GWG@.WU?QCILH=;F-8EEN;=P1M^2,
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M^=U?1O[3G[6\/[1'AG2-)C\+OH)L+PW1E:^%QORA7;CRUQUSG-?.5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5]:_\$U?^2U^(/\ L7I?_2FWKY*KZU_X)J_\EK\0?]B]+_Z4V] 'A/[0
M?_)=_B)_V,-__P"E#UP%=_\ M!_\EW^(G_8PW_\ Z4/7 4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?>O[)O\ R8_\5O\ N,?^FZ*O@JOO7]DW
M_DQ_XK?]QC_TW14 ?!5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!W'P1\;6'PY^+'ACQ-JD<\NG
MZ9>+/,EJH:0J 1\H) )Y[D5]T:Y_P42^&6I:+?VD6F^)1+<6\D2%K.$#+*0,
M_OO>OS?HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OH/]F?\
M:^UCX"1R:->V3:[X4FD,OV,2;)K5S]YHF((P>I0\$\@J2<_/E% 'ZD:'^W[\
M']6@62[U34=%D(YBO=.D9E_&(./UJYJ/[>'P9L;=I(/$ESJ+ 9$5MIER&/\
MW\11^M?E710!]:?M&?MW7GQ.T&\\,>#]/N-"T.\4Q7=[=L/M=S&>L8521&IZ
M'!8D<9 R#\ET44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5\H_$3_D>=<_Z^Y/YU]75\H_$3_D>=
M<_Z^Y/YT >^?!O\ Y)OH_P#VV_\ 1ST4?!O_ ))OH_\ VV_]'/10!\]^-O\
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M_1]3FTV_LKBSU"%_*DM;B)DE1_[I4C(/M0!6,KM&L9=BBDD*3P">O%-K[_\
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M )+O\1/^QAO_ /TH>N KO_V@_P#DN_Q$_P"QAO\ _P!*'K@* "BBB@ HHHH
M**** "BBB@ HHHH **W?!?@;7OB)KJ:-X<TV75M3=&D6VA(#%5&6/) XKN-6
M_99^*VAZ7>:C?>"K^VLK.%[B>9VCQ'&BEF8X;H ": /*J*** "BBB@ HHHH
M**** "BBO6X/V2_B[<0QS1>!M1>.10ZL&CY!&0?O4 >245H>(/#VH^%-;O='
MU>U>QU*SD,-Q;28W1N.H..*[KPM^S?\ $OQKH%IK>A^$;W4=*NU+07431[9
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M (;H^"O_ $-[_P#@JO/_ (U1_P -T?!7_H;W_P#!5>?_ !J@#YN_X=E^*?\
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M_P"'9?BG_H<='_\  >6OI'_ANCX*_P#0WO\ ^"J\_P#C5'_#='P5_P"AO?\
M\%5Y_P#&J /F[_AV7XI_Z''1_P#P'EH_X=E^*?\ H<='_P# >6OI'_ANCX*_
M]#>__@JO/_C5'_#='P5_Z&]__!5>?_&J /F[_AV7XI_Z''1__ >6C_AV7XI_
MZ''1_P#P'EKZ1_X;H^"O_0WO_P""J\_^-4?\-T?!7_H;W_\ !5>?_&J /F[_
M (=E^*?^AQT?_P !Y:/^'9?BG_H<='_\!Y:^D?\ ANCX*_\ 0WO_ ."J\_\
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M^-4 ?-W_  [+\4_]#CH__@/+1_P[+\4_]#CH_P#X#RU](_\ #='P5_Z&]_\
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M_P .R_%/_0XZ/_X#RT?\.R_%/_0XZ/\ ^ \M?2/_  W1\%?^AO?_ ,%5Y_\
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M_P#C5'_#='P5_P"AO?\ \%5Y_P#&J /F[_AV7XI_Z''1_P#P'EH_X=E^*?\
MH<='_P# >6OI'_ANCX*_]#>__@JO/_C5'_#='P5_Z&]__!5>?_&J /F[_AV7
MXI_Z''1__ >6C_AV7XI_Z''1_P#P'EKZ1_X;H^"O_0WO_P""J\_^-4?\-T?!
M7_H;W_\ !5>?_&J /F[_ (=E^*?^AQT?_P !Y:/^'9?BG_H<='_\!Y:^D?\
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M:_\ !-7_ )+7X@_[%Z7_ -*;>@#PG]H/_DN_Q$_[&&__ /2AZX"N_P#V@_\
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MA;6=;F\7:7/%IMG->O$EO(&=8T+E03W.W%<C\$/V(?&OQ>TNWUJ\FA\*Z!<
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M!"NT4C(6 /8E<T 9%%;7@WP7K?Q!\16FA>'M.FU35;IL1V\(Y]V)/"J.I8D
M=S7U]X1_X)GZK>:>DWB7QG;:;=L,FUT^R-R$]C(SIR/9<>] 'Q/7[&?LS_\
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M%N#T''+.<'"CKCG R1]IZ!_P39^'UG8HNKZYKVIWN,/+!)%;QY]538Q'XL:
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MVVDY'/%<E^R?^R[I?[1%CXDN-1UN\T@Z5+!&BVL2OYGF!R<[NF-@_.@#VO\
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M!% '-45:TJS&H:G9VK,46>9(BPZ@,P&?UK[]_P"'9?AK_H=-6_\  6+_ !H
M_/BBOJ7X#?L)Z]\4K5=<\07[^&O#DC'[-^ZWW=X@. ZJ<!$/9FSGJ%((-?0<
MW_!-_P"&;69BCU7Q+'/CBX-W"QS[KY.,?E0!^:]%>\_M)_LE:[^S_P"1JB7J
MZ]X7N9?)2_2/RY(9""0DJ9.,@'# D''8X%>#4 %%%% !1110 4444 %%%% !
M1110 5]Z_LF_\F/_ !6_[C'_ *;HJ^"J^]?V3?\ DQ_XK?\ <8_]-T5 'P51
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z%^S
MO_R7KX>?]A^Q_P#1Z5]V?\%(/^2#:9_V'[?_ -$7%?"?[.__ "7KX>?]A^Q_
M]'I7W9_P4@_Y(-IG_8?M_P#T1<4 ?FC1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'T/^P3_P G+:%_UZWG_HAJ]B_X*@?ZWX;?[NI?
M^VM>._L$_P#)RVA?]>MY_P"B&KV+_@J!_K?AM_NZE_[:T ?"U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?*/Q$_Y'G7/^ON3^=?5U?*/Q$_Y'G7/^ON3
M^= 'OGP;_P"2;Z/_ -MO_1ST4?!O_DF^C_\ ;;_T<]% 'SWXV_Y'37_^PA<?
M^C&KZ*^%7_)/M%_ZY-_Z&U?.OC;_ )'37_\ L(7'_HQJ^BOA5_R3[1?^N3?^
MAM0!UE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !76_";QTOPQ^)'A_Q4UD=172KD7!M1
M+Y9EP",;L''7T-<E10!]SZO_ ,%+K;5-+O;,?#V6,W$#P[_[8!V[E(SCR.>M
M?#%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$BLH"@@C<2<]@!@G[@NIOL]M-+C/EH6Q]!FOPPFF>YFDED8O)(Q9F/4DG)-
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MV]?)5?6O_!-7_DM?B#_L7I?_ $IMZ /"?V@_^2[_ !$_[&&__P#2AZX"N_\
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M$=J_<S29)9M+LY9O]<\*,_\ O%1G]: /R&_:E_Y.'\?_ /85E_I7Z.?L:_\
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MS6GG+<2&-USM>)-S X."I%?E1XZM_#-I\1-7C\/7DM_X2%\QLYTC9)#;%L@
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M[F(2#*ETC9AD>F0*_*S]C'_DYKP/_P!=Y_\ TFEK]2/B=_R3;Q;_ -@B[_\
M1+T ?F!\6?VQ/'/QF\&S^&=>M]&CTZ:6.9FLK9TDW(<C!,C#&?:OH?\ X)B_
M\@3X@?\ 7Q9?^@S5\"U]]?\ !,7_ ) GQ _Z^++_ -!FH Z;_@I5_P D7\._
M]C!'_P"DUQ7Q5^SE\*1\9?B]H7AN;<-.=S<W[QG!%O&-SC/8MP@/8N*^U?\
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M2T#6(6N-+U"_C@N(5=D+(>HW*01^%?5G[7_[+GPY^$WP=FU_PSHTUCJ:WT$
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M_P"2]?#S_L/V/_H]*^[/^"D'_)!M,_[#]O\ ^B+B@#\T:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^A_V"?\ DY;0O^O6\_\ 1#5[
M%_P5 _UOPV_W=2_]M:\=_8)_Y.6T+_KUO/\ T0U>Q?\ !4#_ %OPV_W=2_\
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MPW__ *4/7 5W_P"T'_R7?XB?]C#?_P#I0]<!0 4444 %%%% !1110 5^F'[
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M+?Q_X6N)Y=.N8XXHM:MF9V,3 * 'R23QBOR0T618M8L7=@B+/&69C@ ;AR:
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M?XB?]C#?_P#I0]<!0 4444 %%%% !1110 4444 %%%% 'TA_P3__ .3CM/\
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MKW1M&\7+<ZY:W,5_80-IUW&))%)5EW-$ ,H\F,D#.* /F[]C>58?VE_ S,<
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M<^/'["OB/X1>'+KQ)I&K1^*-$M%\R[ @,%S;IW<IN8,H[D'(ZXP"1/I?A/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0--97.1@E64-M![JX&,XRW6NGB_:._9\^%UG<W>B:CH-E),-TD/A[3@)9SU
M/E1@9_WB![T ?%7Q^_9!U_X ^'8=>U'7])U/3I[I;.)(/,2X=V5F'R%<8 0D
MG=7W)^RE\(] ^$WP;T35[:P2;6M5TV/4K^_6,-/)YD8D$2GKM4$*%'!(SU-?
M!?[4'[25[^T)XJMI(K:33?#>FADL+&1@7);&Z63'&]L 8&0H&!GDGZ3_ &4_
MVV/"VF^ M+\(^.KQM&OM)A6TM=1>-G@N(%&(PQ4$HRJ O(P0H.<G% 'E?CO_
M (*(?$;Q!>W$7ANVT[PS9,Q$&RW%S<A<\;FDRA/T05]YV$FJ-\$X&UHR/K1\
M/*;TR !S<?9OWF0.AW9KY^\3_%3]E_P!K4OC"QL=(UOQ*7-Q%'I-HTKM+G.]
M0<11MGG=P<\CFM[P9^W=\+?%7@V&3Q7JP\.:M=++'=:6+.ZN!$N]E4"1(BK9
M3:<CU/ H ^&/V6O^3A_ '_85B_K7W=_P4)_Y-WN/^PG:_P VKX'^#FOZ%\/O
MCYX>U6\U4/X=TO5][:DL$A#P*Q D$>W?R,'&W//2OJ?]L;]IKX;?%3X,S:%X
M6\2?VIJK7\$PM_L%S#\BD[CNDC5>,CO0!\'T444 %%%% !1110!Z%^SO_P E
MZ^'G_8?L?_1Z5]V?\%(/^2#:9_V'[?\ ]$7%?"?[._\ R7KX>?\ 8?L?_1Z5
M]V?\%(/^2#:9_P!A^W_]$7% 'YHT444 %%%% !1110 4444 %%%:7AOPYJ/B
M_7K'1=(M6O=3OI1!;VZL%,CGH,L0!^)H S:*]J_X8Q^,_P#T(]S_ .!=M_\
M'*9)^QK\98U)/@:[(_V;FW/\I* /&**ZWQQ\)?&?PV\L^)_#.I:+%(=J3W,!
M$3GT$@^4GV!KDJ "BO6_^&4/BQ_8/]L_\(?<?V9]F^V?:/M5OCRMN_=CS,_=
MYQC->24 %%%% !1110 4444 %%%% !1110 4444 %%%% !117JOAO]EGXI>+
M_"5OXFTGPI+<Z)<0M/%=->6\6Z-206V/(&Q\IQQR.1D$4 >54444 %%%% !1
M110 4444 %%%% 'T/^P3_P G+:%_UZWG_HAJ]B_X*@?ZWX;?[NI?^VM>._L$
M_P#)RVA?]>MY_P"B&KV+_@J!_K?AM_NZE_[:T ?"U%%% !1110 4444 %%%>
MP:;^R'\7=6TZUOK3P7<36EU$D\,@NK<!T8 J<&3/((ZT >/T5[2?V,_C,!G_
M (0:Y_"[MO\ XY7.>+/V=?B7X'T^6_UKP9JMK8Q#=+<I#YT<8]69"P4>YXH
M\YHHKTCP'^SI\1OB;H*ZUX8\,S:KIC2M"+A+B%!O7&X8=P>,CM0!YO16GXF\
M-:EX.U^^T76+5K+5+&4PW%NS*QC<=1E20?P-9E !1110 4444 %%%% !1110
M 4444 %%%% !116IX;\+:QXQU6/3-"TN\UC4).5MK*%I9".YPH/ [GH* ,NB
MO9S^QO\ &5;/[5_P@UWY>-VT7-OYG_?'F;OPQ7E7B#PUJWA/59M,UO3;O2=0
MB^_:WL+12+Z':P!Q[]Z ,VBBB@ HHHH **** "OE'XB?\CSKG_7W)_.OJZOE
M'XB?\CSKG_7W)_.@#WSX-_\ )-]'_P"VW_HYZ*/@W_R3?1_^VW_HYZ* /GOQ
MM_R.FO\ _80N/_1C5]%?"K_DGVB_]<F_]#:OG7QM_P CIK__ &$+C_T8U?17
MPJ_Y)]HO_7)O_0VH ZRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "KFBZ/=^(=9L-+L(C/?7T\=M!$O5Y'8*H_$D53
MKZ?_ ."?OPQ_X3/XR/XAN8M^G>&H/M.2,J;F3*0C\!YCCW04 ?HE\-_!-I\.
M/ >@^&;+!@TNTCM]X&/,8#YW/NS%F/N:\%_:2_8^U7]H+QY#KK^-(M)LK:T2
MTMK%M.,OE@$LS%O-7)9F/;H .U>X_%;XB6/PG^'NN>+-03SX--@\P0!]AFD)
M"QQ@X.-S,HS@XSG%?)O_  \\L?\ HGMQ_P"#9?\ XS0!O?!O]A'6/@[\2M$\
M6VGCR&Z:PE)EMAI;)Y\3*4D3/FG&58X.#@X..*^OY(TFC9'4.C AE89!'<$5
M\1?\//+'_HGMQ_X-E_\ C-?1O[//QWT_]H+P7/KUG8-I,]M=O:7%C),)6C8
M,K;@%R&5AVZ@CM0!^87[0GPS;X1_&#Q'X;5"EE#<&:R)_BMI/GCY[X!VD^JF
MOLK_ ()F_P#)./%__863_P!$K6?_ ,%)/A?_ &AX?T#Q[:0YFT]_[-OF4<^2
MY+1,?97W+]916A_P3-_Y)QXO_P"PLG_HE: +W_!2?59+;X/^'[!&*K=:TKN
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M[<7Q(\:WGQJU_P .:CJ-]9:!9^6MEIL4C1V\D1C4B0J.'+$M\QSCD<8Q5_\
MX)Z^!M4UGXUKXDBM9!I&C6DXFNRI\OS9$*+&#W8ABV/1?I0!]T?M+?+^S_\
M$$_]06Y'_CAK\<Z_8G]II2W[/WQ!"\_\2:X/X;#FOQVH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^M?^":O_):
M_$'_ &+TO_I3;U\E5]:_\$U?^2U^(/\ L7I?_2FWH \)_:#_ .2[_$3_ +&&
M_P#_ $H>N KO_P!H/_DN_P 1/^QAO_\ TH>N H **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXQ62RE20001P0>U?HM'_ ,%*?!+:P+=_#&N1:=YFTW3&(R 9^\8]WZ;LU/\
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MO_;6O'?V"?\ DY;0O^O6\_\ 1#5[%_P5 _UOPV_W=2_]M: /A:BBB@ HHHH
M**** "OVM^',WV?X7^%Y2-P31K5L>N(%-?BE7[5?#]6D^%/AM0,LVB6P ]3Y
M"T ?**_\%.=(+#=X!O0OJ-20G_T77T)\!_VBO#'[06DWMSHBW%G?6)5;S3KU
M0)(PV=K @D,IPPR/3D#BOS>C_9$^,,KA1X$U$$_WFB4?F7K[*_8A_9J\2?!>
M/7=<\6+'8:IJD<=M#IT<JRF&-26+.RDKN)Q@ G !SUP #YP_;R^#.F?"[XFV
M.JZ';)8Z3XBADN/LL2[8XKA& E" =%(=&QV+'&!@5]3?\$]O^3=H/^PI=?\
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M'4\-@,@ /').,@8]T^+?[<WA;X.^.+WP@?#.J7T^FE(YI(O+@B7*!@(P3D@
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M%W((H+:W0N\CGH !7UOX'_X)L^*M9L8KGQ1XFL?#LK@,;.U@-[*GLQW(H/\
MNEA[T ?'=%?>=Q_P3#M#"?(^(<R2XZR:0&7\A,*\)^-W[%_CCX,:7-K1>W\1
M>'X>9K[3PP>W']Z6,\J/<%@.Y% '@5%%?5/PY_8!\0?$;P+HGB:V\5:99P:K
M;+<I!+!(60-V)'&: /E:BOI'PK^PWXM\4?%3Q#X334K:WTO09(HKW7VA8Q%W
MB20)$F07<!QD9  ZD9&>\^)'_!.:?PCX2U+6],\=6]RNGVTEU/'J5B;="B*6
M8AU=\< \%?QH ^,J*V?!_@W6O'WB&TT/P_ITVJ:K=-MBMX!R?4DGA5 Y+$@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_8#]G#X+V/P/^&.GZ,D*?VO.BW.J7( +2W!'S#/=4^ZOL,]2: *WA_0/A_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'JY\0^(=4U1HA U]=2W)B#;MF]RV,]\9ZUGT44 %%%% !1110 4444 %%%%
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MGPCXNA\1>)]&T&:>^A>*/4[^*V:11&02H=AD9]* /2_^"CO_ "0.P_[#MO\
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MM<[^S'^T=?\ [/GBR>9X)-1\.:D%34;&-@'^7.V6//&]<G@\,"0<<$ 'NO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K[U_9-_Y,?^*W_<8_]-T5?!5?>O[)O_)C
M_P 5O^XQ_P"FZ*@#X*HHHH *_3W_ ()Y_P#)O2?]A:Z_DE?F%7Z>_P#!//\
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M='\</C-^T58_#WQ#IOC'X=:+IN@7EH]I>:A9PR2B%)/DW!UN753EA@D=2.*
M,C_@F9_R4#QE_P!@R+_T:*]-_;]^.WB/X;:?X>\-^&-1FT>YU9);B[OK5MDZ
MQ*5541QRN26)(P?E&#R:\R_X)F?\E \9?]@R+_T:*;_P4R/_ !<3P>/^H5)_
MZ.- &G_P3]^-7BWQ!\1-6\*Z[KM]K>F3:=)>0C4+AIWAF22,?*SDD*5=LC.,
M@'UJ_P#\%.]/AV_#V^"@7!^W0LX'+*/((!^A+?F:\R_X)V_\G!O_ -@>Y_\
M0HZ]8_X*>_\ (+^'G_7:^_\ 08* -W_@G=\1_$OCG1_%UEKVKW&IVND)I]O8
M138Q;QE9QM7 Z81!_P !%<+^W=\:/&_@?XL1Z!H7B.\TS1KG18GFLX2NQR[R
MJY.1GD #\*U_^"8)_P!%^(X[[]._E<UYK_P4<4K\?+$D8#:%;D>_[V<4 ?+-
M%%% 'H7[._\ R7KX>?\ 8?L?_1Z5]V?\%(/^2#:9_P!A^W_]$7%?"?[._P#R
M7KX>?]A^Q_\ 1Z5]V?\ !2#_ )(-IG_8?M__ $1<4 ?FC1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'T/^P3_R<MH7_7K>?^B&KV+_
M (*@?ZWX;?[NI?\ MK7CO[!/_)RVA?\ 7K>?^B&KV+_@J!_K?AM_NZE_[:T
M?"U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?*/Q$_P"1YUS_ *^Y/YU]
M75\H_$3_ )'G7/\ K[D_G0![Y\&_^2;Z/_VV_P#1ST4?!O\ Y)OH_P#VV_\
M1ST4 ?/?C;_D=-?_ .PA<?\ HQJ^BOA5_P D^T7_ *Y-_P"AM7SKXV_Y'37_
M /L(7'_HQJ^BOA5_R3[1?^N3?^AM0!UE%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ<1S[1O 9(BI&[)&#T(K\ZOB]\0+CXJ?$OQ%XJN-P_M&[:2)'ZQPCY8D_P"
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M_P!@FZ_FE?,M?2__  3WFC@_:#1I'6-?[*N1EC@=4H ^V?V@_P!H+3O@3?\
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M **** "BBB@#Z'_8)_Y.6T+_ *];S_T0U>Q?\%0/];\-O]W4O_;6O'?V"?\
MDY;0O^O6\_\ 1#5[%_P5 _UOPV_W=2_]M: /A:BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OE'XB?\CSKG_7W)_.OJZOE'XB?\CSKG_7W)_.@#WSX-_\
M)-]'_P"VW_HYZ*/@W_R3?1_^VW_HYZ* /GOQM_R.FO\ _80N/_1C5]%?"K_D
MGVB_]<F_]#:OG7QM_P CIK__ &$+C_T8U?17PJ_Y)]HO_7)O_0VH ZRBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZU_
MX)J_\EK\0?\ 8O2_^E-O7R57UK_P35_Y+7X@_P"Q>E_]*;>@#PG]H/\ Y+O\
M1/\ L8;_ /\ 2AZX"N__ &@_^2[_ !$_[&&__P#2AZX"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]QC_ --T5?!5?>O[)O\ R8_\5O\ N,?^FZ*@#X*HHHH **** "BBB@ HHHH
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M_GCJ'_?E?_BJ/^%^>&_^>.H?]^5_^*K]K_\ AAWX _\ 1(_"G_@N2C_AAWX
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MI_X+DH _%#_A?GAO_GCJ'_?E?_BJ/^%^>&_^>.H?]^5_^*K]K_\ AAWX _\
M1(_"G_@N2C_AAWX _P#1(_"G_@N2@#\4/^%^>&_^>.H?]^5_^*H_X7YX;_YX
MZA_WY7_XJOVO_P"&'?@#_P!$C\*?^"Y*/^&'?@#_ -$C\*?^"Y* /Q0_X7YX
M;_YXZA_WY7_XJC_A?GAO_GCJ'_?E?_BJ_:__ (8=^ /_ $2/PI_X+DH_X8=^
M /\ T2/PI_X+DH _%#_A?GAO_GCJ'_?E?_BJ/^%^>&_^>.H?]^5_^*K]K_\
MAAWX _\ 1(_"G_@N2C_AAWX _P#1(_"G_@N2@#\4/^%^>&_^>.H?]^5_^*H_
MX7YX;_YXZA_WY7_XJOVO_P"&'?@#_P!$C\*?^"Y*/^&'?@#_ -$C\*?^"Y*
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MZA_WY7_XJC_A?GAO_GCJ'_?E?_BJ_:__ (8=^ /_ $2/PI_X+DH_X8=^ /\
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M[\$_%7[./PNUK6/AAX;U'5=0\,:;=7=Y<6*M)/*]M&SNQ[DDDD^]>G?\,._
M'_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?
MM?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\
MK_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD
M?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\
M\,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\
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M0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._
M'_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?
MM?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\
MK_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD
M?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\
M\,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\
M%4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_
M ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._
M '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\
M+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R
M4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_H
MD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-
M_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?B
MA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3
M_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/
M'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_PO
MSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %
MR4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %4?\+\\-_P#/'4/^
M_*__ !5?M?\ \,._ '_HD?A3_P %R4?\,._ '_HD?A3_ ,%R4 ?BA_POSPW_
M ,\=0_[\K_\ %4?\+\\-_P#/'4/^_*__ !5?M?\ \,._ '_HD?A3_P %R4?\
M,._ '_HD?A3_ ,%R4 ?BA_POSPW_ ,\=0_[\K_\ %5[M^Q_^W/\ #OX$_$35
M=<\16FN2V5UI3V:"PM(Y'\PS1.,AI5XQ&W?TK].?^&'?@#_T2/PI_P""Y*^)
MO^"L7[.WPQ^$/P!\,ZOX*\#:+X8U.X\3PVLMUIMJL4CQ&TNF*$CMN13CU44
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M#_T2/PI_X+DH_P"&'?@#_P!$C\*?^"Y* /Q0_P"%^>&_^>.H?]^5_P#BJ/\
MA?GAO_GCJ'_?E?\ XJOVO_X8=^ /_1(_"G_@N2C_ (8=^ /_ $2/PI_X+DH
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M#_T2/PI_X+DH_P"&'?@#_P!$C\*?^"Y* /Q0_P"%^>&_^>.H?]^5_P#BJ/\
MA?GAO_GCJ'_?E?\ XJOVO_X8=^ /_1(_"G_@N2C_ (8=^ /_ $2/PI_X+DH
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M#_T2/PI_X+DH_P"&'?@#_P!$C\*?^"Y* /Q0_P"%^>&_^>.H?]^5_P#BJ/\
MA?GAO_GCJ'_?E?\ XJOVO_X8=^ /_1(_"G_@N2C_ (8=^ /_ $2/PI_X+DH
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M#_T2/PI_X+DH_P"&'?@#_P!$C\*?^"Y* /Q0_P"%^>&_^>.H?]^5_P#BJ/\
MA?GAO_GCJ'_?E?\ XJOVO_X8=^ /_1(_"G_@N2C_ (8=^ /_ $2/PI_X+DH
M_%#_ (7YX;_YXZA_WY7_ .*KZ>^!O_!0SX7_  Y_9M\;^!-5L_$3ZWK7V_[,
M]M91-"/.M$A3<QE!'S*<X!X]:_1'_AAWX _]$C\*?^"Y*_-G]M3X)^ _!'_!
M0SX,>$- \)Z7I'A?5?[#^W:3:VX2WN/-U2:.7>HX.Y%"GU H ^=O^%^>&_\
MGCJ'_?E?_BJ/^%^>&_\ GCJ'_?E?_BJ_:_\ X8=^ /\ T2/PI_X+DH_X8=^
M/_1(_"G_ (+DH _%#_A?GAO_ )XZA_WY7_XJC_A?GAO_ )XZA_WY7_XJOVO_
M .&'?@#_ -$C\*?^"Y*/^&'?@#_T2/PI_P""Y* /Q0_X7YX;_P">.H?]^5_^
M*H_X7YX;_P">.H?]^5_^*K]K_P#AAWX _P#1(_"G_@N2C_AAWX _]$C\*?\
M@N2@#\4/^%^>&_\ GCJ'_?E?_BJ/^%^>&_\ GCJ'_?E?_BJ_:_\ X8=^ /\
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MTQ^UU_P4N^$WQR^&-GX>\.V7B:&^AU2*\9KZPBC38L<JG!69CG+CMZU]U_\
M##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_
MPOSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4
M?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_
M\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_O
MRO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQ
MU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_
M *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\
M##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_
MPOSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4
M?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_
M\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_O
MRO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQ
MU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_
M *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\
M##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_
MPOSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4
M?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_
M\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_O
MRO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQ
MU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_
M *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\
M##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_
MPOSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4
M?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_
M\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_O
MRO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQ
MU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_
M *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_POSPW_SQU#_ORO\ \57[7_\
M##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4 ?BA_POSPW_SQU#_ORO\ \51_
MPOSPW_SQU#_ORO\ \57[7_\ ##OP!_Z)'X4_\%R4?\,._ '_ *)'X4_\%R4
M?E1^R_\ MF> _@[\8-,\4:Y;:U)IMM!/&ZV=K&\F7C91@&0#J?6N_P#VS_\
M@H-\,OC\WA ^&K/Q#$-)%V+C^T+**//F^3MV[96S_JVST[5^C'_##OP!_P"B
M1^%/_!<E'_##OP!_Z)'X4_\ !<E 'XH?\+\\-_\ /'4/^_*__%4?\+\\-_\
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MOSPW_P \=0_[\K_\57[7_P###OP!_P"B1^%/_!<E'_##OP!_Z)'X4_\ !<E
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M\K_\57[7_P###OP!_P"B1^%/_!<E'_##OP!_Z)'X4_\ !<E 'XH?\+\\-_\
M/'4/^_*__%4?\+\\-_\ /'4/^_*__%5^U_\ PP[\ ?\ HD?A3_P7)1_PP[\
M?^B1^%/_  7)0!^*'_"_/#?_ #QU#_ORO_Q5'_"_/#?_ #QU#_ORO_Q5?M?_
M ,,._ '_ *)'X4_\%R4?\,._ '_HD?A3_P %R4 ?BA_POSPW_P \=0_[\K_\
M51_POSPW_P \=0_[\K_\57[7_P###OP!_P"B1^%/_!<E'_##OP!_Z)'X4_\
M!<E 'XH?\+\\-_\ /'4/^_*__%5XAXLU.'6O$NI7]N'$%S.TB;QAL$]Q7]#W
M_##OP!_Z)'X4_P#!<E?A1^USX;TKP;^TY\3-#T.P@TO1[#7;FWM;.V39'#&K
MD*JCL!0!O?##Q]I6B>!]-LKE96FB\W<5 QS*Y'?T(HJ_\)_"^E:E\/\ 2KFY
MM(Y)G\W<S+R<2N!^@%% 'AOC;_D=-?\ ^PA<?^C&K]_O^"='_)E7PK_[!\O_
M *4S5^ /C;_D=-?_ .PA<?\ HQJ_?[_@G1_R95\*_P#L'R_^E,U 'TA1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5^3O\ P4 _Y2B? /\ [EW_
M -/$]?K%7Y._\% /^4HGP#_[EW_T\3T ?K%1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7\X_[;_\ R=Y\7?\ L8[O_P!#-?T<5_./^V__ ,G>?%W_ +&.
M[_\ 0S0!UWP;_P"2;Z/_ -MO_1ST4?!O_DF^C_\ ;;_T<]% 'SWXV_Y'37_^
MPA<?^C&K]_O^"='_ "95\*_^P?+_ .E,U?@#XV_Y'37_ /L(7'_HQJ_?[_@G
M1_R95\*_^P?+_P"E,U 'TA1110 45@:]XZ\-^%9XX-;\0Z7H\TB[TCU"]B@9
MER1D!V!(R#S[5F_\+D^'_P#T//AK_P &]O\ _%T =C17'?\ "Y/A_P#]#SX:
M_P#!O;__ !='_"Y/A_\ ]#SX:_\ !O;_ /Q= '8T5QW_  N3X?\ _0\^&O\
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M&2P\3:[I5_X9@:816WB#0]05T27J%\V%]T;'!QNVYP<9Q0!_1/17YY?\$O\
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MX+ECN8XR68T ?T)45_/KX3^,?Q[_ & ?BXNC:G<ZGI5S9LDM[X7U2Z-QI][
MW.0 S(0P! EC.001G@BOW6^#_P 4-(^-'PP\->.-"9O[+URS2[B1R"T3'AXF
MQQN1PR''=30!VE%?CA_P4D_;W\;:M\6-=^%_@+7;SPUX:T&8V.H7.ES&&ZU"
M[7B53(N&6-&S'L4C<58MG("^+ZM^P=^TQX7\!R?$B?0M1MDM[<W\R1:JO]IP
MQ ;S(T0??D#DJ/G'.5!!H _?>BORD_X)>?MY>+_%7Q"M?A%\0M7N/$D.I02-
MH>K:A(9+J&:)#(T$DAYD1D5RI8E@RA<D,-OZMT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?GS_ ,%K?^39?"'_ &-\'_I%>5^@U?GS_P %K?\ DV7PA_V-\'_I%>4 ?5/[
M(7_)JGP=_P"Q1TK_ -)(Z]=KR+]D+_DU3X._]BCI7_I)'7KM !1110 4444
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MU5\7/^A^UC_O\/\ "C_AJKXN?]#]K'_?X?X4 ?L'17X^?\-5?%S_ *'[6/\
MO\/\*/\ AJKXN?\ 0_:Q_P!_A_A0!^P=%?CY_P -5?%S_H?M8_[_  _PH_X:
MJ^+G_0_:Q_W^'^% '[!T5^/G_#57Q<_Z'[6/^_P_PH_X:J^+G_0_:Q_W^'^%
M '[!T5^/G_#57Q<_Z'[6/^_P_P */^&JOBY_T/VL?]_A_A0!^P=%?CY_PU5\
M7/\ H?M8_P"_P_PH_P"&JOBY_P!#]K'_ '^'^% '[!T5^/G_  U5\7/^A^UC
M_O\ #_"C_AJKXN?]#]K'_?X?X4 ?L'17X^?\-5?%S_H?M8_[_#_"C_AJKXN?
M]#]K'_?X?X4 ?L'17X^?\-5?%S_H?M8_[_#_  H_X:J^+G_0_:Q_W^'^% '[
M!T5^/G_#57Q<_P"A^UC_ +_#_"C_ (:J^+G_ $/VL?\ ?X?X4 ?L'17X^?\
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M *'[6/\ O\/\*^Q/^"??Q2\6?$RW\<GQ3KUYKALFL1;F[?=Y6\3[L?7:OY4
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M +&&^_\ 08J^6O\ @MU_R6+X=?\ 8!E_]*&KZE_X(\_\F@C_ +&&^_\ 08J
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M0_\ !%'_ ).:\7?]BA<?^EMG7V]_P5E_Y,I\4?\ 80T__P!*4KXA_P""*/\
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M]=KR+]D+_DU3X._]BCI7_I)'7KM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7X__P#!43_D_'P/_P!BE!_Z.OZ_8"OQ_P#^"HG_ "?CX'_[%*#_
M -'7] 'D]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:'X5T\^,?^$0_L*YGN/,_LO[=Y_F*BXQYT6W&SKDYSVH \,_X(F_\F^^./\
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M@ 5\7?\ #D/QA_:>P_$[0QI^['GC3IO-VYZ^7NQGVW_C0!\@?!W2M3_:$_;
M\._V=9LEYXC\6C4I(H?F^SQ-<FXF;CM'&'8GT6OZ.*^9?V0_V#/ ?[(\-Q?:
M;-/XC\87D7D7/B"_C5&$?!,<$8)$2$@$C+,2.6(  ^FJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOGK]B7PCXITWX.Q>,?'FJ7>I^-?',W_  D6H+<2L8[-)AN@M8HR<1HD97Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI_O.JC/!.:P?@[_P4-^!OQO\36_AS0?%K6>O73B.ULM8M)+0W+'HL;L-A8]
MN[<>P-?*'_!./]AOP=\7/A/IWQ7^*MD_C2]U+=9:-IVH3.UM:65L3;IE 1N.
M8G4!LJ%5<#)S7GW_  5<_93\#? FS\$^._AYI$?A-[Z]DL+RST]V2'S53S(9
MHUS^[8;7!VX!^4X!!) /T8^.W[8OPE_9OFAM?'/BN&RU69!)%I-I$]U=LAZ,
M8XP=BGG#/M!P<$UC? _]N[X,?M!Z^F@>%/%FWQ!("T6E:G;26DTP R?+WC;(
M0 3M5B< G&*\ _8J_8A\&?$GX9Z?\7_C%I__  L;Q]XU4ZM-/K<C2PP0R$^4
M%CR%8E K$L#MR%4 +S\O?\%./V=_#7[)_P 5/ASXU^%]LWA4ZLT]REG:R,8[
M2\M)('66+<25W><ORC@%. ,T ?M+7C_QN_:Q^%/[.OEQ>._&%II-_*GF1:;$
MKW-XZ]F\F)695." S +P>:9\=OCPGPA_9C\0?% P(UQ::-'>6MNY^1KF8(D"
M'OM\V5 ?;-?G5_P3N_9 T_\ :RO_ !+\:_C-)<^+8I]2>"VL[N9E6^N0%:6>
M8J02B[E54!"Y# C"@$ ^Q/!__!4;]G;Q?K$6G?\ "9S:)+*VR.;6-/FMX&.>
M\NTJ@]W*CWKZHT_4;;5K&WO;*YAN[.XC6:*XMY!)'*C#*LK#@@@@@CK7S%\:
MO^";_P $?BKX+O-+TWP9IG@K61$WV'6-!MQ;/!+CY2Z)A95SC*L"2,X*G!'R
MO_P2C^-'BCP#\6?&'[.OB^Y:1-->[?3H99-_V.[MI=ES!&3_  .-S@= 8V('
MSF@#[\^(W[3?PT^$OC[P[X*\6>)ETGQ/X@,7]FV)LKB4S^9*84^>.-D7+@K\
MS#'4\<UYK\1/^"D'P$^&'CZY\):QXP>74K.8V][+I]C-=06D@.&1Y$4@LIX(
M3=@Y!P017PO_ ,%EM4OM#_:4^&^HZ;/):ZE9Z!%<6L\)P\<J7DS(R^X8 CZ5
M]*?#3_@D;\'K?X6Z=9>-K35M7\:W-LDNH:U#J4L+0W#+EUA0'R]JL2 75B<9
M/7% 'V)>?%;PAIWP[A\>WGB33K/P;-:1WZ:U=3B*W:"0 QN&;'W@RX'4D@ 9
M-?-6H_\ !5[]G/3]4:T3Q3J5[&IP;NVT>Y,/X;E#$>X6OES_ (+%:E<:!KOP
M=\ @W&D_#BVLFF$-H#LW1ND)PO1FBAV[0>GFG^]7V)\'OV7/V5O%W@"S_P"$
M*\&^"O&&C- J_P!H^7%?W+9'625LR(_J"5(.1@8Q0!ZS\&OVB/AS\?M-GO?
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MKX/K[P_X)@?\>WQ'_P!_3OY7- 'W11110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?SC_ +;_ /R=Y\7?^QCN_P#T,U_1Q7\X_P"V_P#\G>?%W_L8
M[O\ ]#- '7?!O_DF^C_]MO\ T<]%'P;_ .2;Z/\ ]MO_ $<]% 'SWXV_Y'37
M_P#L(7'_ *,:OW^_X)T?\F5?"O\ [!\O_I3-7X ^-O\ D=-?_P"PA<?^C&K]
M_O\ @G1_R95\*_\ L'R_^E,U 'TA1110!^8G_!4+_DNOAW_L6X?_ $JN:^?/
M@AX4TSQAX\M;+59%\A$>9+=Y5C%PZJ66/<Q  ) SDCBOH/\ X*A?\EU\._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^?/_  6M_P"39?"'_8WP?^D5Y7Z#5^?/
M_!:W_DV7PA_V-\'_ *17E 'U3^R%_P FJ?!W_L4=*_\ 22.O7:\B_9"_Y-4^
M#O\ V*.E?^DD=>NT %?(7[.'_!1#1OV@_CYKGPM?PA=>%M1T^"Z:.YOK])#<
M36\JH\(C"##;2[_>/$;<5]>U^4_[=7[%?Q(^&7QPD^/OP-@O;B>6[.J7UGI"
M>9>6%X<^;,D6"98I<L74!N7<%2AX /U8KYV_:+_89^%7[0WAK5(;_P ,:;HW
MB::)S:>(]-MEM[J&;'RO(R ><N>JOD8)Q@X(^)O O_!:O7-"L!I_Q ^&$=_K
M%N?+FO-*OVL]S#@[K>2-]K>N'QGL*P?BA_P5'^*G[2^FW?P_^$'PXNM&O=8B
M:UEN+*634M0,3C:_E;(T6'()!<AMHR05/( -O_@B;XZU>'Q5\2/ TD[S:(+2
M'5HXMVZ.&X63RG*]OG5ESZ^4OI6)^P?(-!_X*C_$^PU4[-0GN/$%O$'X+3"\
M$AQ]41S]*^OO^"<?[&U[^RG\.=2OO$_DGQWXF:*2^AA<2)8PQAO*MPXX9@7=
MG*\$D 9"!C\]?M[?LO?$3X2_M 6?[2?P<L)]1GCGCOM4LK& S2VEPB;'E,2\
MR02Q@B0#D9<G ;( /U'K\OO^"X&I6J^&?A/8,5-])>:C.@[B-4@5C]"67\O:
MMKP[_P %L/ __",(_B'X?>(K;Q,L>)+73Y()+1I .<2NZNH)[%"1[UXOX/\
MAC\4?^"HO[1&F_$'QIH,_A?X4Z<4C3<&6'[&CE_LULS &:60D[Y0,#)/&$0@
M'UC^TY9W.G_\$GVM+P$7<'@W08I@W4.K68;/X@TO_!'W_DSV#_L/7W_M.N__
M ."D,*6_[#OQ.BC18XTL[1551@*!>6^ !Z5P'_!'W_DSV#_L/7W_ +3H ^9O
MV?O^4ROC'_L*:W_Z(DJK_P %+F_L'_@H=\*]6U1MNE+:Z+<>8_W!%'J$WF#/
MMAB?K[U:_9^_Y3*^,?\ L*:W_P"B)*^H_P#@IC^QSJ/[37PYTS7/"4"S^./#
M!E>WM20IO[5\&2 $X&\%59,G'WA_%D 'VG7P!_P6CNK6/]E[PW;2E?M,OBRV
M:%>_RVEWN/T ('_ A7EWP/\ ^"N3_"_PG!X.^-?@GQ&_BS0XQ9/>V,2+<7&P
M87[3#.T9CDP!N8$[CS@=*^>/VX/CE\1?VO/"]C\3[GPM/X4^$>BWZZ1HL-TQ
M+7=U.CN\N[ $C;;?!*_*GRJ"26) /UQ_8S_Y-,^#_P#V*VG?^DZ5[-7C/[&?
M_)IGP?\ ^Q6T[_TG2O9J "OE'_@J5_R8M\2?][3/_3E:U]75\H_\%2O^3%OB
M3_O:9_Z<K6@#A_\ @CC_ ,FB3_\ 8R7O_HN"ON:OAG_@CC_R:)/_ -C)>_\
MHN"ON:@#\B/V8F$?_!83X@ G!;5?$ 'O_K#7Z[U^.7[8'A+Q_P#L6?MQ-\>?
M#NB2:GX7U"].I)=;&-L7FB\N[M)W4'RV8M(5)[.I&2I ]@OO^"S%IXITNWTO
MP!\)M<U?QS? 0VNGW$RRPB8CC:(@9)@#_"%0GU6@#S)+J.[_ ."VWF1-O4:N
M8RP_O+H^UA^!!%?2G_!8[_DT2#_L9++_ -%SU\5_L[^"?&W@7_@IWX'M_B/*
MDGCC4[J76M55&#>5-=6,\Y0D?+E0X!"_*#D#( -?:G_!8[_DT2#_ +&2R_\
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MYU:&)OL[L,;HH(7D,SC^$':,X)! VGO?^"8?[%OB/X*1ZU\3OB);R6?C7Q!
M;:UTZX;=/:6S.))'F/.)9&5#MZJ%YY8JH!X1_P %=XUF_:T^$L;C<C:5;*P]
M0;^6OUXK\BO^"NG_ "=Q\(O^P7:_^E\M?KK0!X]^TI^SE\/_ -I;P/#X;\>P
M%$2?=IVHV\RPW=I.PVYA<@@EN 4(96XR"0"/SP\9?\$=OB5\/]4;6/A-\3+6
MYGART(NFFTJ]0?W5EB+JQZ<DH/I7IG_!4W]F7QQK'B[PG\<OAM:7FI:QX<2*
M.^M=/0RW%OY$IF@NXXQDOM8D/@$@*AQ@,1%X%_X+5^"QX;A7QQX$\0V7B6)
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MCK^OV K\?_\ @J)_R?CX'_[%*#_T=?T >3T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"DUM7V-7QS_P $O_\ DAOB/_L8Y?\ TFMJ^QJ "BBB@ HKRW]HC]HGP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSY_X+6_\
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M\2/!/[1'@N_U"YT>SN(])\3^'S<O]CN(6R$D,>=JEES&7Q\K"$CG-?:GP_\
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M% !1110 56O+.WU*UDMKJ"*YMY5VO#,@=''H0>"*LT4 86A^"/#OAF>2;1]
MTO29I.'DL;..%F^I51FMVBB@ HHHH *YS5OAWX4UZ\^V:GX9T?4;O.?M%W81
M2R9_WF4FNCHH KVMK%9P)!!$D,,:A4CC4*J@=  .@JQ110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X_P#_  5$_P"3
M\? __8I0?^CK^OV K\?_ /@J)_R?CX'_ .Q2@_\ 1U_0!Y/1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^(H X^O0-)^-.M:/X#D\+16M@\#12V\=])$QN88I&#2(C;L $JIY!^Z*S_\
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M5B0,KGF?^")WPLO[=OB%\1+F%HM.F2'0[&0])G#>;/CV7]P,]"6/I0!\6_\
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M/V=?VI/!OB'Q';S6,?A_6#;ZK$R$R6R'?!<94<DHKN<=<KBOZ"=2^,'@?2O
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M(?4L[L>>V!VKXK_X+A_\B?\ ";_K_P!0_P#1<%??_P !?^2&_#K_ +%S3O\
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M444 %%%% !7Y\_\ !:W_ )-E\(?]C?!_Z17E?H-7Y\_\%K?^39?"'_8WP?\
MI%>4 ?5/[(7_ ":I\'?^Q1TK_P!)(Z]=KR+]D+_DU3X._P#8HZ5_Z21UZ[0
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M"+_C;5M<MKGXF^)=+T#0D<-+9Z'*UU>S =5#,@CCS_>R^/[M?J[\._A_X?\
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M4FO./V??@SIG[/WP=\,> M(;SK?1[41RW)7:;F=B7FF([;Y&9L9. 0.U>CT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^?/_  6M_P"39?"'_8WP?^D5Y7Z#5^?/_!:W_DV7PA_V-\'_ *17E 'U3^R%
M_P FJ?!W_L4=*_\ 22.O7:\B_9"_Y-4^#O\ V*.E?^DD=>NT %?E-_P4S\,W
MO[/_ .UI\*_V@=+MG>PFNK5=0\K^*YM'!*,>WFVV$ ](GK]6:\D_:A^ 6E_M
M+?!3Q!X%U%DMYKR,3:?>NN?LEXG,,OK@'Y6 Y*LP[T >FZ/JUGKVDV6J:?<)
M=V%[ ES;W$9RLL;J&1@?0@@_C5ZOC3_@FMX^\5P_#/4_A'\0-'U#2/%WP]N&
MTZ-KR%ECN;+<1$8Y"-KB,@IE21L\H@G=7V70!\!_MS?L#?$']IK]H7PMX\\,
M:OX9L-(TK2K2QGAU>YN([AI(KN>9BJQP.I4K*H&6!R#P.I^_*** "OR/\1?\
M$J/V@(_BMXH\7^$_'WA7P[+JFI7EU!<6>LZA:W*PS3,X1FCM>.",@,1D=Z_7
M"B@#\F/^';_[8W_1=['_ ,+#6?\ Y'KK/A-^P+^U;X/^*G@S7_$/QGL]4T#2
MM9LK[4;%?%6K3&XMHIT>6,(\ 5]R*PVL0#G!(%?IW10!\M?\%"/V7_%7[6'P
M>T/PGX0O](T[4;'7HM3DEUN:6*$Q+;W$1"F.*0[MTR\$ 8!YZ ^D_LH_"?5_
M@;^SYX+\"Z]<65WJ^BVKP7$VG.[V[,97<%&=$8C##JHYS7KE% !7RS^WQ^QG
M%^UW\.;&WTFXL=+\<:+/YFEZC?%EA:-R!-!*R*S!" &!"DAD'8M7U-10!\R?
ML(_!'XL?L\?"VX\"?$?6/#^NZ983;]#N=&O+B:6")R3)!()8(_D5OF0@D_.P
MX 6O#/VF/^";7BF[^,4WQ?\ @%XLB\&>++B=[RZT^:9[=#<-GS)()45L>9D[
MHW7:2S<X.VOT.HH _+3Q#^R+^VQ^T7:IX:^*'Q/TW2_";,HNT2>("9 >\-I$
M@F((!"R,!D9R#7W;^S+^S-X3_98^'$/A/PLDDSR/]HU#5+@#[1?W! !D?'
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M?^D5Y0!]4_LA?\FJ?!W_ +%'2O\ TDCKUVO(OV0O^35/@[_V*.E?^DD=>NT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7Y\_P#!:W_DV7PA_P!C?!_Z17E?H-7Y\_\ !:W_ )-E
M\(?]C?!_Z17E 'U3^R%_R:I\'?\ L4=*_P#22.O7:\B_9"_Y-4^#O_8HZ5_Z
M21UZ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?GS_P %K?\ DV7PA_V-\'_I
M%>5^@U?GS_P6M_Y-E\(?]C?!_P"D5Y0!]4_LA?\ )JGP=_[%'2O_ $DCKUVO
M(OV0O^35/@[_ -BCI7_I)'7KM !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7Y._\% /^4HGP#_[EW_T\3U^L5?D[_P % /\ E*)\ _\ N7?_ $\3
MT ?K%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU3_XY7ZP44 ?D_\ \///VH_^B#6W_@@U3_XY1_P\\_:C_P"B#6W_ ((-4_\
MCE?K!10!^3__  \\_:C_ .B#6W_@@U3_ ..4?\///VH_^B#6W_@@U3_XY7ZP
M44 ?D_\ \///VH_^B#6W_@@U3_XY1_P\\_:C_P"B#6W_ ((-4_\ CE?K!10!
M^3__  \\_:C_ .B#6W_@@U3_ ..4?\///VH_^B#6W_@@U3_XY7ZP44 ?D_\
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MB@#\G_\ AYY^U'_T0:V_\$&J?_'*/^'GG[4?_1!K;_P0:I_\<K]8** /R?\
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MB@#\G_\ AYY^U'_T0:V_\$&J?_'*/^'GG[4?_1!K;_P0:I_\<K]8** /R?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7Y\_\ !:W_ )-E\(?]C?!_Z17E?H-7Y\_\%K?^39?"'_8WP?\
MI%>4 ?5/[(7_ ":I\'?^Q1TK_P!)(Z]=KR+]D+_DU3X._P#8HZ5_Z21UZ[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?GS_P6M_Y-E\(?]C?!_P"D5Y7Z#5^?
M/_!:W_DV7PA_V-\'_I%>4 ?5/[(7_)JGP=_[%'2O_22.O7:\B_9"_P"35/@[
M_P!BCI7_ *21UZ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^3
MO_!0#_E*)\ _^Y=_]/$]?K%7Y._\% /^4HGP#_[EW_T\3T ?K%1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1AM!-N !YUUC_IFK*!_MNG! - 'Y/P_\%$OVDKB58X_BCJKR.0JHMI;$L3T
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MC_\ 10/%/_@YN?\ XNN)HH [;_A>'Q'_ .B@>*?_  <W/_Q='_"\/B/_ -%
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M4#Q3_P"#FY_^+KB:* .V_P"%X?$?_HH'BG_P<W/_ ,71_P +P^(__10/%/\
MX.;G_P"+KB:* .V_X7A\1_\ HH'BG_P<W/\ \71_PO#XC_\ 10/%/_@YN?\
MXNN)HH [;_A>'Q'_ .B@>*?_  <W/_Q='_"\/B/_ -% \4_^#FY_^+KB:* .
MV_X7A\1_^B@>*?\ P<W/_P 71_PO#XC_ /10/%/_ (.;G_XNN)HH [;_ (7A
M\1_^B@>*?_!S<_\ Q='_  O#XC_]% \4_P#@YN?_ (NN)HH [;_A>'Q'_P"B
M@>*?_!S<_P#Q='_"\/B/_P!% \4_^#FY_P#BZXFB@#MO^%X?$?\ Z*!XI_\
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M .B@>*?_  <W/_Q='_"\/B/_ -% \4_^#FY_^+KB:* .V_X7A\1_^B@>*?\
MP<W/_P 71_PO#XC_ /10/%/_ (.;G_XNN)HH [;_ (7A\1_^B@>*?_!S<_\
MQ='_  O#XC_]% \4_P#@YN?_ (NN)HH [;_A>'Q'_P"B@>*?_!S<_P#Q=?J'
M^R;K&H>(/V>?!NH:I?7.I7\]O*9;J\F:660B>0 LS$D\ #D]J_(:OUO_ &-?
M^39_ W_7M-_Z42T >TT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_./\
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M2Z2VTCQWX:U2Y<X6&RUBWF=CZ *Y)KM* "BBB@ HHHH **** "BBB@ HHHH
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M+Q#_ ,@#4_\ KVE_] -:-9WB'_D :G_U[2_^@&@#^=G]AW_D[SX1?]C%:?\
MH=?T;U_.1^P[_P G>?"+_L8K3_T.OZ-Z "OP,_;B^)VJ?M9_MGWFB:"S7MK;
MZE'X3T&$-E&*R^47&.TDS.V?[I7TK]K/VB_B"_PJ^ _C_P 70OY=SI&B7=S;
M'/\ RW$3"(?C(4%?C%_P2I\ +\0/VRM O+E/M$'AZRN];E5^<LJB*-C[B6>-
MOJHH _;+X0?#'2O@S\,/#/@G14":;HEC':1L%VF5@/GE8?WG<LY]V-=E110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^?/_!:W_DV7PA_V-\'_ *17E?H-7Y\_\%K?^39?
M"'_8WP?^D5Y0!]4_LA?\FJ?!W_L4=*_])(Z]=KR+]D+_ )-4^#O_ &*.E?\
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M%% !1110 4444 %%%% !1110 5^/_P#P5$_Y/Q\#_P#8I0?^CK^OV K\?_\
M@J)_R?CX'_[%*#_T=?T >3T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  5"_P"2Z>'?^Q;A_P#2JYKX[K[$_P""H7_)=/#O_8MP_P#I5<U\=T %%%%
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MCXD^'M*@6VTU;]+Z"%!A(UN88[G8H[*IF*@=@,4 ?T4T5X;^SK\6[6]_8_\
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MW44 ?OO17C?[*O[2N@_M4_"6Q\9Z)']AN=YM-2TN23>]E=* 6C+8&Y2&5E;
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MJ[7NH6]GKUU%##9HQFG5%60!%\M610. 2H% '[P4444 %%%% !1110 4444
M%%%% !1110 5^?/_  6M_P"39?"'_8WP?^D5Y7Z#5^?/_!:W_DV7PA_V-\'_
M *17E 'U3^R%_P FJ?!W_L4=*_\ 22.O7:\B_9"_Y-4^#O\ V*.E?^DD=>NT
M <W\0%\3R>"]97P7_9H\5O:NFF/K$CQVB3D85Y2B.Q5<[L!3G&.,Y'Y+1_\
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M7[ 5^/\ _P %1/\ D_'P/_V*4'_HZ_H \GHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OUO_8U_Y-G\#?\ 7M-_Z42U^2%?K?\
ML:_\FS^!O^O:;_THEH ]IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^<
M?]M__D[SXN_]C'=_^AFOZ.*_G'_;?_Y.\^+O_8QW?_H9H Z[X-_\DWT?_MM_
MZ.>BCX-_\DWT?_MM_P"CGHH ^>_&W_(Z:_\ ]A"X_P#1C5^_W_!.C_DRKX5_
M]@^7_P!*9J_ 'QM_R.FO_P#80N/_ $8U?O\ ?\$Z/^3*OA7_ -@^7_TIFH ^
MD**** /S%_X*A?\ )=/#O_8MP_\ I5<UZO\ LW^$_P!G;4/A5X;@\0)X7N/$
MLL9%Q]OND$[N7. 1N'., <>E>4?\%0O^2Z>'?^Q;A_\ 2JYKNOA+^P1X0^)W
MP;T3Q"NKZGIVN7ENTBO$Z>6L@9@I(VYQP.AH ^HX_P!E7X/S1JZ> M'=& 96
M$9((/?K3_P#AD_X0_P#0@:1_W[;_ !KY&T/QA\>OV.[@:!J6B3>-/#1=GAGC
MBDN=D8/)5D.4SUP]=DW_  5(\.0L8Y? FKI*O#*;J,$'Z8H ^AO^&3_A#@_\
M4!I'_?MO\:^4/V:?"=AHO[>'C*#2+2*PTO3/M,4-M$,+&K)@ ?E2ZI\<OCM^
MU)JCZ5X"T*Y\)>'IMS+>21F,O"?[TK_(QQ_<P:P?V.]"U+X7?MCZUX1U>]%_
M?1PW$4]UD_O65-V1GG^*@#])Z_.7]EGPCX?^-_[3'Q3;QCHUMKD4"2M%'= L
M$9;@1@CG^Z,5^C5?DM\';#XLR?&?Q]?_  I8?:[:]N3?QM+$@EA^T$[3OZ\X
M^[S0!^A__#)_PA_Z$#2/^_;?XT?\,G_"'_H0-(_[]M_C7RS<?M=?M%>'Y&M;
MOX8QW<D9VM(FFW4F2.^5;!I$_:._:9^*2MHNB^!E\/7=P,)>_8YK<Q^^Z8[1
M^- 'TEXB_9Y^!7A'3VO];\)^'=)LE(4W%X?*0$]!DMBOEO\ :^TOX"V_P?NW
M\ KX=7Q+'=P",Z7.KR&,M\^ &.1BMSP_^PO\1OBIJ2ZK\7/&URHF&9[&UF5Y
M=W8@KF/U[5B?M9?L=^!_@I\"[G7]$:\FU2WN[>$37+@[E=L'. * /3/^"7__
M "0WQ'_V,<O_ *36U?8U?'/_  2__P"2&^(_^QCE_P#2:VK[&H **** /R)_
MX+?_ /)0?A;_ -@N\_\ 1L=?0G_!&3_DT[5O^QKO/_2:UKY[_P""W_\ R4'X
M6_\ 8+O/_1L=<[^P#_P40^'?[*OP3O\ P;XKT3Q/J.I7&MSZDLVC6UM)"(WB
MA0 F2>,[LQ-GC&".: /V8K^?O_@IMK<&N?MO?$F6V<210265H6!_CCL8$<?@
MX8?A7VK\2/\ @MCX/A\/W*^ O FN7>M.A6"3Q$8;>WB8CAV6*21G /\ ""N?
M[PKX _9[^"OB[]M?]H8V<C7%W)JE^^J^)-;V_+;0O(7GE8XP&8DA%[L0.F2
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M4:* //\ X)_!'PC^S[X"LO!_@K3?[-TBV8R,7;?-<2MC?-*YY=VP.>@
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MWDQ,V3_SR,K3;\>LE 'NLW_!8K6O&%U)9_#KX$ZQXBFSMCD:^>5\]LPP0/\
MEOKY"_;\^*WQM^+UUX(U?XO^ 8? %JL=XNAV8M9+>:1283,9%ED:3(_==50<
MG ZU^Z&EWGAGP[X1M[K3I])TSPQ;P!X9K5XH;*.''!5EP@3'<<5^*7_!4_\
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M_P#1U_7[ 5^/_P#P5$_Y/Q\#_P#8I0?^CK^@#R>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *_6_P#8U_Y-G\#?]>TW_I1+7Y(5
M^M_[&O\ R;/X&_Z]IO\ THEH ]IHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K^<?]M_\ Y.\^+O\ V,=W_P"AFOZ.*_G'_;?_ .3O/B[_ -C'=_\ H9H
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M0^#/@QX=30O!'ANP\-Z6I!:&RBVM(W]Z1SEI&_VG)/O0!^5W_!%FS?3?CO\
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M0BOR5^+WQ*^*O_!5;XK>']"\'>#YM'\(Z/(Z1%F:2WL_,*^9<W=QM"[MJC"
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MR",]C6Y10!X1^RU^Q_X-_9%TG7]/\':GKFI0ZU/%<7#:Y<0RLK1JRJ$\J&,
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MB@ HHHH **** "BBB@ HHHH *_'_ /X*B?\ )^/@?_L4H/\ T=?U^P%?C_\
M\%1/^3\? _\ V*4'_HZ_H \GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "OUO\ V-?^39_ W_7M-_Z42U^2%?K?^QK_ ,FS^!O^
MO:;_ -*): /::*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_G'_;?_ .3O
M/B[_ -C'=_\ H9K^CBOYQ_VW_P#D[SXN_P#8QW?_ *&: .N^#?\ R3?1_P#M
MM_Z.>BCX-_\ )-]'_P"VW_HYZ* /GOQM_P CIK__ &$+C_T8U?O]_P $Z/\
MDRKX5_\ 8/E_]*9J_ 'QM_R.FO\ _80N/_1C5^_W_!.C_DRKX5_]@^7_ -*9
MJ /I"BBB@#\Q?^"H7_)=/#O_ &+</_I5<UI?"'P+^TKJ/PZT:X\*:Y;6_A]X
MB;2-[EU*KN.> OKFL_\ X*@QO_PN[PY+M/E_\([$N[MG[3<\5Z5^SS^W=\.?
MA_\ "+0/#WB :I!J=A&T<BVUIYJ'YV((;<.Q% %;_A6_[6W_ $,5G_X%R?\
MQ-'_  K?]K;_ *&*S_\  N3_ .)KU'_AY!\'_P#GMKG_ (+O_LZ/^'D'P?\
M^>VN?^"[_P"SH \N_P"%;_M;?]#%9_\ @7)_\31_PK?]K;_H8K/_ ,"Y/_B:
M]1_X>0?!_P#Y[:Y_X+O_ +.C_AY!\'_^>VN?^"[_ .SH \N_X5O^UM_T,5G_
M .!<G_Q-'_"M_P!K;_H8K/\ \"Y/_B:]1_X>0?!__GMKG_@N_P#LZ/\ AY!\
M'_\ GMKG_@N_^SH \N_X5O\ M;?]#%9_^!<G_P 31_PK?]K;_H8K/_P+D_\
MB:]1_P"'D'P?_P">VN?^"[_[.C_AY!\'_P#GMKG_ (+O_LZ /+O^%;_M;?\
M0Q6?_@7)_P#$UY?^T?X-^/\ HOPPNKKXA:O!>>&A<PK)%'<,Y,A;Y#@J.]?4
M/_#R#X/_ //;7/\ P7?_ &=>&_MA?MF^!OC+\)9/"OA>/49KFXNXIY)+RW\E
M8UC8$8Y.<\T >I?\$O\ _DAOB/\ [&.7_P!)K:OL:OCG_@E__P D-\1_]C'+
M_P"DUM7V-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7Y\_\ !:W_ )-E\(?]C?!_Z17E?H-7
MY\_\%K?^39?"'_8WP?\ I%>4 ?5/[(7_ ":I\'?^Q1TK_P!)(Z]=KR+]D+_D
MU3X._P#8HZ5_Z21UZ[0 5^0'[+.?^'P'Q ^U\S?VUXC\K/\ O2[?_'*_7^OR
M,^)5J?V>/^"Q'A[7;D&VTCQ/J%O<0R.,*R7UNUG(Q/H)S(<]L T ?KG7YI_'
M#_@IA\0/&'QBN_A;^SCX1A\2ZE:SR6KZQ<0-<O</&<2/#&&5$B4@_O9"5(YP
MHP3^DUQ'Y\,D8=HRZE0Z]1D=17X@?L9_%6R_X)]?M4>,- ^+.E7>GI+:OH]Q
MJ$-NTCVQ$JR).JCYGAD"@Y3)(*$ XH ^CX/A#_P4*^*ZB/Q!\1--\"6DGWD6
MZMK>2->X!L878GZO^(KYV^!WP\UOX4?\%4?#/A7Q)XGF\::[I^J8O-=N6=I+
MJ1].,A),C,QV[]N2<G;VZ#[M^(O_  5@^!'A70);CPOK-_X]UUUVVFDZ;IUS
M;F20\*'DGC0*"<9QN8=E/2OSX^#&L>---_X*2> _$_Q3TN;PWXE\2:Y'J,EG
M=Q^48UO$=(%"$Y0?.B!6^88 /.: /O/_ (+'?\FB0?\ 8R67_HN>O4_^"<<2
MP_L4_"U4 4&QG;\3=3$_J37EG_!8[_DT2#_L9++_ -%SUZM_P3G_ .3*OA7_
M -@^7_TIFH P?^"I7_)BWQ)_WM,_].5K6)_P25_Y,M\._P#82U#_ -*&K;_X
M*E?\F+?$G_>TS_TY6M8G_!)7_DRWP[_V$M0_]*&H ^5?BC_RFOTC_L)Z7_Z:
MXJ_3GX[?\D/^(?\ V+NH_P#I-)7Y3?MJ>+)/V>/^"H>E_$K6]+N[G1%?3-51
M(% >XMTMDMY?*+$*6!C?@D#( )&<U]\>'OVH?!_[5G[+WQ5\2>#8]3@LM/TS
M4M.FBU2%(9O,%CYFX*KN-I$@ .<Y5N.,D ^7?^"'?_(H_%K_ *_M._\ 1<]8
M7CJ\_P""B'_":>(1H"ZQ_88U&X^P;(='Q]G\UO*QN&[&S;UY]:W?^"'?_(H_
M%K_K^T[_ -%SU^GM 'YP_LJ7?[;\GQ\\*+\6UU0?#TO<?VI]HBTP)C[-+Y63
M"/,_UOE_=_'C-+_P6V_Y(G\/O^QA?_TFDK]':_.+_@MM_P D3^'W_8PO_P"D
MTE 'U+^PC_R9Y\)?^P#!_6OSC_X)X_\ *3#QW_OZ]_Z4U^CG["/_ "9Y\)?^
MP#!_6OR,^!O[1FA_LM_MP>/?&_B'3=0U33UO]8LC;Z8$,NZ2Y.#\[*,#:>]
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MUO7_ (9^$M<UB\L9'N;^_P!%MYIYF$\H!=V0EC@ <GM6'^V7_P $Q? _Q"\
MW^N_"GP[9>$?'FFQFXM[+2QY%IJ049,!B'R)(?X'4+\V W!ROLW_  3J_P"3
M*_A5_P!@Z7_TIEKZ0H _-3_@F3^W9>>+[V+X,?$=H[?Q%:J\>B:C)$L#76S.
M^UF4 #SE 8AL98!@WS %_P!*Z_('_@JI^S'?_!WXF:;\>/ BRZ;9ZE?1RZE)
M9?*VGZHIWQW*X^Z)2N2?^>BDDYD K[:_9_\ VW?#WQ3_ &2]2^*^JR1V^H^%
M["4^(]/C8*4NH8]Q"#^[-\I3K]_;R5- 'PA_P5+\;:Y^T1^U=X<^#W@RVDUJ
MY\/Q+9PV-NZCSM1N LDOS$A1MC$*DL<*5?)'-=UX=U3_ (**>$_#^F:'I7A&
MSL]+TVUBL[2W2#1]L4,:!$4?O.@50/PKG?\ @DWX%U+XT_M+>/OC7XD7[5<:
M=YTJSL.&U&^9R[+G^[%YPQV\U:_7N@#\,_VQ/ /[7'Q&\(6_B_XT>#D71?"J
M.XU"V6P1K>.9XU;<()"[+N"=CMY/ R:_1?\ X)D_'7_A=7[+.A07EQYVO^%3
M_8-]N.79(E!MY#W.82@R>K(]?2GCKP;IWQ$\%Z[X6UF+SM*UFRFT^Z3N8Y4*
M-CT.#D'L<5^/O_!.'QQJ7[+7[:OB'X1^)IOL]MK=Q-X?N WRQ_;X'8VLH]0_
MSHOKYZF@#]HZ_('_ (([Y/[4GQ2-O_QY?V+/C'3_ (_HMGZ;J_4CXU>.H?A?
M\(?&GBV9PBZ)H]U?KGN\<3,BCW+!0/<BOSU_X(D_#B:V\-_$?QY<1$17MS;:
M/:2,,9\I6EFQZC,L/XJ: /U HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K\^?^"UO_)LOA#_L;X/_ $BO*_0:OSY_X+6_\FR^$/\ L;X/
M_2*\H ^J?V0O^35/@[_V*.E?^DD=>NUY%^R%_P FJ?!W_L4=*_\ 22.O7: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ__ ."HG_)^/@?_ +%*
M#_T=?U^P%?D'_P %/(WN/V]O 4,2-)--X6MHHXU&6=VN+Y551W))  '4D4 >
M1T5T_P#PJWQG_P!"CKW_ (+)O_B:/^%6^,_^A1U[_P %DW_Q- ',45T__"K?
M&?\ T*.O?^"R;_XFC_A5OC/_ *%'7O\ P63?_$T <Q173_\ "K?&?_0HZ]_X
M+)O_ (FC_A5OC/\ Z%'7O_!9-_\ $T <Q173_P#"K?&?_0HZ]_X+)O\ XFC_
M (5;XS_Z%'7O_!9-_P#$T <Q173_ /"K?&?_ $*.O?\ @LF_^)H_X5;XS_Z%
M'7O_  63?_$T <Q173_\*M\9_P#0HZ]_X+)O_B:/^%6^,_\ H4=>_P#!9-_\
M30!S%%=/_P *M\9_]"CKW_@LF_\ B:/^%6^,_P#H4=>_\%DW_P 30!S%%=/_
M ,*M\9_]"CKW_@LF_P#B:/\ A5OC/_H4=>_\%DW_ ,30!S%%=/\ \*M\9_\
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M0!S%%=/_ ,*M\9_]"CKW_@LF_P#B:/\ A5OC/_H4=>_\%DW_ ,30!S%%=/\
M\*M\9_\ 0HZ]_P""R;_XFC_A5OC/_H4=>_\ !9-_\30!S%%=/_PJWQG_ -"C
MKW_@LF_^)H_X5;XS_P"A1U[_ ,%DW_Q- ',45T__  JWQG_T*.O?^"R;_P")
MH_X5;XS_ .A1U[_P63?_ !- ',45T_\ PJWQG_T*.O?^"R;_ .)H_P"%6^,_
M^A1U[_P63?\ Q- ',45T_P#PJWQG_P!"CKW_ (+)O_B:/^%6^,_^A1U[_P %
MDW_Q- ',45T__"K?&?\ T*.O?^"R;_XFC_A5OC/_ *%'7O\ P63?_$T <Q17
M3_\ "K?&?_0HZ]_X+)O_ (FC_A5OC/\ Z%'7O_!9-_\ $T <Q173_P#"K?&?
M_0HZ]_X+)O\ XFC_ (5;XS_Z%'7O_!9-_P#$T <Q173_ /"K?&?_ $*.O?\
M@LF_^)H_X5;XS_Z%'7O_  63?_$T <Q173_\*M\9_P#0HZ]_X+)O_B:/^%6^
M,_\ H4=>_P#!9-_\30!S%%=/_P *M\9_]"CKW_@LF_\ B:/^%6^,_P#H4=>_
M\%DW_P 30!S%%=/_ ,*M\9_]"CKW_@LF_P#B:/\ A5OC/_H4=>_\%DW_ ,30
M!S%%=/\ \*M\9_\ 0HZ]_P""R;_XFC_A5OC/_H4=>_\ !9-_\30!S%%=/_PJ
MWQG_ -"CKW_@LF_^)H_X5;XS_P"A1U[_ ,%DW_Q- ',45T__  JWQG_T*.O?
M^"R;_P")H_X5;XS_ .A1U[_P63?_ !- ',45T_\ PJWQG_T*.O?^"R;_ .)H
M_P"%6^,_^A1U[_P63?\ Q- ',45T_P#PJWQG_P!"CKW_ (+)O_B:/^%6^,_^
MA1U[_P %DW_Q- ',45T__"K?&?\ T*.O?^"R;_XFC_A5OC/_ *%'7O\ P63?
M_$T <Q173_\ "K?&?_0HZ]_X+)O_ (FC_A5OC/\ Z%'7O_!9-_\ $T <Q173
M_P#"K?&?_0HZ]_X+)O\ XFC_ (5;XS_Z%'7O_!9-_P#$T <Q173_ /"K?&?_
M $*.O?\ @LF_^)H_X5;XS_Z%'7O_  63?_$T <Q173_\*M\9_P#0HZ]_X+)O
M_B:/^%6^,_\ H4=>_P#!9-_\30!S%%=/_P *M\9_]"CKW_@LF_\ B:/^%6^,
M_P#H4=>_\%DW_P 30!S%%=/_ ,*M\9_]"CKW_@LF_P#B:/\ A5OC/_H4=>_\
M%DW_ ,30!S%?K?\ L:_\FS^!O^O:;_THEK\M_P#A5OC/_H4=>_\ !9-_\37Z
MG_LCZ;=Z3^SKX,LK^UFLKN*WE$D%Q&8Y$/GR'E2 1P10![%1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7\X_[;_\ R=Y\7?\ L8[O_P!#-?T<5_./^V__
M ,G>?%W_ +&.[_\ 0S0!UWP;_P"2;Z/_ -MO_1ST4?!O_DF^C_\ ;;_T<]%
M'SWXV_Y'37_^PA<?^C&K]_O^"='_ "95\*_^P?+_ .E,U?@#XV_Y'37_ /L(
M7'_HQJ_?[_@G1_R95\*_^P?+_P"E,U 'TA1110!#):PSD&2*.0CC+J#3/[/M
MO^?>'_OV*LT4 5O[/MO^?>'_ +]BC^S[;_GWA_[]BK-% %;^S[;_ )]X?^_8
MH_L^V_Y]X?\ OV*LT4 5O[/MO^?>'_OV*/[/MO\ GWA_[]BK-% %;^S[;_GW
MA_[]BC^S[;_GWA_[]BK-% %;^S[;_GWA_P"_8H_L^V_Y]X?^_8JS10!%%#'
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M&]2%B,%D$JL%)  )'I6YI.EV>@Z;::;IME!I^G6<*6]M9VL2Q0P1(H5(T10
MJJH   P  !5^B@ KFO&WP]\*_$C2XM-\7>&-(\5:=#,+B.SUNPBO(4E"LH=4
MD5@&"LPR!G#$=S72T4 9/AOPSI/@_1;71M!TNRT72+12EOI^FVZ6]O"I))"1
MH JC))P!U)K6HHH R/$?A?1_&6AW6B^(-)L==T>Z 6XT_4K9+BWF 8, \;@J
MV" >1U -<EI?[/?PLT?1]6TC3OAKX/LM)U98UU&PMM!M8X+T1MOC$T:QA9 K
M?,NX'!Y%>B44 <SX'^'?A3X:Z9-I_A#PSHWA73YYC<2VFBZ?%9Q/(0%+LD:J
M"V%49(SA0.U=-110 5P>J_ GX;:WXL/BG4OAYX5U#Q/YT=Q_;5UHMM+>^;'M
M\N3SF0ON7:N#G(VC'05WE% 'P+_P5H^+5[!\-?#7P8\,H]_XM\?:A#&;&WYE
M:UCE7:N.QDG\I1V(205]2?LQ?!&S_9U^!OA3P':F.6;3;4&^N8QQ<7;DO/)Z
MX+LV,]%"CM7)Z5^R'HO_  U%J7QR\0ZW>>)O$)M_LND6%W$B6ND1A=H\H#)+
M!2XR>\DC8R01]!4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?GS_P %K?\ DV7PA_V-\'_I%>5^@U?GS_P6M_Y-E\(?]C?!_P"D5Y0!
M]4_LA?\ )JGP=_[%'2O_ $DCKUVO(OV0O^35/@[_ -BCI7_I)'7KM !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7Y._\% /^4HGP#_[EW_T\3U^L
M5?D[_P % /\ E*)\ _\ N7?_ $\3T ?K%1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP: /Z)/^&^/V>_\ HK/AW_O^W_Q-'_#?'[/?_16?#O\ W_;_ .)K^=O['/\
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M]CG_ .>$G_?!H _HD_X;X_9[_P"BL^'?^_[?_$T?\-\?L]_]%9\._P#?]O\
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MW_T5GP[_ -_V_P#B:_G;^QS_ //"3_O@T?8Y_P#GA)_WP: /Z)/^&^/V>_\
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M_P"BL^'?^_[?_$T?\-\?L]_]%9\._P#?]O\ XFOYV_L<_P#SPD_[X-'V.?\
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M?^_[?_$U_.W]CG_YX2?]\&C['/\ \\)/^^#0!_1)_P -\?L]_P#16?#O_?\
M;_XFC_AOC]GO_HK/AW_O^W_Q-?SM_8Y_^>$G_?!H^QS_ //"3_O@T ?T2?\
M#?'[/?\ T5GP[_W_ &_^)H_X;X_9[_Z*SX=_[_M_\37\[?V.?_GA)_WP:/L<
M_P#SPD_[X- ']$G_  WQ^SW_ -%9\._]_P!O_B:/^&^/V>_^BL^'?^_[?_$U
M_.W]CG_YX2?]\&C['/\ \\)/^^#0!_1)_P -\?L]_P#16?#O_?\ ;_XFC_AO
MC]GO_HK/AW_O^W_Q-?SM_8Y_^>$G_?!H^QS_ //"3_O@T ?T2?\ #?'[/?\
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MP[_W_;_XFOYV_L<__/"3_O@T?8Y_^>$G_?!H _HD_P"&^/V>_P#HK/AW_O\
MM_\ $T?\-\?L]_\ 16?#O_?]O_B:_G;^QS_\\)/^^#1]CG_YX2?]\&@#^B3_
M (;X_9[_ .BL^'?^_P"W_P 31_PWQ^SW_P!%9\._]_V_^)K^=O['/_SPD_[X
M-'V.?_GA)_WP: /Z)/\ AOC]GO\ Z*SX=_[_ +?_ !-'_#?'[/?_ $5GP[_W
M_;_XFOYV_L<__/"3_O@T?8Y_^>$G_?!H _HD_P"&^/V>_P#HK/AW_O\ M_\
M$T?\-\?L]_\ 16?#O_?]O_B:_G;^QS_\\)/^^#1]CG_YX2?]\&@#^B3_ (;X
M_9[_ .BL^'?^_P"W_P 31_PWQ^SW_P!%9\._]_V_^)K^=O['/_SPD_[X-'V.
M?_GA)_WP: /Z)/\ AOC]GO\ Z*SX=_[_ +?_ !-'_#?'[/?_ $5GP[_W_;_X
MFOYV_L<__/"3_O@T?8Y_^>$G_?!H _HD_P"&^/V>_P#HK/AW_O\ M_\ $T?\
M-\?L]_\ 16?#O_?]O_B:_G;^QS_\\)/^^#1]CG_YX2?]\&@#^B3_ (;X_9[_
M .BL^'?^_P"W_P 31_PWQ^SW_P!%9\._]_V_^)K^=O['/_SPD_[X-'V.?_GA
M)_WP: /Z)/\ AOC]GO\ Z*SX=_[_ +?_ !-'_#?'[/?_ $5GP[_W_;_XFOYV
M_L<__/"3_O@T?8Y_^>$G_?!H _HD_P"&^/V>_P#HK/AW_O\ M_\ $T?\-\?L
M]_\ 16?#O_?]O_B:_G;^QS_\\)/^^#1]CG_YX2?]\&@#^B3_ (;X_9[_ .BL
M^'?^_P"W_P 31_PWQ^SW_P!%9\._]_V_^)K^=O['/_SPD_[X-'V.?_GA)_WP
M: /Z)/\ AOC]GO\ Z*SX=_[_ +?_ !-'_#?'[/?_ $5GP[_W_;_XFOYV_L<_
M_/"3_O@T?8Y_^>$G_?!H _HD_P"&^/V>_P#HK/AW_O\ M_\ $T?\-\?L]_\
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M_P 31_PWQ^SW_P!%9\._]_V_^)K^=O['/_SPD_[X-'V.?_GA)_WP: /Z)/\
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MK['/_P \)/\ O@TUH9$<*R,&/12.30!_1-_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
MAOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_P
MWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_
MWP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX
M=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_
M -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?SM_8Y_\ GA)_WP:/L<__ #PD
M_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\ AOC]GO\ Z*SX=_[_ +?_ !-?
MSM_8Y_\ GA)_WP:/L<__ #PD_P"^#0!_1)_PWQ^SW_T5GP[_ -_V_P#B:/\
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MO*?#J,='M\ _Q=O]HT4 ?TY4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>/ 'QPAU*7P'XIL?$\>FM&EV]BQ(A+AB@;('78WY4 >@4444 %%%% !1110
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M **** "BBB@ HHKE/B1\4/"GPA\-MX@\9:Y:^'M%65(#>WA(C#MG:O /)P:
M.KHK(\*^*-*\;>'--U_0[Z+4]'U&!;FTO(#E)HV&59?8BM>@ HHHH **** "
MBBB@ HHJK'=P37$T"31O/#M,D2N"R9^[N'49P<9H M4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVKGO^"3_ /R9/X2_Z_M1_P#2N2NA_P""FW_)C?Q/_P"N5C_Z<+:N>_X)/_\
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M2J7NE7<=S"Q'4!T)&?;-:MQ<16EO)-/*D,,2EWDD8*J*!DDD\  =Z_.+X?\
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M_%D/PD\<2>-(=3DMGU%Y-7M-0^SM&)!&,VZ*$W!W^]G.WCH:TOV6/V6?AQ\
M_!BZ[X*T6;3-3\0:+:MJ,LE]-.)2(]_"R.0OS.QX ZU\B_\ !#G_ )%[XO\
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M&_X)_P#[2WPA\;?"NXOM'T[5+IY3ILMT\WE&"6%9X@[$LT4L<X4JQ8_>YP0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBCX17?@#PT=?@T&6];47^WVUMY D>U*<32(6R(I/NYQMYZC/WQ0!^6O[-?\
MRF"^+G_7'4O_ $*WK[Q_:V_Y-7^,?_8G:Q_Z12U\O_!#]F/XE^$/^"CWQ$^*
M>K>&C:>!-6BOEL]6^WVS^:9##L_=+*95SL;[R#&.:^M/VAO"NI^.?@'\2?#>
MAVWV[6M8\-:E86-KYB1^=/+:R)&FYR%7+,!EB ,\D"@#Y4_X(S_\FFZI_P!C
M5>?^D]K7E_\ P3EU>SM_V^/VE]-=U6]NK[4IX5)Y9(]4</C_ +^)7T5_P31^
M!OC;]GW]GF_\->/]$_L#7)-?N;U+7[7!<YA>&!5;="[KR488SGCITKY(T_\
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M[#_P4&^ =U\%OV2OV?=>TA/L^N?#N6VL;B:,<K+-&LKRGV%S ,>\OO67??\
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MA:":.4Q,0P9=Z,RG@]02* /D/_@B+_R23XC_ /8<@_\ 2<5^DM?DE\!?@/\
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MG2?V?/A!X;\ :)))<V.CP%#<S ![B5W:265@.FYW8XYP"!VKT:@#\KO!D?\
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M\DD ]U_X*V:]9:1^QEKMG=2*MQJFJ6%I:*QY:19A,<?\ AD-> _%#PAJT?\
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M?H9\+_A)HOP5^#^D> ?#$+KI>DV+6L!D(\R9SN9Y'/ W.[,YZ#+'H* /S_\
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MM">'4^(OC&_T_P 1_$>2ZBM;;P7I5Q#!:Z9IVV0OMEED6/>)"GRAFR"Q+N<
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M^Z-?=U% %/3]/MM)L;:QLX([:SM8EAA@B4*D:* %50.@   'M5RBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
